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Abstract 
OSW-1 is a cholestane glycoside natural product with potent anti-proliferative 
activity, broad spectrum anti-viral activity, and a novel mechanism of action. The OSW-
1’s cellular targets are oxysterol-binding protein (OSBP) and OSBP-related protein 4 
(ORP4). Recently, OSBP has been determined to execute an essential role in the 
proliferation of many classes of pathogenic viruses. ORP4 has been determined, also 
recently, to be a driver of cellular proliferation and to be a precision cancer target. The 
main project of this dissertation research is focused on using organic synthesis to produce 
new synthetic routes to access new OSW-1-derived compounds. To better understand the 
compound’s mechanism of action and molecular pharmacology, a set of OSW-1 probe 
analogs were designed and produced. To further the potential development of OSW-1-
derived therapeutic compounds, a new approach for the rapid and convergent synthesis 
of a diverse library of OSW-1 analogs based on a new scaffold was developed. This new 
approach to OSW-1 analogs synthesis will allow for the future production of analogs with 
selective affinity for OSBP or ORP4 and improved pharmacological properties. 
Additionally, a set of stable-isotopically-labeled anti-cancer agents were synthesized to 
allow the absolute quantification of the drug inside the individual cancer cells through a 
new mass spectrometry technique. The last project describes the design and synthesis of 
a retinaldehyde’s analog with high selectivity for retinaldehydrogenase (RALDH) 
enzymes. This novel compound could form the basis for the development of new 
treatments for blindness caused by pathological myopia. 
 
1 
Chapter I: Introduction and Background 
I.1 Plant-derived saponin natural products 
Saponins constitute an important class of structurally diverse terpenoid plant-
derived natural products with a wide range of biological properties.1 These compounds 
display a unique physical property of forming a foamy lather upon shaking in aqueous 
condition.2 The trivial name for this class of natural products was therefore derived from 
the Latin sapo, meaning soap.2 Saponins’ general structure consists of a skeleton (either a 
steroidal-C27 or a triterpenoid-C30) with varying numbers of sugar residues attached at 
different positions.2 Plant saponins have been reported to exhibit a wide range of biological 
activities, including cytotoxic, anti-inflammatory, hemolytic, anti-fungal, and anti-
bacterial properties.1 These diverse biological activities of plant saponins have attracted 
considerable interest in structural characterization, total synthesis of saponins and their 
analogs for the development of potential therapeutic applications. 
I.1.1 Isolation and characterization of saponin OSW-1 
In 1992, Sashida group from Tokyo College of Pharmacy reported the isolation and 
characterization of a family of cholestane glycoside compounds, including the OSW-1 
compound (Figure 1, compound 2), from the bulbs of the flowering plant Ornithogalum 
saundersiae .3 This plant species, which produces attractive blooms used as cut flowers, is 
native to the Highveld region of South Africa and Swaziland.3,4 The isolation of the 
cholestane glycoside compounds from the O. saundersiae started with refluxing methanol 
extraction of minced bulb material. The methanol fraction was then extracted with 1-
butanol, and the butanol soluble phase was then fractioned through two rounds of silica gel 
column chromatography using CHCl3-MeOH as eluent.
3 Further compound separation was 
2 
done using octadecylsilanzied (ODS) silica gel column chromatography with methanol-
water (4:1) followed by preparative HPLC with methanol-water (12:1) and acetonitrile-
water (4:1).3 This purification yielded three acylated cholestane glycoside compounds 
(Figure 1).3 16.2 kg of fresh Ornithogalum saundersiae bulbs afforded 25 mg of compound 
1a, 439 mg of compound 2 (OSW-1) and 23.5 mg of compound 1b (Figure 1).3 
 
Figure 1. First natural products isolated from O. saundersiae bulb, and numbering 
system of OSW-1. Figure is adapted from Kubo et al.3 
 
The structural elucidation of the three isolated cholestane glycosides was carried 
out using a combination of spectroscopic techniques [(mass spectrometry, 1D and 2D-
nuclear magnetic resonance spectroscopy (NMR), infrared spectroscopy (IR)] and 
chemical decomposition. Their molecular formulae were identified through negative-ion 
fast atom bombardment (FAB) mass spectrometry and 13C NMR.3 IR absorption bands at 
3450 and 1045 cm-1 indicated that compound 1a possesses a glycosidic moiety.3 The 
3 
presence of a carbonyl group in the molecule was shown by the IR (1695 cm-1) and 13C 
NMR (218.9 ppm) spectra.3 Furthermore, the IR band at 1740 cm-1, 1H NMR [2.34 ppm 
(3H, s)] and 13C NMR (170.0 and 21.5 ppm) indicated the presence of an acetyl group.3 To 
confirm this, alkaline treatment of compound 1a with 3% sodium methoxide in methanol 
resulted in a deacetylated compound.3  
The 13C NMR spectrum of 1a showed 27 carbons associated with the aglycon, and 
10 carbons associated with the saccharide component.3 Further analysis of the aglycon 
carbons by DEPT spectra showed five methyl, nine methylene, eight methine and five 
quaternary carbon groups.3 The signals at δ 219.5 (C), 141.9 (C) and 121.2 (CH) were 
assigned to a carbonyl carbon and a pair of olefinic carbons, respectively.3 There were three 
carbons bearing oxygen functions at δ 88.9 (CH), 86.2 (C), and 71.3 (CH).3 The 1H NMR 
spectrum of 1a contained two singlets for tertiary methyl protons at δ 1.08 and 0.94, and 
three secondary methyl protons at δ 1.32 (d, J = 7.4 Hz), 0.92 (d, J = 6.4 Hz), and 0.87 (d, 
J = 0.63 Hz).3 These data together suggested that the structure of 1a was a cholestane 
derivative with a carbonyl group and three hydroxy groups, one of which is connected to 
the carbohydrate moiety.3 
To characterize the carbohydrate moiety, compound 1a was subjected to acidic 
hydrolysis using 1M hydrochloric acid in dioxane-H2O (1:1).
3 The resulting mixture of 
sugars was converted to 1-[(S)-N-acetyl-α-methylbenzylamino’-1-deoxyalditol acetate 
derivatives, then analyzed by HPLC against standards to confirm the absolute 
configuration 3. L-arabinose and D-xylose was determined to be the carbohydrate 
composition of the compounds.3 By comparing the 13C signals of the sugars with those of 
reference methyl glycosides, the glycosidic bond was revealed to be β-D-xylopyranosyl-
4 
(1→3)-α-L-arabinopyranose.3 The position of the acetyl group attachment as being on the 
C-2 of the arabinose was elucidated by comparing the proton chemical shifts of compound 
1a with the deacetylated compound.3 In addition to this, the 13C signals of the arabinose C-
1 and C-3 of compound 1a was shifted upfield by 4.0 ppm and 3.7 ppm, respectively, as 
compared with those of the deacetylated compound.3 
Compound 2 (later termed OSW-1) had spectral data that were essentially 
analogous with those of compound 1a with one exception.3 In addition to the acetyl group, 
the spectral data suggested the presence of a 4-methoxybenzoyl group through IR [1690 
cm-1 (C=O); 1600 and 1510 cm-1 (aromatic ring)], UV (λmax 259 nm), 
1H NMR [δ 8.32 and 
7.08 (each 2H, d, J = 8.9 Hz); δ 3.75 (3H, s)] and 13C NMR [δ 123.0 (C), 132.4 (CH) x 2, 
114.2 (CH) x 2, 163.9 (C), 165.5 (C), and 55.5 (CH3)] spectra.
3 Furthermore, alkaline 
hydrolysis of 2 with 4% potassium hydroxide in ethanol yielded 1a and 4-methoxybenzoic 
acid. In the 1H NMR spectrum of 2, the signal due to the xylose H-2 were shifted downfield 
by 1.68 ppm as compared with those of 1a to appear at δ 5.67 (dd, J = 8.9, 7.6 Hz)3. Also, 
the 13C signal due to the xylose C-1 and C-3 were shifted upfield by 3.2 and 3.0 ppm 
respectively. These data suggested that the 4-methoxybenzoyl group is linked to the C-2 of 
xylose. The structure of 2 (i.e. OSW-1) was determined to be 3β,16β,17α-
trihydroxycholest-5-en-22-one-16-O-(2-O-4-methoxybenzoyl-β-D-xylopyranosyl)-
(1→3)-(2-O-acetyl-α-L-arabinopyranoside). 
I.1.2 Other cholestane glycosides from O. saundersiae bulb 
In the years subsequent to the isolation of OSW-1 (1992-2017), over 40 additional 
structurally diverse cholestane glycoside compounds have been discovered in 
Ornithogalum saundersiae extracts (see Figure 2 for partial representative of natural 
5 
products isolated from O. saundersiae bulbs).4,5 All of these OSW-1-related compounds 
were identified from either the methanol or n-butanol extracts of the bulb. These natural 
product compounds, despite sharing the general structure similarity of being cholestane 
glycosides, differ in the composition of the cholestane steroidal core, the aliphatic side 
chains, and the composition of glycoside moiety. 
The cholestane glycoside most closely related to OSW-1 retain the 3β,16β,17α-
trihydroxyl cholestane aglycon linked with glycoside moiety (mainly L-arabinose and D-
xylose) through C-16 hydroxyl group (Figure 2). In these related compounds, the C-3 
position is either a free hydroxyl or, in the case of 1d and 1e, the C-3 hydroxyl is 
glycosylated with β-D-glucopyranoside. Remaining differences are observed within the D-
xylopyranosyl moiety.4 The benzoate portion on C-2 have different substitution patterns 
ranging from different numbers of methoxy groups on the benzoate moiety (mono-, di-, or 
tri-methoxybenzoate) to different aromatic motifs (benzoate vs. cinnamoyl). C-3 hydroxyl 
of D-xylose moiety remained free hydroxyls. C-4 hydroxyl, in two instances in compound 
1f and 1g, is linked to β-D-glycopyranoside through a glycosidic link.4  
Some of the isolated compounds have a monosaccharide component (L-
rhamnopyranoside) instead of the disaccharide moiety similar to OSW-1.6 Compounds 3a-
3f shared the same polyhydroxylated cholestane steroidal core with 3β, 11α, 16β-
hydroxyls.7 The hydroxyl group at C-2 of L-rhamnopyranoside can sometimes be 
acetylated.7 The C-3 hydroxyl group of L-rhamnopyranoside either exists as free hydroxyl, 
or capped as either acetate or 3,4,5-trimethoxybenzoate group.8 It is interesting to note that 
the steroidal core of this group of compounds lacks the C-17 hydroxyl group, and C-22 in 
the aliphatic sidechain exists as an alcohol as compared to ketone in OSW-1.4 Compounds 
6 
4a-4c are very similar to compound 3-subfamily, but have an olefin at C-24 and C-25 of 
the aliphatic chain.7,8 Compound 5, even though isolated from the same source, has quite a 
different structure compared to OSW-1.8 C-1 in the steroidal core of 5 is bulkier with the 
appended β-D-glycopyranosyl moiety.8 The aliphatic side chain of 5 is not functionalized 
at C-22, but possesses C-23-C-24 olefin and C-25 hydroxyl group.8 Compound 5 only has 
a monosaccharide of L-arabinopyranoside with 3,4,5-trimethoxybenzoate group on C-2.8  
 
Figure 2. Natural products isolated from O. saundersiae bulb. Figure is adapted from 
Tang et al.4 
 
I.2 Biological activity of steroidal glycoside OSW-1 and related compounds 
The biological activity of the OSW-1 compound has been the subject of extensive 
research.4,9–11 Although upon isolation, OSW-1 was identified as a micromolar inhibitor of 
3’,5’-cyclic adenosine monophosphate (cAMP) phosphodiesterase activity. OSW-1 was 
7 
later determined to have potent anti-proliferative activity. 4,9 cAMP plays an important role 
as a “second messenger” in various biological processes, therefore screening for cAMP 
phosphodiesterase inhibitory activity serves as a useful tool for the screening of 
biologically active compounds in natural sources.12 Following the isolation of natural 
products from O. saundersiae bulbs, they were examined for their cAMP 
phosphodiesterase inhibitory activity.3 Compared to the activity of a known cAMP 
phosphodiesterase inhibitor, papaverine (IC50 = 3.0 x 10
-5 M), OSW-1 exhibited a 
comparable cAMP phosphodiesterase activity (IC50 = 5.0 x 10
-5 M) 3. Compound 1a that 
was missing the benzoate moiety on the disaccharide showed a much weaker inhibitory 
effect (IC50 = 23.0 x 10
-5 M) 3.  
Further investigation into OSW-1 biological activity showed that it exhibited potent 
anti-tumor activity.4,9 OSW-1, compound 1b and 1c strongly inhibited the growth of 
leukemia HL-60 cells with the IC50 values ranging between 0.1 to 0.3 nM, which was much 
more potent than the clinically applied anti-cancer agents used as positive controls 
(etoposide-IC50 = 25 nM, Adriamycin-IC50 = 7.2 nM and methotrexate-IC50 = 12 nM).
9 
Moreover, OSW-1 was found to have exceptionally potent cytostatic activities on many 
malignant tumor cells such as mouse mastrocarcinoma, human pulmonary 
adenocarcinoma, human pulmonary large cell carcinoma, and human pulmonary squamous 
cell carcinoma including ADM-resistant P388 leukemia and camptothecin (CPT)-resistant 
P388 9. The anti-cancer activities of OSW-1 are around 10 to 100 times more potent than 
the clinically used anti-cancer agents such as mitomycin C, cisplatin and taxol, but it 
showed little toxicity to normal human pulmonary cells.9 OSW-1 showed exceptionally 
8 
potent cytostatic activities in the U.S. National Cancer Institute 60 cancer cell lines (NCI-
60) in vitro screen, with the mean IC50 of 0.78 nM.
9  
 
Figure 3. Chemical structures of ORPphillins: cephalostatin, ritterazine B, stelletin E, 
OSW-1(2), schweinfurthin A and B. Figure is adapted from Burgett et al.10 
 
OSW-1 was associated with a group of structurally diverse natural products sharing 
a similar and unique pattern of sensitivity against the NCI-60 cell line panel, as identified 
through the NCI-DTP COMPARE algorithm (Figure 3).10 This algorithm expressed the 
similarity in NCI-60 profiles through Pearson correlation coefficients (r). Compounds with 
high COMPARE correlation (r > 0.6) tend to have related mechanisms of action 13. 
Through COMPARE analysis, the high correlation values of OSW-1, cephalostatin14, 
ritterazine B 15, schweinfurthin A 16, schweinfurthin B 16 and stellettin E 17 suggest that all 
six natural products share a common but unidentified cellular target 13. Through an affinity 
purification and proteomic analysis of an OSW-1 affinity resin, Burgett et al. determined 
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that OSW-1, cephalostatin, ritterazine B and schweinfurthin A share cellular targets of 
oxysterol binding protein (OSBP) and its closest paralog, OSBP-related protein 4L 
(ORP4L).10 Hence, these natural products (Figure 3) were named the ORPphillins, based 
on their ability to interact with OSBP and OSBP-related proteins (i.e., ORPs).10 The 
cellular targets of OSW-1 being OSBP and ORP4L were further supported through 
extensive biological experimentations including measurement of high affinity binding 
between OSW-1 compound and the OSBP and ORP4 proteins.10  
I.2.1 OSBP/ORP protein family 
 
Figure 4. OSBP and ORP4L protein domain sequence and homology diagram. Figure is 
adapted from Juan Nuñez dissertation. 
 
OBSP and ORP4L belongs to the family of oxysterol-binding proteins that is 
conserved in all eukaryotic cells, from yeast to humans.18,19 Oxysterol-binding protein 
(OSBP) was the first identified20 and the most well-studied of this protein family in 
humans. Through genomic analysis it was revealed that beside OSBP, the family consists 
of 11 other OSBP-related proteins (ORPs) 21. All members of OSBP/ORPs family have a 
conserved feature of carboxy-terminal OSBP-related ligand-binding domain (ORD) (~50 
kDa) (Figure 4).19 The ORD is capable of binding oxysterols and potentially other lipid 
ligands.19 A highly conserved “OSBP-fingerprint” sequence, EQVSHHPP, is present in all 
OSBP/ORPs in the ORD.19 Different OSBP/ORP family members possess different 
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regulatory domains such as a pleckstrin homology (PH) domain, a cluster of ankyrin 
repeats, or “two phenylalanines ina an acidic tract” (FFAT) sequence motif, along with the 
conserved sterol binding domain19. The definitive cellular functions of the individual 
OSBP/ORPS are the focus of extended research.22,23 The OBSP/ORP proteins are believed 
to serve as lipid sensors and lipid transport proteins, based on the conversed sterol binding 
domain to bind and transport small lipid molecules (e.g. oxysterols).19 Furthermore, 
members of the protein family have been shown to bind ligands other than oxysterols, 
including phosphatidylserine24 and phosphoinositides25. 
I.2.2 OSBP and ORP4 as therapeutic targets for precision medicine 
OSBP and ORP4 belong to the same subfamily I of the OSBP/ORP family, and 
both have been shown to interact with ORPphillin compounds (Figure 3). These two 
proteins share a 59% overall sequence identity, including a 68% sequence identity in the 
sterol binding domain (ORD) (Figure 4).26 In addition, OBSP and ORP4 share the same 
regulatory domains such as PH and FFAT domain. Despite sharing a strong sequence 
similarity, OSBP and ORP4 have very different biological roles and functions. OSBP is 
expressed ubiquitously in all tissues, while ORP4 has been shown to be expressed in only 
a few selective tissues in the body such as retina, testes and parts of the brain.21,27 OSBP 
and ORP4 have been shown to have different cellular localization patterns and disease 
relevance.10,28 OSBP was demonstrated to play a critical role in the replication of a broad 
spectrum of clinically-important human pathogens that belong to the Enterovirus genus 
such as common cold, myocardial infections, hand, foot, mouth disease (HFMD), and 
several neurologic diseases.11,29–31 Inhibition of OSBP with itraconazole, an anti-viral 
compound, blocked the replication of Flavivirun pathogens dengue virus and Zika virus.32 
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ORP4L (one major variant of ORP4) was shown to be overexpressed and essential for 
cancer cell viability in T-cell acute lymphoblastic leukemia (T-ALL).33,34 Inhibition of 
ORP4L expression in T-ALL cells led to cancer cell death.34 Thus, ORP4L can serve as a 
precision cancer therapeutic target.  
Even though both OSBP and ORP4L binds ligands with similar affinity, such as 
25-hydroxycholesterol and OSW-1, in some instances, the proteins exhibit differences in 
ligand selectivity.10 More specifically, schweinfurthin A (Figure 3) was shown to bind to 
OSBP with a much greater affinity (Ki = 68 ± 23 nM) than ORP4L (Ki = 2600 ± 570 nM).10 
In Burgett’s laboratory, the difference in binding affinity of ligands to OSBP or ORP4L 
have been demonstrated (Juan Nuñez’s doctoral work). These results together indicate that 
analogs derived from the OSW-1 compound can be developed with selective affinity to 
OSBP for anti-viral activity, or to ORP4L for anti-cancer therapeutic agents. 
I.3 OSW-1 as a synthetic target 
When the potent cytotoxicity activity of the OSW-1 compound was recognized, 
many chemists from around the world undertook the synthesis of the molecule. The 
common strategy of OSW-1 disconnection into two parts (the cholestane aglycon and the 
disaccharide moiety) was adopted by the majority of laboratories. Here, the different 
synthetic approaches to each part of OSW-1 from different groups are highlighted. 
I.3.1 Total synthesis of OSW-1 by Yu’s group 
Seven years after its isolation, OSW-1 was first synthesized by Yu’s group from 
Chinese Acedemy of Sciences in 1999 (Scheme 1). The group assembled OSW-1 from 
cholestane aglycon 14 and the functionalized disaccharide trichloroacetimidates 25. The 
protecting group strategy of hydroxyl groups (silyl ether) and ketone group (ethylene 
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glycol ketal) were carefully thought out. These protecting groups can be removed late stage 
in very mild conditions that would not affect other functional groups in the assembled 
molecule.4 Cholestane aglycon 14 was synthesized from the commercially available trans-
dehydroandrosterone 6. Wittig olefination installed C-20 and C-21, followed by protection 
of C-3 hydroxyl group as tert-butyldiphenylsilyl (TBDPS) ether (70% yield over 2 steps).35 
The diene 7 then participated in an ene reaction with paraformaldehyde in the presence of 
catalytic amount of BF3·Et2O to generate the homoallylic alcohol stereoselectively to set 
C-20 stereocenter.35 The homoallylic alcohol was then oxidized to aldehyde 8 with Dess-
Martin periodinane in good yield (65% over 2 steps). The aliphatic side chain was 
appended through Grignard reaction of aldehyde 8 and 3-methylbutylmagnesium bromide 
to yield alcohol 9 with the indicated stereoisomer in high yield (96%).35 C-22 alcohol was 
oxidized to the ketone using PDC reagent. The C-22 ketone was protected as ethylene 
glycol ketal under very mild conditions with a long reaction time (4 days) to give 
compound 10 in satisfactory yield (80% through 2 steps). The silyl ether protecting group 
on C-3 hydroxyl was switched from tert-butyldiphenyl to a more labile tert-butyldimethyl 
silyl (TBS) ether to avoid the possible complications associated with acyl group migration 
and cleavage in the final removal of the TBDPS ether under TBAF or HF/Pyr.35 The diene 
11 was subjected to dihydroxylation condition with OsO4 (1.2 equiv) to give the 
corresponding 16α, 17α-diol 12 in moderate yield (41%). The authors commented that the 
reaction resulted in more polar byproducts, perhaps from dihydroxylation of C-5-C-6 
alkene, along with starting material.35 The stereochemistry at C-17 hydroxyl group was 
inverted through Swern oxidation of diol 12 to afford ketone 13, which was then reduced 
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with NaBH4/CeCl3 to afford the desired 16β-OH aglycon 14 exclusively. The group 
successfully synthesized aglycon 14 of OSW-1 in 12 steps and 10% yield overall from 6.35 
 The glycon part of OSW-1 was constructed from D-xylose and L-arabinose. The 
xylosyl donor 17 was synthesized from D-xylose in 5 steps as shown in Scheme 1. First, 
the anomeric hydroxyl group was protected as a benzyl ether. Then, the 4-methoxybenzoyl 
group was installed regioselectively on C-2 through a reaction of triol 15 with 4-
methoxybenzoyl chloride/pyridine. The free hydroxyl groups on C-3 and C-4 were masked 
as the bis-TES ether to afford compound 16 in 60% yield.35 The anomeric benzyl ether was 
removed in hydrogenolysis condition, then the resulting hemiacetal was converted to the 
corresponding mixture of trichloroacetimidates 17.35 In the meantime, the arabinosyl 
acceptor 20 was prepared in 4 steps from L-arabinose. After the anomeric benzylation, 
isopropylidenation of C-3 and C-4, followed by acetylation at C-2 afforded compound 1935 
The isopropyliden moiety was then removed to reveal hydroxyl groups on C-3 and C-4 in 
arabinosyl acceptor 20. Schmidt glycosylation of trichloroacetimidates 17 and diol 20 in 
presence of BF3·Et2O as the catalyst at low temperature gave the desired 1→3-linked 
disaccharide 22 as the major product, along with the isomer 1→4-linked disaccharide 21 
as the minor product, which were not separable through silica gel column 
chromatography.35 The mixture of 21 and 22 was reacted with TESOTf to mask the free 
hydroxyl, affording disaccharides 23 (21%) and 24 (70%) separately after silica gel column 
chromatography. Hydrogenolysis of disaccharide 24 resulted in the corresponding 
hemiacetal, which was converted to the trichloroacetimidates 25 to serve as glycosyl donor 
in the following Schmidt glycosylation.35  
14 
 The aglycon acceptor 14 and glycosyl donor 25 was joined together through 
Schmidt glycosylation reaction under the promotion of trimethylsilyl triflate (TMSOTf) at 
low temperature to produce the fully protected OSW-1 26 in satisfactory yield (69%).35 
Finally, all the protecting groups (one TBS group, three TES groups and one ethylene 
glycol ketal group) were removed cleanly in a single step with Pd(MeCN)2Cl2 as the 
catalyst to furnish the final target OSW-1 in good yield (79%). Overall, Yu’s group 
accomplished the first total synthesis of OSW-1 through 27 steps, with the longest linear 
sequence being 14 steps, and in 6% overall yield.35 
15 
 
Scheme 1. Total synthesis of OSW-1 by Yu's group. Figure is adapted from Deng et al.35 
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I.3.2 Total synthesis of OSW-1 by Jin’s group 
Shortly after Yu’s group published the first OSW-1 total synthesis, another elegant 
route to OSW-1 was published in 2002 by Jin’s research lab from the University of Iowa. 
The retrosynthesis approach followed the same strategy of independent construction of 
OSW-1 aglycon and glycon moieties, which were joined late stage through Schmidt 
glycosylation reaction. The authors constructed the OSW-1 aglycon through a key 
stereoselective 1,4-addition of α-alkoxyvinyl cuprate to a steroid Δ17(20)-en-16-one.36 
Trans-dehydroandrosterone 6 (Scheme 2) was converted to diene 27 in high yield (94%) 
through masking C-3 hydroxyl group as TBS ether and Wittig olefination. Diene 27 was 
then subjected to a highly regio- and stereoselective selenium dioxide-mediated allylic 
hydroxylation to afford allylic alcohol 28 in great yield (97%).36 This alcohol underwent 
Swern oxidation to afford enone 29 in nearly quantitative yield (96%). TMSCl-activated 
stereoselective 1,4-addition of α-cyclohexyloxy vinyl cuprate 30 to enone 29 went 
smoothly to give silyl enol ether 31 in situ, which was converted to enol acetate 32. The 
conversion of silyl enol ether to enol acetate allowed the group to achieve chemoselective 
transformation of the enol ether at C-22 to ethylene glycol ketal 33.36 Potassium tert-
butoxide generated an enolate from 33, which then underwent stereoselective α-
hydroxylation by Davis reagent to afford α-hydroxy ketone 13.36 C-17 ketone 13 was 
reduced stereoselectively with LAH in THF at -78°C to provide the desired trans-16β,17α-
diol 14. Overall, the aglycon moiety was assembled in eight operations with 48.4% yield.36 
 The disaccharide moiety of OSW-1 was synthesized from tetraacetyl-L-arabinose 
34 and tetraacetyl-D-xylose 38 as starting points. Thioglycoside 35 was obtained from 34 
through glycosylation reaction in presence of tin (IV) chloride as the promoter and the 
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removal of the remaining acetate groups.36 C-3 and C-4 hydroxyl groups were converted 
to an acetonide, which allowed selective protection of C-2 hydroxyl as an acetate group in 
36. The acetonide was deprotected and C-4 hydroxyl was re-protected selectively with 
TESOTf and lutidine at low temperature to afford glycosyl acceptor 37.36 
 Tetraacetyl-D-xylopyranoside 38 was converted to thio ortho ester 39 through 
bromo-glycoside intermediate in moderate yield (75%). Protecting group manipulation 
gave compound 40, followed by zinc chloride-promoted ring opening of thio ortho ester 
yielded thioglycoside 41.36 The 4-methoxybenzoate moiety was installed on C-2 after 
deacetylation step. The thioglycoside 42 was converted to first a hemiacetal, then 
trichloroacetimidates to serve as glycosyl donor 43 in the construction of disaccharide 
moiety.36  
 Glycosylation of 37 and 43 with BF3·Et2O catalyst at low temperature afforded the 
desired β-disaccharide 44 in excellent yield (93%), which was converted to glycosyl donor 
45 after two steps.36 Schmidt glycosylation of aglycon acceptor 14 and disaccharide donor 
45 in presence of catalyst TMSOTf at low temperature gave the fully protected OSW-1 46 
in moderate yield. The p-methoxybenzyl protection groups were cleaved with 2,3-dichloro-
5,6-dicyanobenzoquinone (DDQ); the silyl ethers and acetonide was removed in presence 
of Pd(CN)2Cl2 to accomplish the target OSW-1. Overall, OSW-1 was synthesized in 28 
steps with the reported yield of 6.5%.36. 
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Scheme 2. Total synthesis of OSW-1 from Jin's group. Scheme is adapted from Yu et 
al.36 
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I.3.3 Total synthesis of OSW-1 by Morzycki’s group 
In 2002, Morzycki’s group at University of Bialystok, Poland reported their take 
on OSW-1 total synthesis. The overall approach still followed assembling OSW-1 through 
Schmidt glycosylation of aglycon and glycone moiety. However, the group realized that 
16β,17α-diol motif in the steroidal moiety of OSW-1 can be accessed from ring opening 
of 16α,17α-epoxide with oxygen nucleophiles37, which would eliminate the use of 
expensive and toxic OsO4 and the lengthy process to set the desired stereochemistry at C-
16 in the other OSW-1 syntheses. trans-dehydroandrosterone 6 underwent Horner-
Wadsworth-Emmons reaction with triethyl phosphonoacetate to produce (E)-α,β-enonate 
47 (Scheme 3), which was alkylated at C-20 to install C-21 methyl group.38 The 3β-
hydroxyl group and the olefin in B-ring was protected as an i-steroid ether 49, which 
allowed C-16-C-17 alkene to be transformed to epoxide 50 in presence of m-CPBA in good 
yield (76%).37 Epoxy-ester 50, when subjected to lithium hydroperoxide afforded 
dihydroxy-acid 51, which spontaneously cyclized to lactone 52 upon removal of solvent 
after purification.37 Treatment of 52 with isoamyl lithium installed the aliphatic side chain 
of OSW-1 in lactol 53, which was reduced with LiAlH4 to afford triol 54.
37 C-22 hydroxyl 
group was protected as benzyl ether 55. This aglycon acceptor 55 was joined with 
disaccharide trichloroacetimidates 25 in Schmidt glycosylation conditions to afford 
protected OSW-1 56 in moderate yield (59%).39 The C-22 benzyl ether was removed via 
hydrogenolysis to afford C-22 free hydroxyl, which was oxidized to C-22 keto with PDC.39 
Finally, all the protection groups (3α,5α-cyclo-6β-methoxy and TES ether groups) were 
removed with a soft Lewis acid – Pd(MeCN)2Cl2 at ambient temperature, or alternatively 
with catalytic amound of p-TsOH in dioxane/water at 75°C to afford the target OSW-1.39 
20 
The highlight of the synthesis reported by Morzycki’s group was the direct installation of 
16β,17α-diol motif without utilization of extremely toxic OsO4. 
 
Scheme 3. Total synthesis of OSW-1 by Morzycki's group. Scheme is adapted from 
Morzycki et al.40  
 
I.3.4 Total synthesis of OSW-1 by Yu’s group 
In 2005, Yu’s group from Chinese Academy of Sciences published another total 
synthesis of OSW-1, after their first one in 1999, described an aldol approach to the 
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stereoselective construction of the 16α,17α-dihydroxycholest-22-one structure (Scheme 
4).41 Bromination of acetylated trans-dehydroandrosterone 59 yielded 16α-bromine 60. C-
3 hydroxyl was re-protected as a TBS ether.41 Under alkaline condition, epimerization 
between 16α-bromide and its 16β isomer took place readily. The only 16β-bromide 
underwent SN2 displacement with hydroxide to stereospecifically formed 16α-ol 62 in 
great yield (95%).41 17-ketone 62 was subjected to aldol condensation condition with 
lithium E-enolate of ethyl propionate in THF at low temperature afford desired 20S-aldol 
adduct 63 in good yield (75%).41 Oxidation of C-16 alcohol in presence of 
tetrapropylammonium perruthenate (TPAP) and N-methyl-morpholine N-oxide (NMO) 
resulted in ketone 64 in excellent yield (93%). Reduction of ketone 64 with NaBH4/CeCl3 
led stereoselectively to 16β,17α-diol 66. However, only intramolecular lactonization 
product 65 could be isolated when this reaction was quenched at room temperature with 
addition of methanol and water. Ester 66 can be isolated when the reduction reaction was 
quenched at low temperature.41 Both lactone 65 and ester 66 can be converted to lactol 67 
in presence of isoamyl lithium. Reduction of lactol 67 with LiAlH4 resulted in triol 68, then 
C-22 hydroxyl group was selectively protected as 2-(azidomethyl)benzoyl (AZMB) ester 
in slightly low yielding reaction to afford aglycon acceptor 69.41 Schmidt glycosylation of 
69 and disaccharide donor 25 yielded protected OSW-1 70. The 22-O-AZMB was removed 
with PBu3 to provide 22-ol, which was subsequently oxidized to 22-keto with PDC in great 
yield (97%).41 Finally, the silyl protecting groups were removed in mild condition with 
Pd(MeCN)2Cl2 to achieve the target OSW-1. This synthetic route allowed also the 
synthesis of OSW-1 analogs with a C-22-ester side chain.41 
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Scheme 4. Total synthesis of OSW-1 by Yu's group. Scheme is adapted from Shi et al.41 
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I.3.5 Total synthesis of OSW-1 by Tsubuki’s group 
Tsubuki’s group at Hoshi University in Japan reported their unique synthesis of 
OSW-1 in 2008 through the means of Wittig rearrangement of allyl thiophenemethyl ether 
for the construction of (20S)-22-hydroxy steroidal side chain.42 The group aimed at 
synthesized OSW-1 analogs incorporating heterocyclic rings, such as thiophene and 
thiazole, at the side chain for SAR study of OSW-1 ( Scheme 5). Starting from the readily 
prepared allylic alcohol 73, thiophene-yl methyl ether 74 was prepared by etherification 
with (4-methyl-2-thiphene-yl) methyl bromide in great yield (92%).42 Treatment of 74 with 
t-BuLi in THF at low temperature gave [2,3]-rearranged product 75 (22α- and 22β-alcohols 
in ratio of 78:22) in moderate yield (59%).42 C-22 alcohol was oxidized to ketone 76 with 
Dess-Martin periodinane. Then the olefin in D-ring was subjected to syn-hydroxylation 
condition with OsO4..
42 The stereochemistry at C-16 alcohol of 77 was inverted through 
oxidation-stereoselective reduction sequence to afford the desired trans-diol 79, which 
acted as aglycon acceptor for Schmidt glycosylation reaction with disaccharide donor 25 
in presence of promoter TMSOTf.42 The glycosylated product 80 was obtained in good 
yield (72%). All the protecting groups (one MOM and three TES) were cleanly removed 
by treatment of 80 with TMSBr to give OSW-1 thiophene analog 81.42 Lastly, thiophene 
ring in 81 was reductively desulfurized with W-2 Raney Nickel under an atmosphere of 
hydrogen to give the target OSW-1 in 79% yield.42 
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 Scheme 5. Total synthesis of OSW-1 by Tsubuki's group. Scheme is adapted from 
Tsubuki et al.42 
 
I.3.6 Total synthesis of OSW-1 by Guo’s group 
Most recently, also in 2008, Guo’s group from Wayne State University in Michigan 
reported a total synthesis of OSW-1 that they carried out in gram scale (Scheme 6).43 trans-
dehydroandrosterone 6 underwent an aldol condensation with propanenitrile in presence of 
LDA at low temperature to obtain an epimeric mixture 82 with excellent yield after 
recrystallization.43 The aliphatic side chain was installed with a Grignard reagent in 
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refluxing benzene to give ketone 83. Protection of C-3 OH group as TBS ether, and C-22 
ketone as acetonide went smoothly to afford compound 11. From here, as seen from some 
previous OSW-1 syntheses, C 16-C-17 alkene underwent syn-dihydroxylation, then the C-
16 stereocenter was inverted to afford aglycon 14.43  
 The synthesis of L-arabinose moiety was slightly different from what had been 
done previously. Tetraacetylate-L-arabinose was converted to 1,2-O-(1-
methoxyethylidene)-α-L-arabinose 85 after deacetylation through bromide glycoside 
intermediate.43 Ortho ester 85 was p-methoxybenzylated regioselectively with the 
assistance of dibutyltin complex to afford 86, which was subjected to acetolysis to give 
arabinosyl acceptor 87. Schmidt glycosylation of 87 and xylosyl donor 43 with BF3·Et2O 
promotor afforded desired disaccharide moiety 88 in good yield (80%).43 Anomeric 
deacetylation of 88 with benzyl amine gave hemiacetal, which was immediately converted 
to trichloroacetimidate 89 for the last Schmidt glycosylation with aglycon acceptor 14 to 
yield protected OSW-1 90 in moderate yield (58%).43 Global deprotection of 90 was 
accomplished in two separate steps. First, TBS ether and acetonide protecting group were 
removed under mild acidic condition. Then PMB protecting group on disaccharide moiety 
were removed with DDQ to afford target OSW-1 with the overall yield of 6.4%.43 
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Scheme 6. Total synthesis of OSW-1 by Guo's group. Scheme is adapted from Xue et 
al.43 
  
 The synthetic strategies presented in this section (Section I.3) have provided 
background and insights for the derivatization of OSW-1 with selective affinity to OSBP 
or ORP4 proteins for  the development of anti-viral and anti-cancer therapeutic agents. 
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I.4 Personalized cancer therapy through Single-probe quantitative Single Cell 
Mass Spectrometry 
Personalized cancer medicine has emerged as a targeted and tailored treatment 
approach to maximize the treatment efficacy and reduce toxicity for individual patients.44 
The conventional administration of cancer chemotherapy drugs follows non-personalized 
protocols that bases on the patient’s physical characteristics, but does not take into account 
patient’s individual rate of drug metabolism. This is mainly due to the lack of bioanalytical 
capabilities to provide timely and meaningful feedback from the patient’s well-being 
throughout the course of treatment. In hope to advance personalized cancer therapy, Single-
probe quantitative Single Cell Mass Spectrometry (qSCMS) was developed from the 
collaboration of Dr. Burgett’s and Dr. Yang’s laboratories at the University of Oklahoma 
as a robust bioanalytical method that allows the MS analysis of the intracellular 
constituents of live single eukaryotic cells in real-time45. Furthermore, this technology is 
able to measure the absolute concentration of small molecules in the cellular contents of 
the single cells with the use of internal standards. Chapter IV will describe the synthesis 
and characterization of stable-isotopically labeled analogs of anti-cancer drugs (i.e. 
gemcitabine and cisplatin) as internal standards for Single-probe qSCMS studies of 
mammalian single cells. 
I.5 Precision medicine in myopia: development of selective inhibitor for 
retinaldehyde dehydrogenase enzymes 
The retinaldehyde dehydrogenase (RALDH) enzyme subfamily (including RALDH1, 
RALDH2, and RALDH3) catalyzes the irreversible oxidation of retinaldehyde to all-trans-
retinoic acid (atRA).46 Despite the importance of RALDH enzymes in embryonic 
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development and their disease relevance, there is currently no commercially available 
inhibitor that target these enzymes selectively. Applying structure-based design strategy, 
α,α-dichloro-all-trans-retinone (DAR) was designed based on the structure of the enzymes’ 
natural substrate retinaldehyde.47 Chapter V describes the synthesis, characterization and 
evaluation of first inhibitor, α,α-dichloro-all-trans-retinone (DAR), that exhibits selectivity 
for RALDH1, 2, and 3 proteins.  
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Chapter II : Synthesis and Characterization of Natural Product OSW-
1 Probe Analogs 
Abstract 
 Determining the molecular pharmacology of complex, bioactive natural products 
led to many important discoveries of cellular biology and biochemical processes. The 
elucidation of a natural product’s mechanism of action is often achieved through a use of 
its probe analogs. The probe analog compounds, which carry different functionalities such 
as biotin units or a radioactive-label, allow for the cellular function of a compound to be 
fully understood. Probe analogs can be used to determine the interactions of the natural 
product compound with its cellular target and to understand how the compound causes a 
cellular phenotype. This chapter focuses on the development of probe analogs of OSW-1, 
a natural product with potent anti-cancer and anti-viral activities. The design, syntheses 
and characterization of the following OSW-1 probe analogs will be reported: 1) a 
deuterated OSW-1 analog useful for mass spectrometry (MS) quantification of OSW-1;2) 
a biologically inactive OSW-1 analog useful for serving as a negative control compound, 
and 3) a series of OSW-1 analogs with an introduced amine linker that retains the biological 
activity of OSW-1 while allowing for direct further derivatization. These compounds were 
prepared through both the direct derivatization of the OSW-1 as well as through the total 
synthesis of the OSW-1 compound. This set of OSW-1 probe analogs are powerful reagents 
to fully elucidate the OSW-1 molecular pharmacology, cellular biology and potential for 
drug development.  
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II.1 Introduction 
Determining the biological activity of natural products compounds has profoundly 
advanced the understanding of cellular biology and inspired therapeutic drug development 
in a wide array of human diseases. Through investigation of many natural products’ 
mechanism of action, several biochemical processes were discovered and better 
understood. For example, discovery of natural product rapamycin’s target led to 
understanding of Target of Rapamycin (TOR) signaling pathway.48 Investigation into the 
biological effect of paclitaxel revealed the importance of targeting microtubules for anti-
cancer therapy.49 Natural products hold great potential to guide our understanding of many 
unique and complicated biochemical processes. Hence, research focused on the molecular 
pharmacology of complex and bioactive natural products will likely continue to expand 
our understanding in cellular biology and the development of new therapeutic agents. 
The identification of a natural product compound’s cellular target or the elucidation 
of its mechanism of action usually requires the use of analogs that can serve as biochemical 
probes. These probes are often derivatives of natural products with specific add-on features 
such as a biotin or radioactive-label, and the probe analogs are the used to define the 
connection between a compound and its reported phenotype.50 The production of a natural 
product compound through an adaptable and convergent total synthesis allows for the 
freedom and flexibility in designing analogs suitable for the desired studies. An adaptable 
synthetic approach that allows for modifications at multiple positions on the structure at 
different stages of the synthesis is ideal for incorporation functionalities useful for probing 
biological activities. With a set of probe analogs, the molecular pharmacology of a 
molecule could be investigated and its mechanism of action determined. 
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The OSW-1 natural product compound causes its cellular effects through 
interacting with oxysterol binding protein (OSBP) and OBSP-related protein 4 (ORP4)10, 
but the cellular mechanism of action through which OSW-1 interacting with OSBP and 
ORP4 causes the observed phenotype is not elucidated. OSW-1 has been the target of 
extensive total synthesis approaches (see Chapter I.3), and this research provides a 
foundation of the production of probe OSW-1 analogs. Additionally, reaction methodology 
can be used to directly derivatize the OSW-1 compound into new probe analogs. This 
chapter describes the design and synthesis of multiple OSW-1 probe analogs that will be 
employed to study how OSW-1 interacts its cellular targets OSBP and ORP4 and how the 
compound induces its cellular effects. 
II.2 Design of OSW-1 Analogs 
II.2.1 Deuterated OSW-1: internal standard for MS quantification of OSW-1 
A fundamental requirement to determine the biological activity of a compound is 
the ability to measure the concentration of a compound in a biological or cellular sample. 
Therefore, it is imperative to develop a methodology that can directly quantify the 
concentration of the small molecule and follow its metabolites inside the cells after 
treatment. Single Cell Mass Spectrometry (SCMS) with the Single-probe technology 
developed by Dr. Yang’s lab at University of Oklahoma has the ability to measure in real 
time the concentration of small molecules inside living, in-tact single cells with excellent 
sensitivity.45 Quantification of an analyte through mass spectrometry requires an internal 
standard-a molecule with slightly different molecular mass but yet similar in structure and 
ionization ability. This is usually accomplished through use of a stable isotopically-labeled 
analog compound. Herein, deuterated OSW-1 (or d-OSW-1, 108, Figure 5B) was 
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synthesized via total synthesis (Section II.3.1 through II.3.4). The deuterium label (-CD3) 
is introduced on the benzoate moiety of xylose sugar of OSW-1 (Figure 5B). 
 
Figure 5. A) OSW-1 retrosynthesis; B) d-OSW-1 and TBS-OSW-1 analogs 
 
II.2.2 TBS-OSW-1: a biologically inactive analog as a negative control compound 
Structural-activity-relationship (SAR) studies of OSW-1 revealed the importance 
of the C-3 hydroxyl group in its bioactivity.4 When the hydroxyl group was substituted 
with large groups, OSW-1’s bioactivity is significantly reduced.10 A key probe analog to 
evaluate bioactivity of OSW-1 and its analogs is a negative control compound - a 
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compound that is structurally highly similar to, but lacks the potent OSW-1 bioactivity. 
For this purpose, a sterically-large tert-butyldimethylsilyl (TBS) group was installed to 
deactivate the C-3 hydroxyl group in compound 112 (TBS-OSW-1, Figure 5B). The 
synthesis of this compound is reported in Section II.3.5. 
II.2.3 OSW-1 analogs with amine linker 
The ability to add structural features to a compound while fully retaining the 
biological activity is a useful approach to producing new probe analogs. Burgett et al. 
reported the synthesis and utilization of OSW-1 analogs with an introduced diamine linker, 
and one of the OSW-1-amine linker analog was key to identify the OSW-1 cellular target.10 
Following this report, OSW-1 analogs with a versatile amine linker were synthesized 
(Figure 6). Section II.3.6 describes the installation of the linker on the 3” or 4’’ position in 
the disaccharide moiety of OSW-1 through a carbamate functional group with an amine 
handle for further derivatization.  
 
Figure 6. OSW-1 analogs with amine linker 
 
With the free amine handle installed, the potent anti-cancer molecule OSW-1 can 
be conjugated to an antibody that specifically targets cancer cells, allowing the selective 
delivery of OSW-1 to cancer cells in the Antibody-Drug Conjugate approach (ADC). 
Besides the ability to be conjugated to antibodies, the amine functional group will pave the 
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way for synthesis of different OSW-1 analogs for various biological studies. A fluorescent 
tag could be attached through the linker to allow for the evaluation of OSW-1 localization 
in cell. On the other hand, OSW-1’s drug-like property can be enhanced by transforming 
the free amine to quaternary ammonium salt to increase its hydrophilicity.  
II.3 Results and discussion 
II.3.1 Synthesis of L-arabinose moiety of OSW-1 
With the OSW-1 aglycon moiety 14 (Scheme 11) already synthesized by Dr. Gopal 
Peddabudi (a former postdoctoral fellow in Dr. Burgett’s lab), the synthesis of deuterated 
OSW-1 started with the construction of disaccharide moiety from monosaccharide (L-
arabinose and D-xylose) pieces. 
The L-arabinose moiety was accessed in seven steps (Scheme 7) starting from L-
arabinose, with the sequence similar to Guo’s OSW-1 synthesis43, with an improved 
acetylation procedure and overall yield. L-arabinose was subjected to acetylation 
conditions to afford peracetylated product 34 (Scheme 7). Two acetylation conditions were 
investigated. The first condition consisted of acetic anhydride and used pyridine as the base 
and solvent. The work-up procedure for this condition was quite involved as saturated 
copper (II) sulfate solution was used to wash the organic phase multiple times to 
completely remove the pyridine. 1H NMR analysis of crude product revealed a complex 
mixture of products, which included the following regio- and stereo-isomers: α-, β-L-
arabinofuranoside 34a and α-, β-L-arabinopyranoside 34. The complicated product mixture 
and the use of toxic pyridine prompted the exploration of alternative method to achieve the 
peracetylated product. A report by Burns’ group at University of Louisville showed that 
acetylation reaction can be carried out in DCM as the solvent, with more benign triethyl 
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amine as the base and 4-(N, N-dimethylamino)pyridine (DMAP) as the catalyst.51 When 
this condition was used for the acetylation of L-arabinose, the 1H NMR of crude mixture 
showed mainly tetraacetyl-α-L-arabinopyranoside (>90%) and β-anomer as the minor 
product. The physical appearance of crude product differed vastly, from sticky and thick 
gel of the pyridine method to an easier-to-handle slight sticky solid of the 
triethylamine/DMAP method. Both acetylation methods proceeded smoothly with almost 
quantitative yield. 
The peracetylated L-arabinose was then transformed to bromo-glycoside 92, 
preparing the stage for formation of ortho ester 93 (Scheme 7). Treatment of 34 with a 
hydrobromic solution in acetic acid (33%) at ambient temperature overnight resulted in 
mainly 2,3,4-tri-O-acetyl-β-L-arabinopyranosyl bromide 92, due to the anomeric effect. 
When the mixture of tetraacetyl-α-, β-L-arabinofuranoside 34a and α-, β-L-
arabinopyranoside 34 was subjected to bromination condition, only thermodynamic 
product 92 was obtained. Bromo-glycoside 92 was converted to methyl ortho ester 93 in 
the presence of methanol, with 2,6-lutidine as the base and nitromethane as the solvent. 
Compound 93 was purified by flash chromatography with a triethyl amine additive to the 
eluent (3% NEt3 in hexanes) to prevent the degradation of ortho ester. With C-1 and C-2 
hydroxyl groups tied together in an ortho ester functionality, protecting groups on C-3 and 
C-4 hydroxyls can be manipulated. Deacetylation of 93 with a catalytic amount of sodium 
methoxide in methanol gave diol 85.  
The key step in the synthesis of L-arabinose moiety was the regioselective 
protection of C-4 hydroxyl, which was achieved in high yield and selectivity through the 
assistance of dibutyltin (IV) oxide. Diol 85 formed a stannylene acetal when it was heated 
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in reflux toluene in the presence of dibutyltin (IV) oxide (Scheme 7). It was postulated that 
the fluoride anion (from CsF) attacked tin atom of the stannylene acetal to form the 
pentacoordinated complex, which can reversibly dissociate into a highly reactive alkoxide 
ion to participate in p-methoxybenzylation with PMBCl.52 Only mono-PMB protected 86 
was observed, possibly due to the less sterically hindered C-4 hydroxyl of L-arabinose.43 
Compound 86 was directly subjected to acetolysis in glacial acetic acid to cleave the ortho 
ester, resulting in the desired glycosyl acceptor 87. When “wet” acetic acid was used 
(presence of water), a mixture of products was observed including a hemiacetal (hydroxyl 
group at C-1 instead of an acetyl group). Overall, the L-arabinose moiety was synthesized 
in seven steps with a 26% yield. 
 
Scheme 7. Synthesis of L-arabinose moiety 
II.3.2 Synthesis of D-xylose and disaccharide moieties of OSW-1 
While the L-arabinose moiety was prepared, the D-xylose moiety was also being 
assembled. Since the deuterium label was planned for the D-xylose moiety, the regular D-
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xylose moiety was synthesized first to pave the way for installation of the more expensive 
deuterated label (Scheme 8).  
 2,3,4-tri-O-acetyl-α-D-xylopyranosyl bromide 94 was synthesized employing the 
same reaction sequence that was used in the L-arabinose moiety synthesis (i.e. 
peracetylation followed by anomeric bromination). Thio ortho ester 39 arose from 
treatment of 94 with ethane thiol in presence of 2,6-lutidine and polar aprotic solvent 
nitromethane. With C-1 and C-2 hydroxyl groups incorporated in the thio ortho ester, 
manipulation of protecting groups was carried out on C-3 and C-4 hydroxyls to afford di-
PMB protected compound 40. Intramolecular ring opening promoted by zinc chloride at 
low temperature resulted in thioglycoside 41. Deacetylation of 41 revealed the C-2 
hydroxyl group in 96, this allowed for the installation of the biologically important 
benzoate moiety through a straight-forward esterification reaction. Dethiolation of 42 with 
N-bromosuccinimide (NBS) afforded hemiacetal 97, which was converted to glycosyl 
donor trichloroacetimidate 43 in good yield (80%). 
38 
 
Scheme 8. Synthesis of D-xylose moiety of OSW-1 
 
 With both acceptor and donor for the glycosylation reaction ready, the Schmidt 
glycosylation reaction was attempted and optimized. After various screening of 
temperature, amount of Lewis acid, ratio of donor and acceptor, the optimal condition was 
realized. Schmidt glycosylation of acceptor 87 (1.7 equiv) and donor 43 (1.0 equiv) with 
catalytic amount of Lewis acid BF3·Et2O (0.3 equiv) at low temperature afforded the 
desired 1→3 β-glycosidic linkage to assemble the disaccharide moiety of OSW-1 in 
moderate yield (70%) (Scheme 9). Even though donor 43 was set as the limiting reagent, 
it was never completely consumed based on TLC analysis of the reaction. Attempts to push 
the reaction to completion (higher temperature or more Lewis acid) resulted in the 
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degradation of the product. Presence of unreacted acceptor 87 in the crude reaction mixture 
added difficulty to purification process of the pure desired product 88 since both of them 
possessed similar polarity. At last, disaccharide 88 was purified away from acceptor 87 
with flash chromatography using the atypical mixture of acetone and benzene as the eluent.  
Disaccharide 88 was converted to disaccharide trichloroacetimidate 89 through two 
steps (Scheme 9). First, the acetyl group at the anomeric position was selectively removed. 
In Guo’s synthesis, this step was reported with benzyl amine 43. However, the reaction of 
88 with benzyl amine was found to be very sluggish and low yield. Morpholine was used 
as a replacement of benzyl amine in excess (8 equiv.) to afford the desired hemiacetal 98 
over 24-48 hours in moderate yield (74%). Hemiacetal 98 was converted to 
trichloroacetimidate 89 with treatment of trichloroacetonitrile and catalytic amount of 
DBU with decent yield (65%). 
 
Scheme 9. Synthesis of OSW-1 disaccharide moiety 
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II.3.3 Synthesis of deuterated disaccharide glycosyl donor of OSW-1 
With the OSW-1 disaccharide moiety having been successfully synthesized, and 
the reaction conditions optimized, efforts were then focused on incorporating a deuterium 
label to the disaccharide moiety, more specifically the benzoate moiety of D-xylose 
(Scheme 10). 4-methoxybenzoyl chloride-D3 (101) was readily synthesized from 
commercially available material with high yield. The hydroxyl group on methyl 4-
hydroxybenzoate was alkylated with iodomethane-D3 in presence of NaH to afford methyl 
4-methoxybenzoate-D3 99. Saponification of 99 in basic conditions gave carboxylic acid 
100, which was converted to 4-methoxybenzoyl-D3 chloride 101 by refluxing with thionyl 
chloride in good yield (85% over 3 steps). 
Esterification of thioglycoside 96 with benzoyl chloride 101 installed the deuterium 
label on D-xylose moiety. Dethiolation of 102 with NBS gave hemiacetal 103, then 
trichloroacetimidate formation afforded 104 as glycosyl donor in good yield. Glycosylation 
of 104 with arabinosyl acceptor 87 in Schmidt conditions yielded disaccharide 105. 
Disaccharide donor 106 was accessed in two steps: anomeric deacetylation in morphiline, 
and trichloroacetimidate formation.  
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Scheme 10. Synthesis of deuterated disaccharide glycosyl donor of OSW-1 
 
II.3.4 Synthesis of deuterated OSW-1 
The stage was set for assembling deuterated OSW-1 with both halves ready: 
deuterated disaccharide donor 106 and aglycon acceptor 14 (synthesized by Dr. Gopal 
Peddabudi- a former postdoctoral fellow) (Scheme 11). Schmidt glycosylation conditions 
to couple these moieties have been reported in almost all OSW-1 total syntheses to consist 
of Lewis acid trimethylsilyl trifluoromethanesulfonate (TMSOTf) in anhydrous DCM at 
low temperature.4 The reported yields for the glycosylation reaction ranged from moderate 
(58%) to good (72%)4, but this did not reflect the use of excess disaccharide moiety which 
required almost 20 steps to synthesize. With the materials ready, the glycosylation reaction 
to assemble d-OSW-1 commenced (Scheme 11). 
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Scheme 11. Synthesis of d-OSW-1 
 
First, the inverse addition procedure of glycosylation was investigated. The inverse 
procedure in glycosylation reaction was first introduced by Schmidt in 1991 to increase the 
reaction efficiency when reactive glycosyl donors were employed 53. Here, the glycosyl 
acceptor 14 was allowed to interact with the promoter TMSOTf before the reactive 
glycosyl trichloroacetimidate 106 was introduced. When this method was applied to 
glycosylation to assemble d-OSW-1, TLC analysis of the glycosyl donor 14 and TMSOTf 
mixture showed new spots (2 to 3 spots) with Rf values higher than acceptor 14, which 
suggested the presence of less polar side products. In presence of a strong Lewis acid such 
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as TMSOTf, it could be hypothesized that the acetonide protecting group in 14 was 
cleaved, exposing the C-22 ketone giving compound 109 (Figure 7). The C-16 hydroxyl 
group could then condense with the C-22 ketone to produce lactol 67 (Figure 7). Both 109 
and 67 seemed to be less polar than acceptor 14, and could be the side products observed 
in TLC analysis. These products were attempted to be purified and characterized, but due 
to the small scale, the 1H NMR spectrum did not give enough structural information, only 
that they were not the same as acceptor 14.  
 
Figure 7. Possible side products in glycosylation reaction to assemble d-OSW-1 
 
Addition of glycosyl donor 106 to the mixture of acceptor 14 and TMSOTf 
produced multiple new compounds on TLC analysis. Addition of more TMSOTf reagent 
in order to advance a stalled reaction led to some decomposition of the desired product. 
The main product was isolated and characterized to be the desired glycosylated product 
107 (Scheme 11) in low yield, along with a small amount of side product that showed 
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signals for both steroidal and disaccharide moieties on the 1H NMR spectrum. This side 
product, even though it was not characterized fully due to small quantity, was hypothesized 
to be ortho ester 110 (Figure 7). This product could have been formed when intermediate 
111 (Figure 7) was trapped by nucleophilic attack of acceptor 14. This intermediate 
resulted from the interaction of carbonyl oxygen of the C-2 acetate group and the oxonium 
ion formed after the trichloroacetimidate group left (neighboring group participation 
effect)54. Presence of 111 also explained the stereoselectivity of this glycosylation reaction. 
Due to the neighboring group participation of the C-2 acetate group, only β-glyosidic 
linkage was observed in product 107 (Scheme 11)54.  
In the inverse procedure, presence of only TMSOTf seemed to degrade acceptor 
14, so the glycosylation reaction was carried out in the normal procedure, in which the 
promoter was added to the mixture of glycosyl donor 106 and acceptor 14 at low 
temperature. This reaction condition gave a similar TLC profile as when it was carried out 
with the inverse procedure, but the observed amount of side product 67 and 109 (Figure 
7) was smaller, with the desired protected d-OSW-1 as the main product. Even though in 
published OSW-1 syntheses, the yield of this glycosylation reaction ranged from high 50% 
to low 70%; in my hands, this glycosylation reaction was low-yielding and gave a complex 
mixture of products. The relatively small scale of the reaction (between 2 to 20 µmol) due 
to the availability of both pieces added difficulties to separate and purify multiple products 
from the complex reaction mixture. In the end, the desired glycosylated product 107 was 
obtained in 25% (based on recovered starting material-borsm) yield to carry the synthesis 
of d-OSW-1 forward. 
45 
Intermediate compound 107 (Scheme 11) required two deprotection steps to 
produce deuterated OSW-1 analog. The p-methoxybenzyl ether protecting groups on the 
disaccharide moiety were cleaved oxidatively in the reaction with 2,3-dichloro-5,6-
dicyano-p-benzoquinone (DDQ). Then TBS ether and acetonide was removed in a mildly 
acidic aqueous condition containing bis(Acetonitrile)dichloropalladium (II) 
[Pd(MeCN)2Cl2] to afford the target d-OSW-1 108 in 35% yield after two steps and HPLC 
purification.  
 




d-OSW-1 108 was characterized by NMR and HR-MS (see Chapter appendix). The 
1H NMR spectrum of 108 was almost identical to that of OSW-1 (Figure 8). The singlet 
at 3.86 ppm that corresponded to the p-methoxy of benzoate moiety was absent in the 1H 
NMR of 108, since deuterium can’t be observed in proton’s resonance frequency. 
Furthermore, the chemical shift scales are the same for 2H and 1H, so when 108 was 
analyzed by 2H NMR, a singlet was observed at 3.86 ppm. This observation, along with 
high resolution mass spectrometry analysis, confirmed that the deuterium labeled was 
installed correctly on d-OSW-1.  
In conclusion, deuterated OSW-1 was successfully synthesized and characterized 
in a small quantity (~1.5 mg). This material has been used as the internal standard for 
Single Cell Mass Spectrometry, as it will be discussed in more details in Chapter III.  
II.3.5 Synthesis of TBS-OSW-1-a biologically inactive OSW-1 analog 
 
Scheme 12. Synthesis of TBS-OSW-1 
 
The biologically inactive OSW-1 analog,TBS-OSW-1 (112), was synthesized 
following the established procedure from Burgett’s report in 2011 (Scheme 12).10 OSW-1 
(1 equiv.) was treated with tert-butyldimethylsilyl trifluoromethanesulfonate (TBSOTf, 1.3 
equiv) in the presence of 2,6-lutidine as a base at 0°C for 15 minutes. Only one product 
was observed on the TLC plate, along with the starting OSW-1. When additional TBSOTf 
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(0.5 equiv) was added, side products started to emerge. After isolation and HPLC 
purification, the major product was characterized as TBS-OSW-1 112.  
The yield of the reaction was relatively low, but it was an acceptable outcome 
considering there were four hydroxyl groups that could undergo the etherification 
transformation (C-3 hydroxyl group, along with 3 hydroxyl groups on the disaccharide 
moiety). The controlled reaction condition (low temperature, limited amount of TBSOTf, 
short reaction time) allowed the most reactive and exposed hydroxyl group – C-3-OH to 
undergo the reaction selectively. The side products observed when additional TBSOTf was 
added could be attributed to other hydroxyl groups participating in the reaction when more 
TBSOTf was available.  
The TBS-OSW-1 was prepared as 10 mM stock solution in DMSO, aliquoted and 
passed on to the biochemists for utilization as negative control in biochemical assays.  
II.3.6 Synthesis of OSW-1 analogs with amine linker 
 
Scheme 13. Synthesis of diamine linker 
 
The introduction of the versatile amine linker to OSW-1 analogs that retain OSW-
1 bioactivity will allow for further derivatization of the analogs to produce different probes 
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for biological studies. The diamino linker was first synthesized for the preparation of this 
group of OSW-1 derivatives (Scheme 13). p-xylylene diamine is an excellent reagent 
because it possesses two amino functional groups that can participate in various chemical 
reactions making it easy to manipulate chemically. Compound 113, with one amine group 
capped with the tert-butyloxycarbonyl (Boc) protecting group underwent a stable 
allyloxycarbonyl (Alloc) protection at the remaining free amine group to afford bis-
protected amine 114 in moderate yield (77%). Then, the Boc group was removed in acidic 
condition with trifluoroacetic acid to reveal the free amine 115, which was converted to 
isocyanate 116 in presence of triphosgene in refluxing ethyl acetate. Compound 116 was 
used in the subsequence reaction without purification due to the instability of the isocyanate 
group. The isocyanate functional group served as the reactive handle to functionalize 
OSW-1. 
The linker 116 was installed on OSW-1 through a carbamate formation between 
the OSW-1 hydroxyl group and isocyanate on the linker (Scheme 14). The carbamate 
formation reaction proceeded smoothly to afford C-3’’ (117) and C-4’’ (118) carbamate in 
~30% borsm yield for each compound after preparative TLC and HPLC purifications. 
When more than 2 equivalents of isocyanate were used, bis-carbamate was observed. In 
presence of copper (I) chloride, only hydroxyl groups on the D-xylose moiety underwent 
the transformation. The C-3 hydroxyl group on the A ring of the steroid, being the most 
reactive hydroxyl group as observed in the synthesis of TBS-OSW-1, did not participate in 
this carbamate formation reaction. It was plausible that Lewis-acidic copper (I) chloride 
interacts with Lewis-basic and accessible C-3-OH group, which reduced the 
nucleophilicity of the hydroxyl group to react with the isocyanate moiety. Dr. Burgett had 
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observed that in absence of copper (I) chloride, the reaction of OSW-1 with isocyanate 116 
produced mainly carbamate at the C-3 hydroxyl. In addition, no carbamate formation on 
C-3’ of the L-arabinose moiety was observed. This group could be sterically unavailable 
in the OSW-1 structure, which could provide limited access for the interaction with the 
isocyanate linker. 
Removal of the Alloc group mediated by tetrakis(triphenylphosphine)palladium (0) 
[Pd(PPh3)4] and morpholine afforded free amines 119 and 120 in low (21%) to moderate 
yield (40%) (Scheme 14). The free amines had very limited solubility, which made 
handling difficult and possibly reduced the reaction yield. HPLC purification gave amines 
119 and 120 in analytical purity.  
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Scheme 14. Synthesis of OSW-1-linker derivatives 
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The OSBP-binding affinity of the amine analogs was evaluated through binding 
assays with OSBP to determine whether the addition of the linker affects the interaction of 
the compound and the target protein (Figure 9). These high through-put binding assays 
were performed by another member of the lab, Juan Nuñez. The binding affinity can be 
interpreted through inhibition constant, Ki value. The lower Ki value of a compound 
indicates that it binds to the protein with high affinity. Amine 119 (Figure 9B) with the 
linker attached to C-3’’ of xylose moiety showed the apparent Ki value of 40 nM, which 
was comparable with OSW-1 (29 nM) (Figure 9A). Amine 120, however, exhibited the 
apparent Ki value of 226 nM (Figure 9C), which was about 8-fold higher than the value 
obtained from OSW-1. Furthermore, the carbamate 117 also had a comparable Ki value 
with OSW-1 (Figure 9D). Taken together, the information suggested that C-3’’ position 
on the D-xylose moiety could be solvent-exposed while bound the OSBP and ORP4 
proteins, and therefore these proteins can tolerate the introduction of a sterically bulky 
group without compromising the potent bioactivity of OSW-1.  
The free amine, after being installed on OSW-1 with the linker, can be transformed 
to analogs for different purposes. The primary goal for installing the amine linker was to 
develop OSW-1 into an Antibody-Drug-Conjugate. The amine can be used to conjugate 
the OSW-1 molecule with antibodies that are specific to the target cancer type. 
Furthermore, the amine can be linked to a fluorescent tag that can be used to study the 
localization of the molecule once it gets inside the cell. Being so versatile, the free amine 
could also be converted to a quaternary ammonium salt to increase the hydrophilicity of 
the saponin OSW-1. 
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Figure 9. Representative Inhibition Binding Curves of OSBP for the OSW-1 compound 




A set of OSW-1 probe analogs including deuterated OSW-1, TBS-OSW-1 and 
OSW-1 analogs with an amine linker were successfully synthesized and characterized. 
Deuterated OSW-1 was utilized as internal standard to timely quantify the concentration 
of OSW-1 inside individual treated cells. TBS-OSW-1 acted as a negative control and 
confirmed the SAR of the C-3 hydroxyl group of OSW-1. OSW-1 analog 119 (Scheme 
14) with the amine linker on the C-3’’ position retained the bioactivity of OSW-1 and can 
be further derivatized for different purposes. These OSW-1 probe analogs will be powerful 
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reagents to help elucidate the molecular pharmacology and cellular biology of the OSW-1 
compound in cells.  
II.5 Experimental section 
II.5.1 General methods 
All reactions were performed in oven-dried glassware under a positive pressure of 
nitrogen unless noted otherwise. Flash column chromatography was performed as 
described by Still et al.55 employing E. Merck silica gel 60 (230-400 mesh ASTM). TLC 
analyses and preparative TLC (pTLC) purification was performed on 250µm Silica Gel 60 
F254 plates purchased from EM Science and Fluka Analytical. All solvents and chemicals 
were used as purchased without further purification. Solvents used in the reactions were 
collected under nitrogen from a Pure Solv 400-5-MD Solvent Purification System 
(Innovative Technology). Infrared spectra were recorded on a Shimadzu IRAffinity-1 
instrument, or Bruker Tensor 27 spectrometer, and IR spectra peaks are reported in terms 
of frequency of absorption (cm-1). 1H and 13CNMR spectra were recorded on VNMRS 300, 
VNMRS 400, VNMRS 500 or VNMRS 600 MHz-NMR Spectrometer. Chemical shifts for 
proton and carbon resonances are reported in ppm (δ) relative to the residual proton or the 
specified carbon in chloroform (δ 7.26, proton; 77.16, carbon). High-resolution mass 
spectrometry (HRMS) analysis was performed using Agilent 6538 high-mass-resolution 
QTOF mass spectrometer. HPLC purification was performed on Shimadzu LCMS 2020 
system [LC-20AP (pump), SPD-M20A (diode array detector), LCMS-2020 (mass 
spectrometer)]. Semi-preparative HPLC purification was performed using Phenomenex 
Luna C-18(2) column, 5µm particle size (250 mm x 4.6 mm), supported by Phenomenex 
Security Guard cartridge kit C18 (4.0 mm x 3.0 mm); Phenomenex Luna C-8(2) column, 
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5µm particle size (250 mm x 4.6 mm), supported by Phenomenex Security Guard cartridge 
kit C8 (4.0 mm x 3.0 mm) and HPLC-grade solvents. 
II.5.2 Compound data 
 
Compound 34 was synthesized as describe previously.51 A suspension of L-arabinose (5.0 
g, 33.3 mmol), DMAP (406.8 mg, 3.33 mmol), triethylamine (37.1 mL, 266.4 mmol) in 
anhydrous DCM (25 mL, 1.33 M) was stirred at 0°C for 30 minutes. To the reaction 
mixture was then added Ac2O (22 mL, 233.1 mmol) dropwise slowly over 1 hour using an 
addition funnel. The mixture was stirred at 0°C for 1 hour, then at RT overnight to afford 
a clear, dark yellow solution. The reaction progress was monitored by TLC (10% 
MeOH/DCM, KMnO4 stain). The reaction mixture was cooled to 0°C for 20 minutes, 
quenched with chilled DI H2O (50 mL), stirred at 0°C for additional 30 minutes. The bi-
phasic, yellow mixture was transferred to a separatory funnel, extracted with DCM (40 mL 
x 3). The combined organic phase was washed with 1N HCl (40 mL x 4), chilled DI H2O 
(30 mL x 3), sat’d NaHCO3 (30 mL x 3), chilled DI H2O (30 mL x 2), and brine (50 mL), 
dried over Na2SO4, and filtered. The solvent was removed in vacuo to afford desired 
product 34 as a light yellow, sticky solid (10.6 g). The desired product was used in 
subsequent reaction without further purification. 1H NMR (500 MHz, Chloroform-d) δ 6.35 
(d, J = 3.1 Hz, 1H), 5.42 – 5.32 (m, 3H), 4.06 (dd, J = 12.9, 1.5 Hz, 1H), 3.82 (dd, J = 13.2, 
2.0 Hz, 1H), 2.15 (d, J = 1.6 Hz, 6H), 2.02 (s, 6H). 13C NMR (126 MHz, Chloroform-d) δ 
170.4, 170.3, 170.0, 169.3, 90.3, 68.6, 67.2, 66.8, 62.9, 21.0, 21.0, 20.84, 20.7. See 
Appendix for NMR spectra. 
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Compound 92 was synthesized as describe previously. 56 To a solution of 34 (10.6 g, 33.3 
mmol) in anhydrous DCM (33.5 mL, 1M) at 0°C was added HBr in AcOH solution (18.1 
mL, 99.9 mmol) dropwise over 1 hour using an addition funnel. The reaction mixture was 
stirred at 0°C for 1 hours, then at RT for 3 hours. The reaction progress was monitored by 
TLC (5% MeOH/DCM, KMnO4 stain). After completion, the reaction mixture was 
quenched with DI H2O (50 mL). The organic phase was then added to chilled, sat’d 
NaHCO3 solution (50 mL). The mixture was stirred for 10 minutes. The aqueous phase 
was extracted with DCM (30 mL x 2). The combined organic phase was washed with sat’d 
NaHCO3 solution (30 mL x 4), DI H2O (40 mL), and brine, dried over Na2SO4, and filtered. 
The solvent was removed in vacuo to afford desired product 92 as a light-yellow solid (10.1 
g, 89%). The desired product was used in subsequent reaction without further purification. 
1H NMR (500 MHz, Chloroform-d) δ 6.69 (d, J = 3.8 Hz, 1H), 5.44 – 5.35 (m, 2H), 5.08 
(ddd, J = 11.7, 3.9, 1.5 Hz, 1H), 4.20 (dt, J = 13.2, 1.0 Hz, 1H), 3.93 (dd, J = 13.4, 1.8 Hz, 
1H), 2.15 (s, 3H), 2.11 (s, 3H), 2.02 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 170.2, 
170.2, 169.9, 89.8, 68.1, 68.0, 67.7, 64.8, 21.0, 20.9, 20.8. See Appendix for NMR spectra. 
 
Compound 93 was synthesized as describe previously.56 To a clear, yellow solution of 92 
(10.1 g, 29.8 mmol) in nitromethane (30 mL, 1M) at RT under N2 was added 2,6-lutidine 
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(8.7 mL, 74.7 mmol) and anhydrous MeOH (8.5 mL, 209.0 mmol). The reaction mixture 
was stirred at RT, the reaction progress was monitored by TLC (60% EtOAc/hexanes with 
3% NEt3, UV, CAM stain, TLC plates were pre-eluted before sample spotted). The reaction 
was completed after 20 hours based on TLC. The reaction was quenched with sat’d 
NaHCO3 solution (30 mL). The aqueous phase was extracted with DCM (30 mL x 3). The 
combined organic phase was washed with DI H2O (50 mL x 3), sat’d CuSO4 solution (to 
removed 2,6-lutidine, continuous washing until CuSO4 solution color remained 
unchanged), DI H2O (50 mL), brine, and dried over Na2SO4, and filtered. The solvent was 
removed in vacuo to afford crude mixture as an orange/brown, clear oil (7.4 g). The crude 
mixture was purified by flash chromatography (Biotage, 50g column x 3, EtOAc/hexanes 
with 3% NEt3 gradient -7% to 60%) to afford the desired mixture of ortho esters 93 as a 
clear, light-yellow gel (6.6 g, 76 %). 1H NMR spectrum of 93 showed a mixture of two 
isomers. 1H NMR (500 MHz, Chloroform-d) δ 5.56 (d, J = 3.9 Hz, 1H), 5.41 – 5.36 (m, 
1H-minor isomer), 5.33 – 5.29 (m, 1H-minor isomer), 5.29 – 5.22 (m, 2H), 5.16 (dd, J = 
9.5, 7.0 Hz, 1H-minor isomer), 5.02 (dd, J = 9.4, 3.5 Hz, 1H-minor isomer), 4.32 (d, J = 
7.0 Hz, 1H-minor isomer), 4.29 (dd, J = 5.1, 3.9 Hz, 1H), 4.16 (d, J = 1.5 Hz, 1H-minor 
isomer), 4.09 – 4.05 (m, 1H-minor isomer), 4.02 (dd, J = 12.4, 4.5 Hz, 2H), 3.79 – 3.75 (m, 
1H-minor isomer), 3.73 (dd, J = 12.5, 4.9 Hz, 1H), 3.62 (dd, J = 13.1, 1.8 Hz, 1H-minor 
isomer), 3.48 (s, 1H), 3.36 (s, 1H), 3.27 (s, 3H), 2.14 – 2.08 (m, 5H), 2.08 – 2.03 (m, 5H), 
2.03 – 1.99 (m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 170.4, 170.3, 169.9, 169.9, 
123.2, 102.0, 97.3, 96.7, 76.1, 75.6, 70.4, 70.0, 69.3, 69.2, 67.8, 66.7, 66.2, 63.3, 63.1, 62.5, 




Compound 85 was synthesized as describe previously.56 To a clear, light-yellow solution 
of 93 (6.6 g, 22.8 mmol) in anhydrous MeOH (76 mL, 0.3 M) was added NaOMe (61.6 
mg, 1.14 mmol) at RT. The reaction mixture was stirred at RT under N2, the reaction 
progress was monitored by TLC (50% EtOAc/hexanes with 3% NEt3, UV, CAM stain, 
TLC plates were pre-eluted before sample spotted). The reaction was completed after 6 
hours based on TLC. The solvent was removed in vacuo to afford the desired mixture of 
isomers 85 as a clear, light-yellow gel (4.4 g, 94%). The desired product was used in the 
subsequent reaction without further purification. 1H NMR (600 MHz, Chloroform-d) δ 5.52 
(d, J = 3.6 Hz, 1H), 5.33 (d, J = 3.6 Hz, 1H-minor isomer), 4.29 (t, J = 3.6 Hz, 1H), 4.21 (t, 
J = 3.7 Hz, 0H), 4.14 (t, J = 3.7 Hz, 1H), 4.12 – 4.08 (m, 1H), 4.05 (dt, J = 7.6, 4.0 Hz, 1H-
minor isomer), 4.01 – 3.98 (m, 1H), 3.96 (dd, J = 12.8, 2.5 Hz, 1H-minor isomer), 3.92 (d, 
J = 2.7 Hz, 1H-minor isomer), 3.79 (dd, J = 12.0, 4.6 Hz, 1H), 3.71 (dd, J = 11.7, 7.4 Hz, 
1H-minor isomer), 3.67 (dd, J = 11.8, 6.9 Hz, 1H), 3.62 (dd, J = 4.4, 1.6 Hz, 1H), 3.56 – 
3.48 (m, 6H), 3.47 (s, 1H), 3.40 (s, 1H-minor isomer), 3.37 (s, 1H), 3.28 (s, 3H). 13C NMR 
(151 MHz, Chloroform-d) δ 123.2, 122.8, 104.4, 96.9, 95.5, 78.7, 78.6, 73.0, 71.5, 69.0, 
68.5, 68.3, 66.2, 65.9, 65.3, 63.3, 63.1, 57.2, 50.9, 50.3, 50.0, 23.8, 23.5. See Appendix 
for NMR spectra. 
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Compound 86 was synthesized as describe previously.56 To a solution of 85 (3.3 g, 16.1 
mmol) in anhydrous toluene (60 mL, 0.27 M) was added dibutyltin (IV) oxide (4.22 g, 
16.96 mmol). The reaction mixture was heated under reflux for 3 hours using a Dean Stark 
trap to remove water. The solvent was removed in vacuo to afford crude mixture as a light 
brown, waxy solid. To the flask containing this crude mixture was added CsF (4.5 g, 29.8 
mmol), KI (4.0 g, 23.9 mmol) and anhydrous DMF (32.3 mL, 0.5 M). The reaction mixture 
was then cooled to 0°C. To the reaction mixture was added p-methoxybenzyl chloride 
solution (2.6 mL, 19.2 mmol, dissolved in 5 mL DMF) dropwise. The reaction mixture was 
stirred at 0°C for 2 hours, then at RT overnight. The reaction progress was monitored by 
TLC (60% EtOAc/hexanes with 3% NEt3, UV, CAM stain, TLC plates were pre-eluted 
before sample spotted). The reaction was completed after 16 hours by TLC. The reaction 
mixture was diluted with DCM (30 mL), washed with DI H2O (30 mL). The aqueous phase 
was extracted with DCM (10 mL x 2). The combined organic phase was washed with DI 
H2O (20 mL x 4), brine (20 mL x 2), dried over Na2SO4, and filtered. The solvent was 
removed in vacuo to afford crude mixture as white solid suspension in yellow oil (8.0 g). 
The crude mixture was purified by flash chromatography (Biotage, 50g column x 3, 
EtOAc/hexanes with 3% NEt3 gradient -15% to 60%) to afford the desired mono-PMB 
protected sugar 86 as an off-white, waxy solid (3.28 g, 63 % over 2 steps). 1H NMR (500 
MHz, Chloroform-d) δ 7.28 – 7.23 (m, 2H), 6.92 – 6.86 (m, 2H), 5.49 (d, J = 3.0 Hz, 1H), 
5.27 (d, J = 3.0 Hz, 1H-minor isomer), 4.55 (s, 2H), 4.29 (dq, J = 6.5, 3.2 Hz, 2H), 4.07 (t, 
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J = 3.1 Hz, 1H-minor isomer), 3.81 (s, 3H), 3.79 – 3.71 (m, 2H), 3.67 (dd, J = 10.9, 7.5 Hz, 
1H), 3.36 (s, 1H), 3.28 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 159.7, 129.6, 129.6, 
129.5, 123.0, 114.2, 96.8, 94.8, 78.5, 78.1, 72.2, 71.8, 71.6, 71.5, 66.8, 66.2, 60.3, 60.2, 
55.4, 49.9, 24.3, 23.8. See Appendix for NMR spectra. 
 
Compound 87 was synthesized as describe previously.43 To a RBF containing 86 (1.58 g, 
4.8 mmol) under N2 was added glacial AcOH (9 mL) at RT. The clear, colorless solution 
was stirred at RT. The reaction progress was monitored by TLC (60% EtOAc/hexanes with 
3% NEt3, UV, CAM stain, TLC plates were pre-eluted before sample spotted; TLC plates 
were placed under vacuum after sample spotted to reduce streaking). After 40 minutes, the 
reaction was completed base on TLC. The reaction mixture was diluted with EtOAc (50 
mL). The organic phase was washed with DI H2O (until the aqueous phase was not acidic 
anymore by pH paper), brine, dried over Na2SO4, and filtered. The solvent was removed 
in vacuo to afford crude mixture as off-white, waxy solid (1.4 g). The crude mixture was 
purified by flash chromatography (Biotage, 50g column, EtOAc/hexanes gradient -30% to 
100%) to afford the desired product 87 as an off-white, waxy solid (1.14 g, 66 %). 1H NMR 
(500 MHz, Chloroform-d) δ 7.27 (d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.5 Hz, 2H), 5.59 (d, J = 
6.6 Hz, 1H), 5.11 (dd, J = 7.9, 6.7 Hz, 1H), 4.66 (d, J = 11.4 Hz, 1H), 4.48 (d, J = 11.4 Hz, 
1H), 4.08 (dd, J = 12.8, 3.7 Hz, 1H), 3.81 (s, 3H), 3.79 – 3.71 (m, 2H), 3.53 (dd, J = 12.9, 
1.9 Hz, 1H), 2.11 (s, 3H), 2.09 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 170.3, 169.6, 
165.1, 129.7, 129.4, 114.8, 92.1, 74.0, 71.5, 71.4, 70.7, 62.4, 55.5, 26.1, 21.1, 21.0. See 
Appendix for NMR spectra. 
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Compound 38 was synthesized as describe previously.43 To a mixture of D-xylose (5.0 g, 
33.3 mmol) in pyridine (48.0 mL, 0.7 M) was added Ac2O (18.9 mL, 199.8 mmol) fast 
dropwise under N2. The reaction mixture was stirred at RT. The reaction progress was 
monitored by TLC (10% MeOH/DCM, KMnO4 stain). After 2 hours, the reaction was 
completed based on TLC. The reaction was quenched with DI H2O (3 mL), neutralized 
with sat’d NaHCO3 solution (160 mL), extracted with EtOAc (40 mL x 3). The organic 
phase was washed with sat’d NaHCO3 solution (50 mL x 3), sat’d CuSO4 solution (washed 
until the color of CuSO4 remained the same to remove pyridine), brine (50 mL x 2), dried 
over Na2SO4, and filtered. The solvent was removed in vacuo to afford desired products 38 
(a mixture of α and β-furanose and α and β-pyranose) as a clear, light yellow thick gel (10.1 
g, 95 %). 1H NMR (500 MHz, Chloroform-d) δ 6.25 (d, J = 3.7 Hz, 1H), 5.71 (d, J = 6.9 
Hz, 1H), 5.45 (t, J = 9.8 Hz, 1H), 5.19 (t, J = 8.3 Hz, 1H), 5.05 – 4.99 (m, 3H), 5.00 – 4.94 
(m, 1H), 4.16 – 4.08 (m, 1H), 3.92 (dd, J = 11.2, 5.9 Hz, 1H), 3.73 – 3.67 (m, 1H), 3.52 
(dd, J = 12.0, 8.5 Hz, 1H), 2.16 (s, 3H), 2.12 – 2.07 (m, 3H), 2.05 – 2.02 (m, 12H), 2.01 (s, 
3H). See Appendix for NMR spectra. 
 
Compound 94 was synthesized as describe previously.43 To a solution of 38 (9.86 g, 31.0 
mmol) in anhydrous DCM (140 mL, 0.22M) at 0°C under N2 was added HBr in AcOH 
solution (16.3 mL, 30% w/v, 93.0 mmol) dropwise over 30 minutes. The reaction mixture 
was stirred at 0°C for 1.5 hours, then at RT for 2.5 hours. The reaction progress was 
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monitored by TLC (5% MeOH/DCM, KMnO4 stain). The reaction was completed after 4 
hours based on TLC. The reaction mixture was washed with DI H2O (75 mL). The aqueous 
phase was extracted with DCM (50 mL x 3). The combined organic phase was washed 
with sat’d NaHCO3 solution (50 mL x 3), brine (50 mL x 2), dried over Na2SO4, and 
filtered. The solvent was removed in vacuo to afford desired product 94 as a white solid 
(9.4 g, 89%). 1H NMR (300 MHz, Chloroform-d) δ 6.58 (d, J = 4.0 Hz, 1H), 5.56 (t, J = 
9.8 Hz, 1H), 5.04 (ddd, J = 10.9, 9.6, 6.0 Hz, 1H), 4.77 (dd, J = 9.9, 4.0 Hz, 1H), 4.05 (dd, 
J = 11.4, 6.0 Hz, 1H), 3.88 (td, J = 11.2, 0.7 Hz, 1H), 2.12 – 2.08 (m, 3H), 2.08 – 2.04 (m, 
6H). See Appendix for NMR spectra. 
 
Compound 39 was synthesized as describe previously.43 To a solution of 94 (14.1 g, 41.5 
mmol) in anhydrous CH3NO2 (75.0 mL, 0.55 M) at RT under N2 was added EtSH (6.14 
mL, 82.9 mmol) and 2,6-lutidine (9.66 mL, 82.9 mmol) slowly. The reaction mixture was 
stirred at RT. The reaction progress was monitored by TLC (30% EtOAc/hexanes with 3% 
NEt3, TLC plates were pre-eluted before sample spotting). After 24 hours, the reaction was 
completed based on TLC. The reaction was quenched with sat’d NaHCO3 solution (30 
mL). The reaction mixture was diluted with DCM (70 mL), washed with DI H2O (50 mL). 
The aqueous phase was extracted with DCM (50 mL x 3). The combined organic phase 
was washed with sat’d CuSO4 solution (washed until the color of CuSO4 remained the 
same to remove 2,6-lutidine), brine, dried over Na2SO4, and filtered. The solvent was 
removed in vacuo to afford desired product 39 as a yellow, thick gel (12.87 g, 95%). The 
product was used in the subsequent reaction without further purification, but alternatively, 
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the product can be purified by silica gel column chromatography with EtOAc/hexanes with 
3% NEt3 gradient. 
1H NMR (300 MHz, Chloroform-d) δ 5.58 (d, J = 4.8 Hz, 1H), 5.24 (t, 
J = 2.6 Hz, 1H), 4.89 (dddd, J = 9.3, 6.4, 2.7, 1.1 Hz, 1H), 4.38 (ddd, J = 4.8, 2.6, 1.1 Hz, 
1H), 3.95 (dd, J = 11.9, 6.4 Hz, 1H), 3.62 (ddd, J = 11.8, 8.5, 0.6 Hz, 1H), 2.62 (q, J = 7.5 
Hz, 2H), 2.12 (s, 3H), 2.08 (s, 3H), 1.95 (s, 3H), 1.25 (t, J = 7.5 Hz, 3H). See Appendix 
for NMR spectra. 
 
Compound 95 was synthesized as describe previously.43 To a clear, light-yellow solution 
of acetylated thio ortho ester 39 (5.74 g, 17.9 mmol) in anhydrous MeOH (110 mL, 0.16 
M) at 0˚C under N2 was added NaOMe (48.3 mg, 0.893 mmol) dissolved in MeOH (9 mL) 
slowly. The reaction mixture was stirred at RT; the reaction progress was monitored via 
TLC (30% EtOAc/hexanes with 3% NEt3, TLC plates were pre-eluted before sample 
spotting). The reaction mixture appearance did not change. After 2 hours, the reaction was 
completed based on TLC. The solvent was removed in vacuo to afford desired product 95 
as a yellow oil, which turned into a yellow waxy solid under high vacuum (4.0g, 95% 
yield). 1H NMR (500 MHz, Chloroform-d) δ 5.50 (d, J = 3.5 Hz, 1H), 4.31 (td, J = 3.5, 1.1 
Hz, 1H), 4.16 (s, 1H), 3.96 (dd, J = 12.0, 3.3 Hz, 1H), 3.76 – 3.70 (m, 1H), 3.70 – 3.63 (m, 




4-methoxybenzyl chloride (PMB-Cl): To a 100mL-RBF was added 4-methoxybenzyl 
alcohol (20.79 g, 143.6 mmol), a stir bar, 37% HCl solution (~38 mL). The flask was sealed 
and vented with a needle. The reaction mixture was biphasic, one was milky white and the 
other one was clear, light yellow. The reaction mixture was stirred at RT the reaction 
progress was monitored by TLC (30% EtOAc/hex with NEt3). After 1.5hr, the reaction was 
completed based on the absence of SM on TLC. To the reaction mixture was added hexane 
(50 mL) and DI H2O (50mL). The aqueous layer was extracted with hexane (50 mL x 2). 
The combined organic layer was washed with DI H2O (50 mL x 3), dried with Na2SO4, 
and concentrated in vacuo to afford desired. product as a clear oil (22 g, 97% yield). The 
product was stored at -20˚C with K2CO3 as a stabilizer. The NMR data agreed with the 
published reference found on Sigma-Aldrich website. 1H NMR (400 MHz, Chloroform-d) 
δ 7.36 – 7.31 (m, 2H), 6.92 – 6.87 (m, 2H), 4.58 (s, 2H), 3.82 (s, 3H). 
 
Compound 40 was synthesized as describe previously.43 To a clear, yellow solution of de-
protected thio ortho ester 95 (1.4 g, 5.92 mmol) in anhydrous DMF (30 mL, 0.2 M) at RT 
under N2 atmosphere was wadded NaH (1.02 g, 23.7 mmol, 60% suspension in mineral 
oil). The cloudy, grayish mixture was stirred at RT for 10 minutes, then PMB-Cl solution 
(2.3 g, 14.8 mmol, diluted in 10 mL anhydrous DMF) was added dropwise. The reaction 
mixture was stirred at RT; the reaction progress was monitored by TLC (30% 
EtOAc/hexanes with 3% NEt3, TLC plates were pre-eluted before sample spotting). After 
~ 5 hours, no PMB-Cl was observed on TLC. To the reaction was added more PMB-Cl 
(0.58 g, 3.7 mmol, dissolved in 2 mL DMF). After 6 hours, the reaction was completed 
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based on TLC. The reaction was quenched with sat’d NaHCO3 solution (40 mL). The 
aqueous phase was extracted with EtOAc (30 mL x 3). The combined organic phase was 
washed with brine, dried over Na2SO4, filtered, and the solvent was removed in vacuo to 
afford crude mixture. The mixture was purified through silica gel column chromatography 
(Biotage, 50 g column x 2, EtOAc/hexanes with 3% NEt3 gradient) to afford the desired 
PMB-protected thio ortho ester 40 (2.0 g, 70.8 %). 1H NMR (500 MHz, Chloroform-d) δ 
7.29 – 7.24 (m, 2H), 7.23 – 7.19 (m, 2H), 6.91 – 6.84 (m, 4H), 5.60 (d, J = 5.1 Hz, 1H), 
4.63 – 4.58 (m, 1H), 4.55 – 4.49 (m, 2H), 4.48 – 4.42 (m, 2H), 3.84 (dd, J = 4.1, 2.7 Hz, 
1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.77 (dd, J = 11.2, 5.7 Hz, 1H), 3.65 (ddd, J = 9.8, 5.6, 4.1 
Hz, 1H), 3.56 (dd, J = 11.2, 9.5 Hz, 1H), 2.62 (q, J = 7.5 Hz, 2H), 1.91 (s, 3H), 1.26 (t, J = 
7.4 Hz, 3H). See Appendix for NMR spectra. 
 
Compound 41 was synthesized as describe previously.43 To a solution of 40 (2.1 g, 4.41 
mmol) in anhydrous DCM (18 mL, 0.25 M) at -78°C was added ZnCl2 solution (40 mg, 
0.29 mmol, dissolved in 2 mL anhydrous THF). The clear, light yellow solution was stirred 
at - 78°C for 45 minutes, then at 0°C for 2h15m. The reaction progress was monitored by 
TLC (30% EtOAc/hexanes with 3% NEt3, TLC plates were pre-eluted before sample 
spotting). After 3 hours, the reaction mixture was warmed up to RT, diluted with DCM (50 
mL), washed with sat’d NH4Cl solution (40 mL), sat’d NaHCO3 solution (40 mL), and DI 
H2O (40 mL). The combined aqueous phase was back extracted with DCM (10 mL x 2). 
The combined organic phase was washed with brine, dried over Na2SO4, and filtered. The 
solvent was removed in vacuo to afford crude product 41 as a tan, thick gel (2.06 g, 98%). 
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The crude product was used in the subsequent reaction without further purification. 1H 
NMR (500 MHz, Chloroform-d) δ 7.25 – 7.19 (m, 4H), 6.90 – 6.83 (m, 4H), 4.92 (dd, J = 
9.1, 8.3 Hz, 1H), 4.74 (d, J = 11.2 Hz, 1H), 4.65 – 4.60 (m, 2H), 4.53 (d, J = 11.3 Hz, 1H), 
4.36 (d, J = 9.1 Hz, 1H), 4.02 (dd, J = 11.6, 4.9 Hz, 1H), 3.80 (d, J = 1.0 Hz, 6H), 3.61 
(ddd, J = 9.3, 8.3, 4.9 Hz, 1H), 3.55 (t, J = 8.3 Hz, 1H), 3.24 (dd, J = 11.6, 9.4 Hz, 1H), 
2.71 – 2.59 (m, 2H), 2.01 (s, 3H), 1.23 (t, J = 7.5 Hz, 3H). See Appendix for NMR spectra. 
 
Compound 96 was synthesized as describe previously.43 To a mixture of 41 (2.06 g, 4.32 
mmol) in anhydrous MeOH (22 mL, 0.2 M) at RT under N2 was added NaOMe (94 mg, 
1.73 mmol). The reaction mixture was stirred at RT; the reaction progress was monitored 
by TLC (30% EtOAc/hexanes with 3% NEt3). After 14 hours, the reaction as not 
completed, so to the reaction mixture was added more NaOMe (94 mg, 1.73 mmol). After 
38 hours, the reaction was completed based on TLC. The solvent was removed to afford 
crude mixture, which was purified by silica gel column chromatography to afford desired 
product 96 as a white solid (1.47 g, 78.3 %). 1H NMR (400 MHz, Chloroform-d) δ 7.32 – 
7.27 (m, 2H), 7.25 – 7.20 (m, 2H), 6.90 – 6.84 (m, 4H), 4.76 – 4.69 (m, 2H), 4.63 – 4.51 
(m, 3H), 4.11 (dd, J = 11.9, 3.6 Hz, 1H), 3.81 (s, 6H), 3.59 – 3.48 (m, 2H), 3.38 – 3.31 (m, 
1H), 2.90 (d, J = 4.5 Hz, 1H), 2.68 (qd, J = 7.4, 5.0 Hz, 2H), 1.29 (t, J = 7.4 Hz, 3H). 13C 
NMR (101 MHz, Chloroform-d) δ 159.6, 159.5, 130.6, 130.0, 129.7, 129.7, 114.0, 114.0, 
86.5, 80.9, 76.3, 74.0, 72.5, 71.7, 65.1, 55.4, 25.2, 15.4. See Appendix for NMR spectra. 
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Compound 42 was synthesized as describe previously.43 To a mixture of 96 (970.0 mg, 
2.23 mmol), DMAP (27.3 mg, 0.223 mmol), NEt3 (466.7 µ, 3.35 mmol) in anhydrous DCM 
(8.9 mL, 0.25 M) at RT was added 4-methoxybenzoyl chloride solution (761.6 mg, 4.46 
mmol, dissolved in 8 mL anhydrous DCM). The clear, light-yellow reaction mixture was 
stirred at RT; the reaction progress was monitored by TLC (5% EtOAC/DCM, or DCM, 
UV, CAM stain). After 22 hours, the reaction was completed based on TLC. The reaction 
was quenched with sat’d NaHCO3 (30 mL), diluted with DCM (50 mL). The organic phase 
was washed with sat’d NaHCO3 (20 mL x 2), DI H2O (20 mL x 2). The combined aqueous 
phase was back extracted with DCM (10 mL x 2). The combined organic phase was washed 
with brine, dried over Na2SO4, and filtered. The solvent was removed in vacuo to afford 
crude mixture as a yellow gel. The crude mixture was purified by silica gel column 
chromatography (eluted with EtOAC/DCM gradient from 0 to 5%) to afford desired 
product 42 as a clear, sticky gel (1.15 g, 90 %). 1H NMR (400 MHz, Chloroform-d) δ 7.95 
(d, J = 8.9 Hz, 1H), 7.24 (d, J = 8.6 Hz, 2H), 7.09 (d, J = 8.6 Hz, 2H), 6.89 (d, J = 8.9 Hz, 
2H), 6.86 (d, J = 8.6 Hz, 2H), 6.68 (d, J = 8.6 Hz, 2H), 5.17 (t, J = 8.3 Hz, 1H), 4.71 – 4.59 
(m, 3H), 4.58 – 4.52 (m, 2H), 4.09 (dd, J = 11.6, 4.4 Hz, 1H), 3.86 (s, 3H), 3.80 (s, 3H), 
3.72 (s, 3H), 3.70 – 3.61 (m, 2H), 3.36 – 3.29 (m, 1H), 2.74 – 2.59 (m, 2H), 1.21 (t, J = 7.4 
Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 165.1, 163.6, 159.5, 159.2, 132.1, 130.3, 
130.3, 129.8, 129.7, 122.5, 114.0, 113.8, 113.7, 84.1, 81.2, 77.1, 74.3, 73.0, 71.5, 67.1, 
55.6, 55.4, 55.2, 24.3, 21.2, 15.0, 14.3. See Appendix for NMR spectra. 
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Compound 97 was synthesized as describe previously.43 To a mixture of 42 (1.13 g, 1.99 
mmol) in DCM (13.2 mL, 0.15 M) and DI H2O (1.3 mL, 1.5 M) at RT was added NBS 
(389.0 mg, 2.19 mmol) as a solid. The reaction mixture was stirred at RT under N2. The 
reaction progress was monitored by TLC (30% EtOAc/hexanes, UV, CAM stain). The 
appearance of the reaction mixture changed from clear, light yellow to cloudy, dark orange 
after 15 minutes, when the reaction was completed based on TLC. The reaction was 
quenched with sat’d Na2S2O3 solution (20 mL). The reaction mixture was diluted with 
DCM (50 mL), washed with sat’d Na2S2O3 solution (20 mL x 2). The combined aqueous 
phase was back extracted with DCM (10 mL x 2). The combined organic phase was washed 
with DI H2O (20 mL x 2), brine, dried over Na2SO4, and filtered. The solvent was removed 
in vacuo to afford crude mixture as a clear gel. The crude mixture was purified by silica 
gel column chromatography (eluted with EtOAc/hexanes gradient, 30% to 80%) to afford 
desired mixture of products 97 (α and β anomers) as a clear, thick gel (722.6 mg, 69%).1H 
NMR (500 MHz, Chloroform-d) δ 8.02 – 7.91 (m, 4H), 7.26 – 7.21 (m, 3H), 7.17 – 7.11 
(m, 3H), 6.95 – 6.83 (m, 7H), 6.77 – 6.72 (m, 3H), 5.41 (t, J = 3.9 Hz, 1H), 4.99 (ddd, J = 
9.3, 3.5, 1.0 Hz, 1H), 4.95 (dd, J = 8.4, 7.0 Hz, 1H), 4.79 – 4.64 (m, 5H), 4.64 – 4.54 (m, 
3H), 4.04 (ddd, J = 16.9, 10.6, 6.6 Hz, 2H), 3.93 – 3.85 (m, 7H), 3.84 – 3.78 (m, 6H), 3.77 
– 3.74 (m, 5H), 3.71 (dd, J = 11.3, 5.2 Hz, 1H), 3.69 – 3.60 (m, 2H), 3.38 (dd, J = 12.0, 9.0 
Hz, 1H), 2.76 (dd, J = 4.3, 1.1 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 165.8, 159.6, 
132.2, 132.1, 130.6, 130.4, 129.8, 129.7, 129.7, 129.6, 122.2, 114.1, 114.0, 114.0, 113.9, 
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113.8, 113.82, 96.2, 91.0, 79.4, 78.0, 74.9, 74.7, 74.57, 73.4, 73.1, 72.9, 63.3, 60.7, 55.6, 
55.6, 55.4, 55.3. See Appendix for NMR spectra. 
 
Compound 43 was synthesized as describe previously.43 To a solution of 97 (718.0 mg, 
1.37 mmol) in anhydrous DCM (9.1 mL, 0.15 M) under N2 at RT was added 
trichloroacetonitrile (686 µL, 6.84 mmol) and DBU (20.4 µL, 0.136 mmol). The reaction 
color changed from light to dark yellow. The reaction mixture was stirred at RT. The 
reaction progress was monitored by TLC (30% EtOAc/hexanes with 3% NEt3, TLC plates 
were pre-eluted before sample spotting). After 1.5 hours, an aliquot of the reaction was 
analyzed by 1H NMR to show the completion of the reaction. The solvent was removed in 
vacuo to afford crude mixture as a yellow, thick gel. The crude mixture was purified by 
silica gel column chromatography (eluted with EtOAc/hexanes with 3% NEt3 gradient) to 
afford desired mixture of products 43 (α and β anomers) as a light yellow, thick gel (881.0 
mg, 96 %). 1H NMR (400 MHz, Chloroform-d) δ 8.58 (s, 1H), 8.48 (s, 1H), 7.91 (dt, J = 
9.1, 2.6 Hz, 3H), 7.29 – 7.20 (m, 3H), 7.14 (t, J = 8.5 Hz, 3H), 6.91 – 6.82 (m, 6H), 6.75 – 
6.68 (m, 3H), 6.46 (d, J = 3.6 Hz, 1H), 5.97 (d, J = 5.7 Hz, 1H), 5.41 (dd, J = 7.0, 5.7 Hz, 
1H), 5.21 (dd, J = 9.9, 3.6 Hz, 1H), 4.82 – 4.73 (m, 1H), 4.73 – 4.66 (m, 3H), 4.66 – 4.53 
(m, 3H), 4.17 – 4.08 (m, 2H), 3.89 – 3.83 (m, 5H), 3.83 – 3.75 (m, 7H), 3.75 – 3.70 (m, 
5H), 3.62 (dd, J = 11.9, 7.2 Hz, 1H). See Appendix for NMR spectra. 
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Compound 88 was synthesized as describe previously.43 A mixture of imidates 43 (306.0 
mg, 0.457 mmol), L-arabinose moiety 87 (95.4 mg, 0.269 mmol) and 4Å molecular sieves 
powder (400 mg) in anhydrous DCM (2.7 mL, 0.1 M) was stirred at RT under N2 for 1 
hour, then cooled down to -35°C. To the reaction was added BF3·Et2O (10.0 µL, 0.0807 
mmol, dissolved in 100 µL of anhydrous DCM). The reaction mixture was stirred at -35°C. 
The reaction progress was monitored by TLC (55% EtOAc/hexanes with 3% NEt3, UV, 
CAM stain). After 30 minutes, the reaction mixture was allowed to warm up to -20°C. 
After 1 hour, since not much change was observed by TLC, the reaction was quenched 
with NEt3 (100 µL). The reaction mixture was warmed up to RT, filtered through celite. 
The solvent was removed in vacuo to afford crude mixture as a yellow gel. The crude 
mixture was purified by silica gel column chromatography (eluted with acetone/benzene 
gradient from 0% to 8%) to afford desired product 88 as a white, foamy solid (193.0 mg, 
83%). 1H NMR (500 MHz, Chloroform-d) δ 7.85 – 7.79 (m, 2H), 7.19 – 7.12 (m, 4H), 7.02 
– 6.94 (m, 2H), 6.81 – 6.71 (m, 6H), 6.58 (d, J = 8.6 Hz, 2H), 5.43 (d, J = 5.8 Hz, 1H), 5.08 
(ddd, J = 12.9, 7.2, 5.8 Hz, 2H), 4.62 – 4.49 (m, 6H), 4.48 – 4.42 (m, 1H), 3.88 (dd, J = 
11.9, 4.2 Hz, 1H), 3.83 (dd, J = 12.1, 5.2 Hz, 1H), 3.78 – 3.72 (m, 4H), 3.71 (s, 3H), 3.70 
– 3.66 (m, 4H), 3.65 – 3.55 (m, 6H), 3.40 (dd, J = 12.1, 2.4 Hz, 1H), 3.23 (dd, J = 11.7, 7.8 
Hz, 1H), 1.86 (s, 3H), 1.69 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 169.7, 169.1, 
164.8, 163.6, 159.5, 159.3, 159.2, 132.0, 130.4, 130.2, 130.1, 129.8, 129.74, 129.73, 
129.71, 129.7, 128.4, 122.3, 114.0, 113.7, 113.7, 113.69, 101.9, 92.1, 79.1, 77.4, 76.7, 73.8, 
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72.74, 72.70, 71.9, 71.6, 69.8, 63.0, 55.5, 55.38, 55.36, 55.2, 20.8, 20.6. See Appendix for 
NMR spectra. 
 
To a clear, colorless solution of 88 (193.0 mg, 0.224 mmol) in anhydrous THF (2.5 mL, 
0.1 M) at RT under N2 was added morpholine (154.7 µL, 1.79 mmol). The reaction mixture 
was stirred at RT. The reaction progress was monitored by TLC (70% EtOAc/hexanes, 
UV, CAM stain). After 19 hours, TLC showed only 50% conversion. To the reaction 
mixture was added more morpholine (70.0 µL, 0.81 mmol). After 48 hours, the reaction 
was mostly completed based on TLC. The solvent was removed in vacuo to afford crude 
mixture, which was purified by silica gel column chromatography (EtOAc/hexanes 
gradient- 20% to 100%) to afford desired mixture of products 98 (α and β anomers) as a 
white powder (119.0 mg, 65%). 1H NMR (400 MHz, Chloroform-d) δ 7.94 – 7.87 (m, 2H), 
7.30 – 7.21 (m, 4H), 7.09 (dd, J = 8.9, 2.7 Hz, 2H), 6.91 – 6.81 (m, 6H), 6.71 – 6.64 (m, 
2H), 5.25 – 5.13 (m, 2H), 5.04 (dd, J = 9.1, 3.1 Hz, 1H), 4.94 (td, J = 9.1, 8.4, 6.0 Hz, 0H), 
4.78 – 4.47 (m, 10H), 4.11 – 4.06 (m, 1H), 4.02 – 3.86 (m, 2H), 3.87 – 3.83 (m, 4H), 3.81 
– 3.80 (m, 3H), 3.79 (s, 6H), 3.75 – 3.69 (m, 6H), 3.68 – 3.57 (m, 1H), 1.76 (s, 3H). 13C 
NMR (101 MHz, Chloroform-d) δ 171.3, 170.2, 164.8, 163.57, 159.5, 159.3, 159.22, 
159.21, 132.0, 131.9, 130.7, 130.3, 130.2, 130.1, 129.8, 129.78, 129.75, 129.6, 122.4, 
114.0, 113.8, 113.77, 113.75, 113.72, 113.6, 102.2, 91.1, 80.0, 76.6, 74.5, 74.1, 72.9, 72.6, 
72.1, 70.8, 63.4, 61.9, 60.5, 55.5, 55.4, 55.38, 55.24, 55.22, 21.2, 20.7, 20.7, 14.3. See 
Appendix for NMR spectra. 
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Compound 89 was synthesized as describe previously.43 To a solution of 98 (71.4 mg, 
0.087 mmol) in anhydrous DCM (0.58 mL, 0.15 M) under N2 at RT was added 
trichloroacetonitrile (61.2 µL, 0.61 mmol) and DBU (1.3 µL, 0.0087 mmol). The reaction 
color changed from light to dark yellow. The reaction mixture was stirred at RT. The 
reaction progress was monitored by TLC (30% EtOAc/hexanes with 3% NEt3, TLC plates 
were pre-eluted before sample spotting). After 1.5 hours, an aliquot of the reaction was 
analyzed by 1H NMR to show the completion of the reaction. The solvent was removed in 
vacuo to afford crude mixture as a yellow, thick gel. The crude mixture was purified by 
silica gel column chromatography (eluted with EtOAc/hexanes with 3% NEt3 gradient) to 
afford desired mixture of products 89 (α and β anomers) as a light yellow, thick gel (68.0 
mg, 81 %). The products were used in the subsequent reaction as a mixture of anomers. α-
anomer: 1H NMR (500 MHz, Chloroform-d) δ 8.48 (s, 1H), 7.93 – 7.88 (m, 2H), 7.31 – 
7.23 (m, 4H), 7.12 – 7.06 (m, 2H), 6.86 (td, J = 8.7, 6.7 Hz, 6H), 6.71 – 6.65 (m, 2H), 6.43 
(d, J = 3.5 Hz, 1H), 5.34 (dd, J = 10.3, 3.5 Hz, 1H), 5.20 (dd, J = 8.0, 6.5 Hz, 1H), 4.78 – 
4.72 (m, 2H), 4.70 – 4.54 (m, 5H), 4.15 – 4.08 (m, 2H), 3.96 (dd, J = 11.8, 4.5 Hz, 1H), 
3.92 – 3.88 (m, 2H), 3.87 – 3.84 (m, 4H), 3.81 (s, 3H), 3.81 – 3.77 (m, 4H), 3.77 – 3.65 
(m, 6H), 3.34 (dd, J = 11.8, 8.2 Hz, 1H), 1.61 (s, 3H). β-anomer: 1H NMR (500 MHz, 
Chloroform-d) δ 8.55 (s, 1H), 7.96 – 7.89 (m, 2H), 7.30 – 7.27 (m, 2H), 7.24 – 7.19 (m, 
2H), 7.16 – 7.10 (m, 2H), 6.90 – 6.80 (m, 6H), 6.73 – 6.68 (m, 2H), 5.72 (d, J = 5.9 Hz, 
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1H), 5.42 (dd, J = 8.0, 5.9 Hz, 1H), 5.22 (dd, J = 6.9, 5.3 Hz, 1H), 4.81 (d, J = 5.3 Hz, 1H), 
4.73 – 4.48 (m, 7H), 4.06 (ddd, J = 11.8, 4.5, 2.4 Hz, 2H), 3.95 – 3.91 (m, 1H), 3.88 – 3.82 
(m, 5H), 3.82 – 3.77 (m, 7H), 3.76 – 3.70 (m, 4H), 3.63 (dt, J = 6.9, 3.4 Hz, 1H), 3.59 (dd, 
J = 12.1, 2.4 Hz, 1H), 3.38 (dd, J = 11.9, 7.3 Hz, 1H), 1.79 (s, 3H). See Appendix for NMR 
spectra. 
 
To a clear, colorless solution of methyl 4-hydroxybenzoate (1.0 g, 6.57 mmol) in anhydrous 
DMF (13.1 mL, 0.5 M) at 0°C under N2 was added NaH (315.5 mg, 7.9 mmol, 60% 
dispersion in oil) in portion. The mixture was then stirred at RT for 45 minutes, then cooled 
back down to 0°C. To the reaction mixture was added CD3I (0.9 mL, 14.45 mmol) 
dropwise. The reaction mixture was stirred at RT. The reaction progress was monitored by 
TLC (20% EtOAc/hexanes, UV). After 2 hours 45 minutes, the reaction mixture was 
diluted with CHCl3 (40 mL), washed with brine (50 mL x 3). The aqueous layer was 
extracted with CHCl3 (20 mL). The combined organic layer was washed with brine, dried 
over Na2SO4, and filtered. The solvent was removed in vacuo to afford desired product 99 
as a white, waxy solid (1.07 g, 97%). The NMR data agreed with that of methyl p-
methoxybenzoate with the absence of the singlet due to the deuterium moiety. 1H NMR 
(400 MHz, Chloroform-d) δ 7.99 (d, J = 9.2 Hz, 2H), 6.91 (d, J = 8.9 Hz, 2H), 3.88 (s, 3H). 
See Chapter appendix for NMR spectra. 
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To a clear, colorless solution of 99 (1.07 g, 6.35 mmol) in 200-proof ethanol (42.3 mL, 
0.14 M) was added KOH (534.7 mg, 9.53 mmol, dissolved in the minimum amount of DI 
H2O). The reaction mixture was heated under reflux for 3 hours. Then the solvent was 
removed in vacuo to afford a white solid, which was dissolved in DI H2O and cooled to 
0°C. The solution was made acidic with 6N HCl added dropwise, which resulted in white 
precipitation. The precipitation was filtered and dried under vacuum to afford the desired 
product 100 as a white solid (950.0 mg, 96%). The NMR data agreed with that of p-
methoxybenzoic acid with the absence of the singlet due to the deuterium moiety. 1H NMR 
(400 MHz, Chloroform-d) δ 8.06 (d, J = 8.9 Hz, 2H), 6.95 (d, J = 8.9 Hz, 2H). See Chapter 
appendix for NMR spectra. 
 
To a mixture of acid 100 (500.0 mg, 3.22 mmol) in anhydrous DCM (6.4 mL, 0.5 M) at 
RT under N2 was added SOCl2 (0.7 mL, 9.67 mmol) dropwise. The reaction mixture was 
heated under reflux for 3 hours. The solvent was then removed in vacuo to afford desired 
product 101 as an off-white, waxy solid (555.0 mg, 98 %). The product was used in 
subsequent reaction without further purification. The NMR data agreed with that of p-
methoxybenzoyl chloride with the absence of the singlet due to the deuterium moiety. 1H 
NMR (400 MHz, Chloroform-d) δ 8.07 (d, J = 9.0 Hz, 2H), 6.96 (d, J = 9.0 Hz, 2H). 13C 
NMR (101 MHz, Chloroform-d) δ 167.24, 165.52, 134.12, 125.54, 114.35. See Chapter 
appendix for NMR spectra. 
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To a mixture of 96 (453.9mg, 1.04 mmol), DMAP (19.5 mg, 0.159 mmol), NEt3 (218.0 
µL, 1.57 mmol) in anhydrous DCM (3.5 mL, 0.29 M) at RT was added 4-methoxybenzoyl 
chloride-D3 101 solution (442.7 mg, 2.55 mmol, dissolved in 1 mL anhydrous DCM). The 
clear, light-yellow reaction mixture was stirred at RT; the reaction progress was monitored 
by TLC (5% EtOAC/DCM, or DCM, UV, CAM stain). After 4 days, the reaction was 
completed based on TLC. The reaction was quenched with sat’d NaHCO3 (30 mL), diluted 
with DCM (50 mL). The organic phase was washed with sat’d NaHCO3 (20 mL x 2), DI 
H2O (20 mL x 2). The combined aqueous phase was back extracted with DCM (10 mL x 
2). The combined organic phase was washed with brine, dried over Na2SO4, and filtered. 
The solvent was removed in vacuo to afford crude mixture as a yellow gel. The crude 
mixture was purified by silica gel column chromatography (eluted with EtOAC/DCM 
gradient from 0 to 5%) to afford desired product 102 as a clear, sticky gel (513.6 mg, 86 
%). The NMR data agreed with that of compound 42 with the absence of the singlet due to 
the deuterium moiety. 1H NMR (400 MHz, Chloroform-d) δ 7.95 (d, J = 8.9 Hz, 2H), 7.25 
– 7.21 (m, 2H), 7.12 – 7.05 (m, 2H), 6.91 – 6.81 (m, 4H), 6.68 (d, J = 8.7 Hz, 2H), 5.17 (t, 
J = 8.2 Hz, 1H), 4.71 – 4.59 (m, 3H), 4.58 – 4.51 (m, 2H), 4.12 – 4.06 (m, 1H), 3.80 (s, 
3H), 3.72 (s, 3H), 3.70 – 3.60 (m, 1H), 3.33 (dd, J = 11.5, 8.6 Hz, 1H), 2.76 – 2.57 (m, 2H), 
1.21 (t, J = 7.4 Hz, 3H). See Chapter appendix for NMR spectra. 
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To a mixture of 102 (513.6 mg, 0.898 mmol) in DCM (5.4 mL, 0.15 M) and DI H2O (0.54 
mL, 1.5 M) at RT was added NBS (180.0 mg, 1.01 mmol) as a solid. The reaction mixture 
was stirred at RT under N2. The reaction progress was monitored by TLC (30% 
EtOAc/hexanes, UV, CAM stain). The appearance of the reaction mixture changed from 
clear, light yellow to cloudy, dark orange after 15 minutes, when the reaction was 
completed based on TLC. The reaction was quenched with sat’d Na2S2O3 solution (10 
mL). The reaction mixture was diluted with DCM (25 mL), washed with sat’d Na2S2O3 
solution (10 mL x 2). The combined aqueous phase was back extracted with DCM (5 mL 
x 2). The combined organic phase was washed with DI H2O (10 mL x 2), brine, dried over 
Na2SO4, and filtered. The solvent was removed in vacuo to afford crude mixture as a clear 
gel. The crude mixture was purified by silica gel column chromatography (eluted with 
EtOAc/hexanes gradient, 30% to 80%) to afford desired mixture of products 103 (α and β 
anomers) as a clear, thick gel (320.5 mg, 67%). The NMR data agreed with that of 
compound 97 with the absence of the singlet due to the deuterium moiety. 1H NMR (400 
MHz, Chloroform-d) δ 8.04 – 7.91 (m, 2H), 7.33 – 7.21 (m, 2H), 7.18 – 7.10 (m, 2H), 6.96 
– 6.83 (m, 6H), 6.79 – 6.70 (m, 2H), 6.29 (d, J = 2.8 Hz, 1H), 5.41 (d, J = 3.4 Hz, 1H), 4.99 
(dd, J = 9.3, 3.5 Hz, 1H), 4.88 (d, J = 11.0 Hz, 1H), 4.80 – 4.63 (m, 4H), 4.63 – 4.53 (m, 
1H), 4.06 (dd, J = 9.3, 8.2 Hz, 1H), 3.90 – 3.82 (m, 1H), 3.82 – 3.79 (m, 5H), 3.75 (s, 3H), 
3.73 – 3.60 (m, 2H), 3.38 (dd, J = 12.0, 9.0 Hz, 0H), 2.74 (s, 1H). See Chapter appendix 
for NMR spectra. 
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To a solution of 103 (314.0 mg, 0.595 mmol) in anhydrous DCM (4.0 mL, 0.15 M) under 
N2 at RT was added trichloroacetonitrile (298.4 µL, 2.98 mmol) and DBU (4.5 µL, 0.030 
mmol). The reaction color changed from light to dark yellow. The reaction mixture was 
stirred at RT. The reaction progress was monitored by TLC (30% EtOAc/hexanes with 3% 
NEt3, TLC plates were pre-eluted before sample spotting). After 1.5 hours, an aliquot of 
the reaction was analyzed by 1H NMR to show the completion of the reaction. The solvent 
was removed in vacuo to afford crude mixture as a yellow, thick gel. The crude mixture 
was purified by silica gel column chromatography (eluted with EtOAc/hexanes with 3% 
NEt3 gradient) to afford desired mixture of products 104 (α and β anomers) as a light 
yellow, thick gel (342.3 mg, 85 %). The NMR data agreed with that of compound 43 with 
the absence of the singlet due to the deuterium moiety. 1H NMR (400 MHz, Chloroform-
d) δ 8.58 (s, 1H), 8.48 (s, 1H), 7.94 – 7.86 (m, 2H), 7.25 – 7.20 (m, 2H), 7.18 – 7.10 (m, 
2H), 6.90 – 6.80 (m, 4H), 6.75 – 6.67 (m, 2H), 6.46 (d, J = 3.6 Hz, 1H), 5.97 (d, J = 5.7 
Hz, 1H), 5.41 (dd, J = 7.0, 5.7 Hz, 1H), 5.21 (dd, J = 9.9, 3.6 Hz, 1H), 4.81 – 4.51 (m, 5H), 
4.17 – 4.08 (m, 1H), 3.84 – 3.78 (m, 5H), 3.78 – 3.69 (m, 5H), 3.62 (dd, J = 11.9, 7.3 Hz, 
1H). See Chapter appendix for NMR spectra. 
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A mixture of imidates-D3 104 (74.0 mg, 0.110 mmol), L-arabinose moiety 87 (26.0 mg, 
0.0734 mmol) and 4Å molecular sieves powder (100 mg) in anhydrous DCM (734 µL, 0.1 
M) was stirred at RT under N2 for 1 hour, then cooled down to -35°C. To the reaction was 
added BF3·Et2O (2.8 µL, 0.022 mmol, dissolved in 50 µL of anhydrous DCM). The 
reaction mixture was stirred at -35°C. The reaction progress was monitored by TLC (55% 
EtOAc/hexanes with 3% NEt3, UV, CAM stain). After 30 minutes, the reaction mixture 
was allowed to warm up to -20°C. After 1 hour, since not much change was observed by 
TLC, the reaction was quenched with NEt3 (20 µL). The reaction mixture was warmed up 
to RT, filtered through celite. The solvent was removed in vacuo to afford crude mixture 
as a yellow gel. The crude mixture was purified by silica gel column chromatography 
(eluted with EtOAc/hexanes with 3% NEt3 gradient from 18% to 70%) to afford desired 
product 105 as a white, foamy solid (55.0 mg, 86%). The NMR data agreed with that of 
compound 88 with the absence of the singlet due to the deuterium moiety. 1H NMR (400 
MHz, Chloroform-d) δ 7.95 – 7.86 (m, 2H), 7.29 – 7.21 (m, 4H), 7.13 – 7.07 (m, 2H), 6.92 
– 6.79 (m, 6H), 6.71 – 6.64 (m, 2H), 5.53 (d, J = 5.7 Hz, 1H), 5.18 (dt, J = 13.3, 6.5 Hz, 
2H), 4.73 – 4.50 (m, 7H), 3.98 (dd, J = 11.8, 4.0 Hz, 1H), 3.93 (dd, J = 12.0, 5.2 Hz, 1H), 
3.84 (dd, J = 7.7, 3.1 Hz, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.79 – 3.74 (m, 1H), 3.73 – 3.64 
(m, 5H), 3.50 (dd, J = 11.9, 2.5 Hz, 1H), 3.33 (dd, J = 11.6, 7.4 Hz, 2H), 1.96 (s, 3H), 1.80 
(s, 3H). See Chapter appendix for NMR spectra. 
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To a clear, colorless solution of 105 (52.0 mg, 0.060 mmol) in anhydrous THF (0.60 mL, 
0.1 M) at RT under N2 was added morpholine (45.0 µL, 0.48 mmol). The reaction mixture 
was stirred at RT. The reaction progress was monitored by TLC (70% EtOAc/hexanes, 
UV, CAM stain). After 48 hours, the reaction was mostly completed based on TLC. The 
solvent was removed in vacuo to afford crude mixture, which was purified by silica gel 
column chromatography (EtOAc/hexanes gradient- 20% to 100%) to afford desired 
mixture of products 105a (α and β anomers) as a clear gel (36.7 mg, 74%). The NMR data 
agreed with that of compound 98 with the absence of the singlet due to the deuterium 
moiety. 1H NMR (400 MHz, Chloroform-d) δ 7.94 – 7.87 (m, 2H), 7.29 – 7.20 (m, 4H), 
7.12 – 7.06 (m, 2H), 6.92 – 6.81 (m, 6H), 6.72 – 6.61 (m, 2H), 5.26 – 5.12 (m, 2H), 5.04 
(dd, J = 8.9, 3.1 Hz, 1H), 4.95 (dd, J = 7.5, 5.0 Hz, 1H), 4.77 – 4.49 (m, 9H), 4.09 (dd, J = 
9.0, 3.0 Hz, 1H), 4.02 – 3.83 (m, 3H), 3.81 (s, 3H), 3.80 – 3.77 (m, 5H), 3.73 – 3.70 (m, 
4H), 3.69 – 3.65 (m, 1H), 3.62 (dd, J = 11.9, 4.2 Hz, 1H), 3.47 (dd, J = 12.2, 2.9 Hz, 0H), 
3.37 – 3.27 (m, 1H), 2.44 (d, J = 4.3 Hz, 1H), 1.85 (s, 1H), 1.78 (s, 3H). See Chapter 
appendix for NMR spectra. 
 
To a solution of 105a (36.7 mg, 0.045 mmol) in anhydrous DCM (0.30 mL, 0.15 M) under 
N2 at RT was added trichloroacetonitrile (22.4 µL, 0.22 mmol) and DBU (0.33 µL, 0.0022 
mmol). The reaction color changed from light to dark yellow. The reaction mixture was 
stirred at RT. The reaction progress was monitored by TLC (30% EtOAc/hexanes with 3% 
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NEt3, TLC plates were pre-eluted before sample spotting). After 1.5 hours, an aliquot of 
the reaction was analyzed by 1H NMR to show the completion of the reaction. The solvent 
was removed in vacuo to afford crude mixture as a yellow, thick gel. The crude mixture 
was purified by silica gel column chromatography (eluted with EtOAc/hexanes with 3% 
NEt3 gradient) to afford desired mixture of products 106 (α and β anomers) as a light 
yellow, thick gel (25.5 mg, 60 %). The products were used in the subsequent reaction as a 
mixture of anomers. 1H NMR signals with integration of 0H correspond to the minor 
anomer. The NMR data agreed with that of compound 89 with the absence of the singlet 
due to the deuterium moiety. 1H NMR (400 MHz, Chloroform-d) δ 8.55 (s, 1H), 8.48 (s, 
0H), 7.96 – 7.88 (m, 2H), 7.30 – 7.24 (m, 2H), 7.23 – 7.19 (m, 2H), 7.16 – 7.11 (m, 2H), 
6.90 – 6.80 (m, 6H), 6.73 – 6.66 (m, 2H), 6.42 (d, J = 3.5 Hz, 0H), 5.72 (d, J = 5.9 Hz, 1H), 
5.42 (dd, J = 8.0, 5.9 Hz, 1H), 5.22 (dd, J = 6.8, 5.3 Hz, 1H), 4.80 (d, J = 5.3 Hz, 1H), 4.75 
– 4.48 (m, 7H), 4.09 – 4.03 (m, 2H), 3.96 – 3.88 (m, 1H), 3.88 – 3.82 (m, 1H), 3.80 (s, 3H), 
3.79 (s, 3H), 3.76 – 3.70 (m, 4H), 3.66 – 3.56 (m, 2H), 3.46 – 3.34 (m, 2H), 1.79 (s, 3H). 
See Chapter appendix for NMR spectra. 
 
Compound 107 was synthesized with the procedure adapted from Xue et al.43 A mixture 
of disaccharide imidates 106 (22.5 mg, 0.0233 mmol), aglycone 14 (12.5 mg, 0.0211 
mmol) and 4Å molecular sieve powder (60 mg) in anhydrous DCM (266 µL, 0.08M) was 
stirred at RT under N2 for 30 minutes before cooling to -45°C. To the reaction mixture was 
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added TMSOTf (0.38 µL in 9.6 µL solution in anhydrous DCM, 0.0021 mmol). The 
reaction mixture was stirred at -45°C. The reaction progress was monitored by TLC (40% 
EtOAc/hexanes, UV, CAM stain). After 25 minutes, no further progress was observed. To 
the reaction mixture was added more TMSOTf (0.12 µL in 3.0 µL solution in anhydrous 
DCM, 0.66 µmol). After 50 minutes, no further progress was observed. The reaction was 
quenched with sat’d NaHCO3 solution (1 mL). The reaction mixture was diluted with DCM 
(10 mL). The organic phase was washed with sat’d NaHCO3 solution (10 mL x 3). The 
combined aqueous phase was back extracted with DCM (5 mL x 2). The combined organic 
phase was washed with brine, dried over Na2SO4, and filtered. The solvent was removed 
in vacuo to afford crude mixture as a white foamy solid. The crude mixture was purified 
by pTLC (eluted with 30% EtOAc/hexanes) to afford desired product 107 (6.3 mg, 21%). 
1H NMR (400 MHz, Chloroform-d) δ 7.96 (d, J = 8.8 Hz, 2H), 7.30 – 7.22 (m, 4H), 7.17 
(d, J = 8.5 Hz, 2H), 6.85 – 6.77 (m, 6H), 6.73 (d, J = 8.5 Hz, 2H), 5.29 – 5.21 (m, 2H), 5.12 
– 5.07 (m, 1H), 5.03 (s, 1H), 4.76 (d, J = 11.3 Hz, 1H), 4.66 – 4.42 (m, 6H), 4.43 – 4.25 
(m, 2H), 4.17 – 4.07 (m, 2H), 4.00 – 3.82 (m, 3H), 3.81 – 3.78 (m, 3H), 3.77 (s, 3H), 3.76 
– 3.68 (m, 5H), 3.58 – 3.42 (m, 3H), 2.65 (q, J = 7.3 Hz, 1H), 2.30 – 2.21 (m, 1H), 2.18 – 
2.09 (m, 2H), 1.98 (s, 3H), 1.85 – 1.64 (m, 5H), 1.64 – 1.50 (m, 2H), 1.50 – 1.34 (m, 5H), 
1.32 – 1.17 (m, 4H), 1.13 (d, J = 7.4 Hz, 3H), 1.09 – 0.94 (m, 2H), 0.92 (s, 3H), 0.89 (s, 
9H), 0.86 (s, 3H), 0.67 (d, J = 6.2 Hz, 3H), 0.58 (d, J = 6.2 Hz, 3H), 0.06 (s, 6H). See 
Chapter appendix for NMR spectra. 
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Compound 107a was synthesized with the procedure adapted from Xue et al.43 To a stirring 
solution of 107 (3.9 mg, 0.0028 mmol) in H2O/DCM (1:10, 0.28 mL) at RT under N2 was 
added DDQ (2.3 mg, 0.01 mmol). The reaction mixture changed color from colorless to 
dark green to yellow with dark red water droplets. The reaction progress was monitored by 
TLC (4% MeOH/DCM) until the starting material was all consumed. The reaction mixture 
was then diluted in DCM (5 mL), washed with sat’d NaHCO3 solution (5 mL x 3). The 
combined dark orange aqueous phase was back extracted with DCM (5 mL x 2). The 
combined light tan organic layer was washed with brine, dried over Na2SO4, and filtered. 
The solvent was removed in vacuo to afford crude mixture as a tan gel, which was then 
separated on pTLC (1/2 plate, 4% MeOH/DCM, 1 elution) to afford desired product 107a 
as a colorless film (1.5 mg, 52 % yield). 1H NMR (400 MHz, Chloroform-d) δ 8.00 (d, J = 
8.8 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 5.33 – 5.28 (m, 1H), 5.08 – 5.04 (m, 1H), 5.01 (d, J 
= 4.0 Hz, 1H), 4.96 (t, J = 4.8 Hz, 1H), 4.70 – 4.68 (m, 1H), 4.28 (dd, J = 12.2, 3.3 Hz, 
1H), 4.10 (s, 1H), 4.04 – 3.83 (m, 7H), 3.82 – 3.73 (m, 2H), 3.58 – 3.43 (m, 3H), 3.09 (s, 
1H), 2.92 (s, 1H), 2.70 – 2.62 (m, 1H), 2.51 (d, J = 7.3 Hz, 1H), 2.32 – 2.19 (m, 2H), 2.19 
– 2.13 (m, 1H), 2.01 – 1.92 (m, 2H), 1.80 (d, J = 13.3 Hz, 2H), 1.75 – 1.64 (m, 4H), 1.52 – 
1.37 (m, 2H), 1.37 – 1.27 (m, 2H), 1.28 – 1.21 (m, 4H), 1.20 – 1.09 (m, 1H), 1.04 (d, J = 
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7.5 Hz, 3H), 1.03 – 0.99 (m, 4H), 0.91 (s, 3H), 0.89 (s, 9H), 0.77 (d, J = 6.6 Hz, 3H), 0.71 
(d, J = 6.6 Hz, 3H), 0.05 (s, 6H). See Chapter appendix for NMR spectra. 
 
Stock solution of Pd(MeCN)2Cl2 was prepared (0.9 mg dissolved in 0.24 mL acetone). To 
a stirring solution of 107a (0.9 mg, 0.87 µmol) in H2O/acetone (1:20, 100.0 µL total) at RT 
under N2 was added Pd(MeCN)2Cl2 solution (53 µL solution, 0.19 mg, 0.72 µmol). The 
reaction was stirred at RT. The reaction progress was monitored by TLC (10% 
MeOH/DCM). After 10 hours, the reaction was completed based on TLC. The solvent was 
then removed in vacuo to afford crude product as a yellow film. The crude product was 
purified by HPLC (85% MeCN/H2O) to afford desired 108 d-OSW-1 (0.5 mg, 66% yield). 
1H NMR (400 MHz, Acetonitrile-d3) δ 8.02 (d, J = 9.0 Hz, 2H), 7.02 (d, J = 8.9 Hz, 2H), 
5.31 (d, J = 4.9 Hz, 1H), 4.84 (t, J = 8.2 Hz, 1H), 4.73 (dd, J = 8.3, 6.2 Hz, 1H), 4.61 (d, J 
= 7.7 Hz, 1H), 4.20 (s, 1H), 4.01 (d, J = 6.2 Hz, 1H), 3.92 (dd, J = 11.5, 4.9 Hz, 1H), 3.88 
(s, 1H), 3.76 (dd, J = 12.4, 4.2 Hz, 1H), 3.67 (dt, J = 8.2, 4.2 Hz, 2H), 3.64 – 3.50 (m, 2H), 
3.42 (dd, J = 12.4, 2.3 Hz, 1H), 3.38 – 3.22 (m, 2H), 2.86 (q, J = 7.3 Hz, 1H), 2.69 (s, 1H), 
2.46 (ddd, J = 18.2, 9.0, 6.5 Hz, 1H), 2.23 – 2.08 (m, 5H), 1.99 – 1.90 (m, 1H), 1.85 – 1.76 
(m, 1H), 1.75 – 1.68 (m, 2H), 1.67 (s, 3H), 1.64 – 1.38 (m, 5H), 1.32 (dt, J = 13.1, 6.6 Hz, 
1H), 1.29 – 1.14 (m, 3H), 1.07 (d, J = 7.4 Hz, 3H), 1.04 – 1.01 (m, 1H), 1.00 (s, 3H), 0.94 
– 0.83 (m, 1H), 0.82 – 0.74 (m, 9H). 13C NMR (101 MHz, Acetonitrile-d3) δ 220.09, 
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187.51, 169.95, 165.66, 164.73, 143.45, 142.44, 132.79, 123.33, 121.86, 118.31, 114.81, 
102.92, 100.98, 88.19, 86.20, 80.82, 75.74, 74.47, 71.90, 71.72, 70.49, 67.67, 66.46, 65.22, 
50.89, 49.20, 46.94, 46.54, 43.07, 39.71, 38.13, 37.35, 35.74, 33.19, 32.86, 32.69, 32.63, 
32.37, 28.19, 22.88, 22.67, 21.34, 21.04, 19.79, 13.56, 12.16, 1.94, 1.73. 2H NMR (77 
MHz, Acetonitrile-d3) δ 3.85. HRMS calcd for C47H65D3O15Na: 898.4639 [M + Na]
+, 
found 898.4611. See Chapter appendix for NMR spectra. 
 
Compound 112 was synthesized as describe previously.10 Under N2, OSW-1 2(5.4 mg, 
0.0062 mol) was dissolved in dry DCM (0.125 mL). The solution was cooled in an ice bath. 
2,6-lutidine (0.7 µL, 0.0062 mmol) was added via syringe. Tert-
Butyldimethylsilyltrifluoromethane sulfonate (2.1 µL, 0.0093 mmol) was then added via 
syringe. After 5 minutes, the ice bath was removed, and the reaction was allowed to warm 
to ambient temperature- the total reaction time was 15 minutes. The reaction progress was 
monitored via TLC (7.5% MeOH/DCM, UV and CAM stain). The reaction was diluted in 
CHCl3 (5 mL), washed with sat’d aqueous NaHCO3 solution (5 mL) and DI H2O (5 mL x 
2). The combined aqueous layer was back extracted with CHCl3 (2 mL x 2). The combined 
organic layer was washed with brine, dried over Na2SO4, and filtered. The solvent was 
removed in vacuo to afford crude product. The crude product was purified by preparative-
TLC, eluted with 5% MeOH/DCM to afford desired product 112 as a white solid (1.8 mg, 
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30% yield). The desired product was further purified by HPLC (Luna C8(2) column; flow 
rate of 2.2mL/min; isocratic of 95% MeOH/water in 10 minutes, gradient from 95% 
MeOH/water to 100% MeOH in 2 minutes, isocratic at 100% MeOH for 6 minutes before 
re-equilibrating at 95% MeOH/water for 7 minutes. Retention time of desired compound 
was at 14.1 minutes). 2.5 mg of compound 2 (combination from ATL-III-081 and ATL-
III-085) was purified through HPLC, and 1.4 mg was obtained as analytical pure 
compound. 1H NMR (500 MHz, Acetonitrile-d3) δ 8.04 – 7.98 (m, 2H), 7.05 – 6.99 (m, 
2H), 5.31 (d, J = 5.0 Hz, 1H), 4.84 (dd, J = 8.9, 7.7 Hz, 1H), 4.73 (dd, J = 8.3, 6.2 Hz, 1H), 
4.61 (d, J = 7.7 Hz, 1H), 4.20 (s, 1H), 4.00 (d, J = 6.2 Hz, 1H), 3.92 (dd, J = 11.6, 5.1 Hz, 
1H), 3.90 – 3.83 (m, 4H), 3.76 (dd, J = 12.4, 4.3 Hz, 1H), 3.72 – 3.64 (m, 2H), 3.62 – 3.51 
(m, 2H), 3.51 – 3.39 (m, 2H), 3.27 (dd, J = 11.6, 9.7 Hz, 2H), 2.86 (q, J = 7.4 Hz, 1H), 2.46 
(ddd, J = 18.2, 9.2, 6.4 Hz, 1H), 1.83 – 1.76 (m, 1H), 1.74 – 1.65 (m, 5H), 1.63 – 1.39 (m, 
7H), 1.32 (dp, J = 13.4, 6.7 Hz, 1H), 1.27 – 1.15 (m, 3H), 1.07 (d, J = 7.4 Hz, 3H), 1.05 – 
0.98 (m, 4H), 0.88 (s, 9H), 0.81 – 0.75 (m, 9H), 0.04 (d, J = 1.7 Hz, 6H). 13C NMR (101 
MHz, Acetonitrile-d3) δ 220.15, 170.00, 164.76, 142.42, 132.84, 123.44, 122.09, 114.86, 
102.97, 101.04, 88.21, 86.25, 75.90, 75.77, 75.12, 74.51, 73.54, 71.76, 70.46, 66.52, 56.40, 
50.95, 49.26, 48.32, 47.05, 46.59, 43.65, 39.71, 38.10, 37.38, 35.81, 33.24, 33.04, 32.91, 
32.66, 28.25, 26.32, 22.95, 22.74, 21.38, 21.11, 19.87, 13.62, 13.25, 12.23, -4.34. HRMS 
(TOF): calculated for C53H82NaO15Si [M+Na+]: 1009.5321; found: 1009.5348; Δ = 
2.67ppm. See Appendix for NMR spectra. 
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Compound 114 was synthesized as describe previously.10 1-(N-Boc-aminomethyl)-4-
(aminomethyl) benzene 113 (200 mg, 0.85 mmol) was partially dissolved in dry THF (3.0 
mL, 0.28M) to create a yellow suspension. Pyridine (68.5 µL, 0.85 mmol) was added via 
syringe, and then the reaction was cooled to -78°C. Allyl chloroformate (90.3 µL, 0.85 
mmol) was added fast drop-wise. After 10 minutes, the reaction was allowed to warm to 
room temperature and stirred for ~ 2.5 hours. The reaction progress was monitored by TLC 
(10% MeOH/DCM, I2 stain). After 2.5 hours, more white precipitation was observed, and 
TLC indicated the reaction completion.  The reaction was then stopped via addition of 
methanol (3mL), and then concentrated in vacuo. The crude reaction mixture was purified 
by silica gel column chromatography (15g silica, MeOH/DCM gradient- 2% to 5% in 250 
mL total, crude mixture was loaded in 5%MeOH/DCM as a slurry). The purification 
yielded 2 fractions. Fraction 1 (130 mg) had TLC of multiple spots, and 1H NMR of mainly 
desired product. Fraction 2 (106 mg) had TLC of less spots than fraction 1, and 1H NMR 
of mainly desired product. Each fraction was purified again by silica gel column 
chromatography (2.5% MeOH/DCM) to afford pure desired product 114 (210 mg, 77% 
yield). 1H NMR (500 MHz, Chloroform-d) δ 7.28 – 7.24 (m, 4H), 5.99 – 5.89 (m, 1H), 
5.36 – 5.28 (m, 1H), 5.23 (d, J = 10.4 Hz, 1H), 5.02 (bs, 1H), 4.83 (bs, 1H), 4.61 (d, J = 5.6 
Hz, 2H), 4.37 (d, J = 6.0 Hz, 2H), 4.30 (d, J = 5.9 Hz, 2H), 1.47 (s, 9H). See Appendix for 
NMR spectra. 
 
Compound 115 was synthesized as describe previously.10 At room temperature, 1-(N-
Alloc-aminomethyl)-4-(N-Boc-aminomethyl) benzene 114 (78.9 mg, 0.246 mmol) was 
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partially dissolved in DCM (990 µL, 0.25M). TFA (380 µL, 4.93 mmol) was added fast 
drop-wise to produce a yellow homogenous solution. After 1 hour, the solution was directly 
concentrated in vacuo to afford crude mixture as a thick yellow oil, which was dried on 
high vacuum for 1 hour. The crude reaction mixture was dissolved in chloroform (10 mL) 
and washed with 0.2M NaOH solution (5 mL x 3). The aqueous layer was back extracted 
once with chloroform (5 mL x 2), and the combined organic layer was washed with brine, 
dried over Na2SO4, and filtered. The solvent was removed in vacuo to afford desired 
product 115 as a thick yellow oil (47.2 mg, 87% yield). The desired product was used 
directly for the next reaction without further purification. 1H NMR (500 MHz, Chloroform-
d) δ 7.31 – 7.22 (m, 4H), 5.93 (ddt, J = 16.7, 11.0, 5.8 Hz, 1H), 5.30 (d, J = 17.2 Hz, 1H), 
5.21 (d, J = 10.4 Hz, 1H), 5.03 (s, 1H), 4.59 (d, J = 5.6 Hz, 2H), 4.36 (d, J = 6.0 Hz, 2H), 
3.85 (s, 2H). See Appendix for NMR spectra. 
 
Compound 116 was synthesized as describe previously.10 Alloc-(N) diaminomethyl 
benzene 115 (43.0 mg, 0.195 mmol) under N2 was partially dissolved in dry EtOAc (1.6 
mL, 0.12M). Solid triphosgene (36.2 mg, 0.122 mmol) was added, and the reaction was 
heated to 88°C under reflux condition for 5 hours. The reaction mixture turned clearer, but 
still slightly cloudy. The solvent was evaporated during the reaction period, so EtOAc was 
added. After cooling, the solvent was removed in vacuo and the crude mixture was dried 
on high vacuum to afford crude product 116 as a yellow paste (47.3mg, 98% yield). 1H 
NMR (500 MHz, Chloroform-d) δ 5.92 (ddd, J = 16.4, 10.8, 5.4 Hz, 1H), 5.31 (d, J = 17.1 
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Hz, 1H), 5.22 (d, J = 10.0 Hz, 1H), 4.60 (d, J = 5.7 Hz, 2H), 4.48 (s, 2H), 4.37 (dd, J = 
11.5, 6.2 Hz, 2H). IR (NaCl, cm-1): 3329 (Csp3-H), 2921 (Csp2-H), 2360 (O=C=O), 2341 
(O=C=O), 2263 (N=C=O), 1702 (amide C=O), 1515 (C-H benzene), 1508 (C-H benzene), 
1248 (C-O). See Appendix for NMR spectra. 
 
 
Compound 117 and 118 was synthesized as describe previously.10 OSW-1 (50 mg, 0.057 
mmol) under N2 was dissolved in anhydrous DMF (0.9 mL). In a nitrogen glove bag, 
copper (I) chloride (18 mg, 0.18 mmol) was added to a flask containing Alloc-(N)-
dimaminomethyl benzene isocyanate (43 mg, 0.18 mmol), then the mixture was dissolved 
in DMF (1.7 mL) to make a reagent stock solution. 1.1 mL of the reagent stock solution 
(copper (I) chloride 11.4 mg (0.114 mmol), Alloc-(N)-diaminomethyl benzene isocyanate 
28.2 mg, (0.114 mmol)) was added to the OSW-1 solution via syringe at ambient 
temperature and stirred for 5 hours. The reaction was diluted with CHCl3 (30 mL), washed 
twice with sat’d NaHCO3 solution. The blue aqueous layer was back extracted twice with 
CHCl3, and the combined yellow organic layer was washed with brine. The organic layer 
was dried over Na2SO4, filtered and reduce in vacuo to produce a yellow crude oil in 
residual DMF, which was evaporated to a crude solid mixture after 4 hours on the high 
vacuum pump. A mixture of OSW-1 carbamate 117 and 118 were produced, with 
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recovered unreacted OSW-1. Both OSW-1 carbamate compounds were purified via pTLC 
(three plates) eluted with 7.5% MeOH/CH2Cl2. Carbamate 117 was obtained as a white 
solid (9.0 mg, 14%, 28% borsm). Carbamate 118 was obstained as a white solid (9.2mg, 
14%, 29% borsm). Both carbamate were purified to analytical purity via HPLC (Luna 
C18(2) column, 2.4 mL/min, isocratic 75% acetonitrile/(0.1% formic acid in water) for 16 
minutes, 100% acetonitrile wash for 8 minutes, re-equilibriate at 75% acetonitrile/(0.1% 
formic acid in water) for 8 minutes). Retention time of carbamate 117 was 19.9 min, and 
of carbamate 118 was 23.1 min. The NMR data agreed with the published reference.10 
Carbamate 117: 1H NMR (500 MHz, Acetonitrile-d3) δ 7.98 – 7.92 (m, 2H), 7.10 – 6.86 
(m, 6H), 6.02 – 5.88 (m, 2H), 5.33 – 5.15 (m, 2H), 5.01 – 4.91 (m, 2H), 4.75 – 4.69 (m, 
2H), 4.53 (dt, J = 5.4, 1.6 Hz, 2H), 4.20 (s, 2H), 4.17 (d, J = 6.5 Hz, 2H), 4.01 (d, J = 6.4 
Hz, 1H), 3.99 – 3.93 (m, 1H), 3.91 – 3.85 (m, 4H), 3.80 – 3.72 (m, 2H), 3.71 – 3.64 (m, 
2H), 3.62 (d, J = 5.0 Hz, 1H), 3.46 – 3.25 (m, 3H), 3.21 (d, J = 4.4 Hz, 1H), 2.85 (q, J = 
7.3 Hz, 1H), 2.71 (d, J = 4.6 Hz, 1H), 2.47 (dt, J = 16.8, 8.0 Hz, 1H), 1.84 – 1.77 (m, 1H), 
1.74 – 1.66 (m, 1H), 1.64 (s, 2H), 1.62 – 1.56 (m, 0H), 1.56 – 1.48 (m, 3H), 1.47 – 1.38 
(m, 1H), 1.33 (dp, J = 13.2, 6.2 Hz, 1H), 1.28 – 1.15 (m, 3H), 1.07 (d, J = 7.4 Hz, 3H), 1.03 
(dd, J = 13.9, 3.6 Hz, 1H), 0.99 (s, 3H), 0.88 (td, J = 12.3, 11.4, 4.7 Hz, 1H), 0.79 (dd, J = 
6.6, 1.7 Hz, 6H), 0.75 (s, 3H). Low resolution MS: calculated for C60H86N3O18 [M+NH4
+]: 
1136.59; found: 1136.35; calculated for C61H83N2O20 [M+CO2H
-]: 1163.5545; found: 
1163.35. Carbamate 118: 1H NMR (500 MHz, Acetonitrile-d3) δ 8.04 – 7.97 (m, 2H), 7.22 
(s, 4H), 7.03 – 6.97 (m, 2H), 6.10 – 6.01 (m, 2H), 5.92 (ddt, J = 16.3, 10.6, 5.4 Hz, 1H), 
5.17 (d, J = 10.5 Hz, 1H), 4.93 (dd, J = 8.2, 6.8 Hz, 1H), 4.75 (dd, J = 8.2, 6.0 Hz, 1H), 
4.70 (d, J = 6.7 Hz, 1H), 4.63 (td, J = 8.2, 4.9 Hz, 1H), 4.51 (dt, J = 5.3, 1.5 Hz, 2H), 4.30 
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– 4.19 (m, 5H), 4.10 (dd, J = 11.8, 4.9 Hz, 1H), 4.04 (d, J = 6.0 Hz, 1H), 3.90 (s, 1H), 3.85 
(s, 3H), 3.83 – 3.73 (m, 2H), 3.69 (td, J = 8.0, 4.0 Hz, 2H), 3.46 – 3.35 (m, 2H), 3.32 (p, J 
= 6.0 Hz, 1H), 3.25 (s, 1H), 2.91 (q, J = 7.2 Hz, 1H), 2.71 (s, 1H), 2.51 (dt, J = 18.1, 7.9 
Hz, 1H), 1.84 – 1.78 (m, 1H), 1.74 – 1.67 (m, 4H), 1.63 – 1.48 (m, 3H), 1.48 – 1.38 (m, 
1H), 1.33 (dq, J = 13.2, 6.8 Hz, 1H), 1.29 – 1.18 (m, 3H), 1.08 (d, J = 7.3 Hz, 3H), 1.06 – 
0.97 (m, 4H), 0.92 – 0.85 (m, 1H), 0.81 – 0.76 (m, 9H). Low resolution MS: calculated for 
C60H86N3O18 [M+NH4
+]: 1136.59; found: 1136.35; calculated for C61H83N2O20 [M+CO2H-
]: 1163.5545; found: 1163.35. See Chapter appendix for NMR spectra. 
 
Compound 120 was synthesized with the procedure adapted from Burgett et al.10 
Carbamate 118 (3.5 mg, 0.0031 mmol) was dissolved in anhydrous THF (0.24 mL) under 
N2. Morpholine (1.8 µL, 0.021 mmol) was added via syringe. In a glove bag, Pd(PPh3)4 
(13.8 mg) was dissolved in anhydrous THF (0.51 mL) to make a 27 mg/mL reagent stock 
solution (20 µL = 15 mol%). To the reaction mixture at RT was added Pd(PPh3)4 solution 
in 15 mol% portions, with reaction progress being monitored by TLC (10% MeOH/DCM, 
UV and CAM stain) after each addition. Overall, 65 µL (48.8 mol%) of Pd(PPh3)4 was 
added over 2 hours. The reaction was quenched by three drops of water, and then was 
concentrated in vacuo. Amine 120 was purified to analytical purity from crude mixture via 
HPLC (Luna C8(2) column, 1.2 mL/min, gradient from 65% methanol/(0.1% formic acid 
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in water) to 82% methanol/(0.1% formic acid in water) in 4 minutes, isocratic 82% 
methanol/(0.1% formic acid in water) for 13 minutes, 100% methanol wash for 10 minutes, 
re-equilibriate at 65% methanol/(0.1% formic acid in water) for 17 minutes). Retention 
time of amine 120 was 16.7 min. Amine 120 was obtained as a white solid (1.1mg, 40%). 
The NMR data agreed with the published reference10. 1H NMR (500 MHz, 25% Methanol-
d4 in Acetonitrile-d3) δ 8.04 – 7.96 (m, 2H), 7.32 – 7.13 (m, 4H), 6.98 (dd, J = 8.6, 5.7 Hz, 
2H), 5.30 (d, J = 5.0 Hz, 1H), 4.92 (dd, J = 8.1, 6.4 Hz, 1H), 4.77 (dd, J = 8.2, 6.1 Hz, 1H), 
4.70 (d, J = 6.5 Hz, 1H), 4.65 – 4.56 (m, 1H), 4.32 – 4.18 (m, 2H), 4.13 – 4.07 (m, 1H), 
4.06 (d, J = 6.1 Hz, 1H), 3.89 (s, 1H), 3.84 (s, 3H), 3.82 – 3.73 (m, 2H), 3.69 (dd, J = 8.1, 
4.2 Hz, 2H), 3.45 – 3.40 (m, 1H), 3.40 – 3.34 (m, 5H), 2.95 – 2.88 (m, 1H), 2.57 – 2.47 
(m, 1H), 2.28 – 2.05 (m, 4H), 1.84 – 1.78 (m, 2H), 1.74 – 1.68 (m, 4H), 1.61 – 1.47 (m, 
3H), 1.41 (qd, J = 14.7, 12.3, 6.0 Hz, 3H), 1.36 – 1.29 (m, 1H), 1.29 – 1.19 (m, 5H), 1.08 
(d, J = 7.4 Hz, 3H), 1.03 (dd, J = 13.7, 3.9 Hz, 1H), 0.98 (s, 3H), 0.87 (dq, J = 11.8, 5.6 Hz, 
2H), 0.82 – 0.74 (m, 9H). Low resolution MS: calculated for C56H79N2O16 [M+H
+]: 
1035.5424; found: 1035.55; calculated for C57H79N2O18 [M+CO2H
-]: 1079.5333; found: 
1080.35. See Chapter appendix for NMR spectra. 
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Compound 119 was synthesized with the procedure adapted from Burgett et al.10 
Carbamate 117 (4.8 mg, 0.0043 mmol) was dissolved in anhydrous THF (0.32 mL) under 
N2. Morpholine (2.5 µL, 0.029 mmol) was added via syringe. In a glove bag, Pd(PPh3)4 
(13.8 mg) was dissolved in anhydrous THF (0.37 mL) to make a 37 mg/mL reagent stock 
solution (20 µL = 15 mol%). To the reaction mixture at RT was added Pd(PPh3)4 solution 
in 15 mol% portions, with reaction progress being monitored by TLC (10% MeOH/DCM, 
UV and CAM stain) after each addition. Overall, 90 µL (67 mol%) of Pd(PPh3)4 was added 
over 1.5 hours. The reaction was quenched by three drops of water, and then was 
concentrated in vacuo. Amine 119 was purified to analytical purity from crude mixture via 
HPLC (Luna C8(2) column, 1.2 mL/min, gradient from 65% methanol/(0.1% formic acid 
in water) to 82% methanol/(0.1% formic acid in water) in 4 minutes, isocratic 82% 
methanol/(0.1% formic acid in water) for 13 minutes, 100% methanol wash for 10 minutes, 
re-equilibrate at 65% methanol/(0.1% formic acid in water) for 17 minutes). Retention time 
of amine 119 was 16.1 min. Amine 119 was obtained as a white solid (1.0 mg, 21%). The 
NMR data agreed with the published reference10. 1H NMR (500 MHz, , 25% Methanol-d4 
in Acetonitrile-d3) δ 7.97 – 7.91 (m, 2H), 7.07 (d, J = 8.0 Hz, 1H), 7.02 – 6.96 (m, 4H), 
5.30 (d, J = 5.0 Hz, 1H), 4.99 – 4.91 (m, 2H), 4.75 (dd, J = 8.8, 6.7 Hz, 1H), 4.71 – 4.67 
(m, 1H), 4.18 – 4.11 (m, 1H), 4.06 – 4.00 (m, 2H), 3.96 (dd, J = 11.7, 5.4 Hz, 1H), 3.92 – 
3.87 (m, 1H), 3.85 (s, 4H), 3.76 (dd, J = 12.6, 3.7 Hz, 1H), 3.69 (ddt, J = 12.6, 8.8, 4.7 Hz, 
2H), 3.45 – 3.34 (m, 2H), 2.87 (q, J = 7.4 Hz, 1H), 2.50 (dt, J = 16.8, 7.9 Hz, 1H), 2.25 – 
2.06 (m, 5H), 1.83 – 1.76 (m, 1H), 1.74 – 1.64 (m, 2H), 1.62 (s, 3H), 1.59 – 1.46 (m, 2H), 
1.46 – 1.38 (m, 1H), 1.34 (dq, J = 13.1, 6.6 Hz, 1H), 1.30 – 1.17 (m, 4H), 1.07 (d, J = 7.4 
Hz, 3H), 1.02 (dd, J = 13.9, 3.8 Hz, 1H), 0.97 (s, 3H), 0.86 (p, J = 6.7, 6.2 Hz, 1H), 0.79 
92 
(dd, J = 6.6, 1.1 Hz, 6H), 0.74 (s, 3H). Low resolution MS: calculated for C56H79N2O16 
[M+H+]: 1035.5424; found: 1035.50; calculated for C57H79N2O18 [M+CO2H
-]: 1079.5333; 
found: 1079.35. See Chapter appendix for NMR spectra. 
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Chapter III : Design and Synthesis of Modified OSW-1 Scaffolds- 
a Two-component Approach 
Abstract 
 Since the identification of OSW-1’s cellular targets as OSBP and ORP4, the natural 
product OSW-1 has shown significant potential for therapeutic applications. The OSW-1 
compound exhibits broad spectrum anti-viral activity through its inhibition of OSBP, and 
potent anti-proliferative activity through its interaction with ORP4. OSBP and ORP4 are 
closely related members of the oxysterol binding protein family. Despite their sequence 
similarity, the two proteins possess different cellular function and disease relevance. The 
comparable binding affinities of OSW-1 to OSBP and ORP4 thereby hinder the use of 
OSW-1 as the molecular probe to determine the proteins’ biological activities, as well as 
examined its therapeutic potentials. Hence, the development of OSBP- or ORP4-selective 
OSW-1 analog is important and would allow for the selective studies of each protein’s 
function and disease relevance. The low-yield and non-convergent established syntheses 
of OSW-1 (as discussed in Section I.3) do not allow for the rapid construction and diverse 
derivatization of OSW-1 analogs, therefore a concise and convergent approach to synthesis 
OSW-1 analogs is desired. We have developed an efficient two-component approach to the 
OSW-1 scaffolds. The OSW-1 side chain and disaccharide moiety will compose the imine 
component, and this will join the steroidal alkene component through a tandem ene-
cyclization operation. This will result in a heterocyclic E-ring that appends on the steroidal 
core. This approach was demonstrated successfully here with the aldehyde-ene reaction 
version with only the side chain attached, while the imino-ene type is under investigation. 
Furthermore, a set of OSW-1-related analogs with the E-ring is being synthesized through 
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the conventional OSW-1 syntheses to determine the effect of these new scaffolds on the 
biological activity of OSW-1.  
III.1 Introduction and Background 
 The emergence of precision medicine as an evolving approach to cancer treatment 
requires the identification and characterization of new, druggable and cancer-specific 
therapeutic targets, along with the customizable and responsive course of treatment.57 
Developments in high-throughput genomic sequencing, bioanalysis, identification of 
diagnostic and prognostic biomarkers 58 have allowed the characterization of individual 
patient’s unique state of disease. This information can be used along with molecularly 
targeted therapies to provide the patient with the most effective treatment. To date, many 
targeted therapies have been approved for patient treatment with several types of cancer, 
along with many more that are being developed. Despite this, there are still needs for the 
continuing identification and development of new precision therapeutic targets to treat 
deadly cancers.  
 As described in Section I.2.2, the major variant ORP4L of the protein ORP4 has 
recently been validated as an anti-cancer precision medicine target.34,59 ORP4L was first 
identified as a general molecular marker for blood dissemination of solid tumors in the 
peripheral blood.60 Later, ORP4 mRNA levels were reported to be expressed in myeloid 
cells of chronic myeloid leukemia (CML) patients.61 In 2014, ORP4L’s expression and 
cellular function were demonstrated to be important in cancer cell proliferation and 
viability.33 In 2016, Zhong et al. showed that ORP4L is selectively expressed and is crucial 
for T-cell acute lymphoblastic leukemia (T-ALL) cell survival.34 In this report, ORP4L 
expression was not detected in normal T-cells, but was at a high level in isolated leukemia 
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cells from a panel of T-ALL patients; and inhibition of ORP4L expression in T-ALL cells 
led to cancer cell death.34 Furthermore, another report demonstrated the similar role of 
ORP4L in the survival of cervical carcinoma cell lines.59 These results, together with the 
discovery of OSBP/ORP4 as cellular targets of the anti-cancer natural product compounds 
(the ORPphillins-Figure 3), present ORP4L as a potential druggable precision cancer 
therapeutic target.  
 Recently, OSBP was implicated as an important host factor for enterovirus 
replication through its discovery as the cellular target responsible for the observed anti-
viral activity of itraconazole – an antifungal agent.29,62,63 Itraconazole was identified as a 
broad-spectrum inhibitor of enteroviruses29, polioviruses62 and rhinoviruses63. The natural 
product compound OSW-1, a high affinity ligand of OSBP, has also been demonstrated to 
exhibit anti-viral activity through its interaction with OSBP.11,29 Therefore, OSW-1 analogs 
with high selectivity to OSBP can be developed to effective anti-viral therapeutic agents.  
 The natural product OSW-1 can serve as a starting point for development of 
precision cancer therapeutic agent, however it cannot itself be a lead compound for ORP4 
drug development. The OSW-1 compound causes its cellular effects through interacting 
with OBSP and ORP4; but it shows approximately similar binding affinities for OSBP as 
it does for ORP4.10 This non-selective interaction would damper the proposed idea of 
ORP4 being a precision cancer protein target since OSW-1 can interact with OBSP in non-
cancer cells.21 Ligands with binding selectivity with ORP4 should be attainable since 
schweinfurthin A compound (Figure 3) exhibits binding affinity to OSBP at ~ 40 fold 
higher than to ORP4.10 
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Using OSW-1’s structure as a starting point, a series of modified OSW-1 scaffolds 
can be designed for rapid assembly of a focused OSW-1 analog library, then the analogs 
will be evaluated for their selective binding to ORP4 over OSBP and anti-proliferative 
activity against ORP4-dependent cancer cell lines. Multiple total syntheses of OSW-1 have 
been reported with very similar synthetic strategy (Section I.3).35,36,39,41–43 Many OSW-1 
analogs have been reported, but the OSW-1 analog development has largely been driven 
by derivatization that was synthetically convenient during the total synthesis route, as 
opposed to a directed effort to identify the crucial pharmacophore for OSW-1.4 This 
chapter describes the efforts and advances made in the design and synthesis of OSW-1-
related scaffolds. 
III.2 Designs of simplified scaffolds for OSW-1 mimetics 
III.2.1 Structure-activity relationship (SAR) of the OSW-1 compound 
The limited on-target structure-activity relationship (SAR) of compound OSW-1 
provides guidance for the design for new and improved OSW-1 scaffolds.4,10 Even though 
several OSW-1 analogs have been synthesized, their biological evaluation did not provide 
useful comparative activity information since they were not evaluated against the same 
cancer cell lines.4 Thus far, there has been only one report that provided the SAR 
information of the OSW-1 compound based on its direct cellular targets.10 The on-target 
SAR for the OSW-1 compound (Figure 10) demonstrated that: 1) sterically bulky 
substituents at the 3-hydroxyl position of the steroidal core block OSBP/ORP4 binding and 
therefore limit all biological activity (Section II.2.2); 2) the C-2’ arabinosyl acetate and C-
2” xylosyl benzoate are important for high affinity binding and potent cytotoxic activity; 
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and 3) introduction of large groups at C-3” hydroxyl of xylose did not affect OSBP/ORP4 
binding affinity or cytotoxicity (Section II.3.6).10 
 
Figure 10. Structure-activity relationship (SAR) of the OSW-1 compound 
 
III.2.2 Rationale and design of new OSW-1 scaffolds through a two-component 
approach 
Based on the SAR information for OSW-1 presented above along with the close 
examination of the known protein structures of the yeast OSBP/ORP homologs25, the key 
components of the OSW-1 compound that make direct contact with the OSBP/ORP4 
proteins are hypothesized to be the 1) steroidal core, 2) side chain and 3) benzoate group 
on C-2” of xylosyl moiety. In the working hypothesis, the steroidal aglycon loads into the 
binding pocket of the proteins produced by the conserved sterol binding domain (Figure 
4, Section I.2.1), with the side chain and disaccharide units extending out of the binding 
pocket making contact with other regions of the protein. This brings the side chain and 
benzoate moiety to close proximity (Figure 10). Since the side chain is hypothesized to 
make contact with other regions of the proteins outside of the conserved binding pocket, 
modifications to the side chain could be critical for the enhanced selectivity of the analogs 
to ORP4 over OSBP. The arabinose and likely the xylose moieties are hypothesized to 
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serve as a spacer for the extension of the critical benzoate moiety to the desired position 
near the side chain component, while the C-17 hydroxyl, C-22 ketone and the acetate 
moiety on the arabinose participate in a hydrogen-bonding network to provide the optimal 
conformation of the OSW-1 molecule. Therefore, a series of OSW-1-related scaffolds that 
will allow for the rapid generation of analogs with different side chains and simplified 
spacer units to position the benzoate into the optimal location and orientation are desired. 
The established total syntheses of OSW-135,36,39,41–43 are unsuitable for the rapid 
generation of the proposed analogs for the identification of ORP4-selective lead 
compounds. The published syntheses of OSW-1 mainly follow a 3-component strategy 
(i.e., steroidal aglycon, L-arabinose and D-xylose moieties), with each component requires 
8 to 10 steps of preparation (Section I.3). The L-arabinose and D-xylose components are 
combined through a Schmidt glycosylation reaction to form the disaccharide moiety; then 
the steroidal aglycon and disaccharide moiety are combined through a late-stage, low 
yielding Schmidt glycosylation reaction. This Schmidt glycosylation reaction to produce 
protected OSW-1 were problematic in my hands, with low yield and no recovery of starting 
materials (Section II.3.4). Therefore, any modification to the side chain or disaccharide 
unit will require several steps, capped by a very low-yield glycosylation reaction.  
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Scheme 15. A) Structure of OSW-1; B) proposed OSW-1-related scaffolds; C) the 
proposed two-component approach to OSW-1-related scaffolds 
 
The proposed series of OSW-1-related scaffolds are envisioned to arise from a two-
component combination synthesis strategy, with the side chain and the disaccharide units’ 
attachment to the steroidal aglycon through an E-ring bridge – a heterocyclic expansion on 
the steroidal aglycon (Scheme 15B). In this approach, the side chain and disaccharide 
replacement units can first be combined to form one component, and then that component 
will merge with the aglycon component to make the E-ring bridge. This approach will 
allow for rapid and convergent synthesis of OSW-1 analog compounds, since various side 
chain and disaccharide modifications can be prepared separately in the form of imines 
(compound 3.3, Scheme 15B), then this imine component can be combined with an alkene 
protected sterol 3.4 via a Lewis-acid mediated imino-ene type reaction (Scheme 15C). 
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Moreover, the size and stereochemistry of the appended E-ring bridge introduces rigidity 
and a new dimension of subtle modification to the relative position of the side chain and 
disaccharide to the aglycon moiety. Both spiro and fused substituted azacycle E-rings can 
possibly be constructed through the careful choice of Lewis acid. This reaction can both 
link and cyclize the two components in a one-pot operation. The aldehyde ene version of 
this reaction on sterol 3.4 has been successfully demonstrated (Scheme 16B, Section 
III.3.1). The screening of Lewis acid to activate the imino-ene reaction is being 
investigated by another lab member – Cori Malinky. In the meantime, it is critical to 
evaluate the effect of the introduction of the E-ring bridge on the biological activity of 
OSW-1-analogs. Therefore, OSW-1-closely-related analogs with only E-ring modification 
were synthesized and characterized (Scheme 16B, Section III.3.2.4). 
 




III.3 Results and discussion 
III.3.1 Validation of the two-component approach to OSW-1-related scaffolds 
The validation of the two-component approach to OSW-1-related scaffolds started 
with aldehydes instead of imines as one of the components, since one intermediate, namely 
homoallylic alcohol 3.10a (Scheme 17), was synthesized from paraformaldehyde during 
the OSW-1 steroidal aglycon synthesis (performed by Dr. Peddabudi). This homoallylic 
alcohol provided a great starting point for the investigation of intramolecular addition of 
C-22 alcohol to C16-17 alkene to form the appended E-ring (Scheme 17). Depending on 
the mechanism that the Lewis-acid mediated reaction proceeds through, spiro-oxetane 3.11 
(Markovnikov, Scheme 17) product or fused-tetrahydrofuran 3.12 (anti-Markovnikov, 
Scheme 17) product can be obtained. Both products will provide useful knowledge once 
they are evaluated for their biological activity.  
III.3.1.1 Intramolecular hydroalkoxylation reaction 
Several Lewis acids have been reported to catalyze this intramolecular 
hydroalkoxylation of inert alkenes.64–66 Some Lewis acids were examined for their ability 
to form the desired E-ring on the homoallylic alcohol 3.10 (Error! Reference source not f
ound.). 
 





Table 1. Condition screening for intramolecular hydroalkoxylation reaction 
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 Lewis acids scandium (III) trifluoromethanesulfonate [Sc(OTf)3], and silver (I) 
trifluoromethanesulfonate (AgOTf), in the presence of TBS-protected sterol 3.10a 
produced the spiro-oxetane product 3.11a and b along with a mixture of undesired side 
products (entry 1-2, Error! Reference source not found.), while silane-iodine failed to give a
ny cyclized product (entry 4, Error! Reference source not found.) and boron trifluoride 
diethyl etherate (BF3·Et2O) mainly deprotected sterol 3.10a (entry 3, Error! Reference s
ource not found.) . The TBS group seemed labile in the presence of Lewis acids, as seen in 
the observed deprotected starting material sterol 3.10b and deprotected spiro-oxetane 
product 3.11b. The report by Yang et al. showed that both Sc(OTf)3 and AgOTf catalyzes 
the anti-Markovnikov intramolecular hydroalkoxylation, with AgOTf giving higher yield 
of the cyclized product.64 When the conditions were applied to TBS-protected sterol 3.10a, 
mainly spiro-oxetane product (Markovnikov) was observed, possibly due to Baldwin’s rule 
for cyclization. The cyclization to produce the spiro-oxetane product is classified as 4-exo-
trig, which is favored as compared to the unfavored 5-endo-trig for the case of fused-
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tetrahydrofuran ring. Sc(OTf)3 gave the spiro-oxetane product 3.11a in 7% yield, and a 
trace amount of deprotected spiro-oxetane product 3.11b, along with deprotected sterol 
3.10a (28%) (entry 1, Error! Reference source not found.). AgOTf afforded higher yields o
f both protected (3.11a, 10%) and deprotected spiro-oxetane (3.11b, 12%) (entry 2, Error! 
Reference source not found.). The sterol 3.10a showed rearrangement in presence of 
AgOTf to compound 3.13b (27%). This type of rearrangement has been observed in steroid 
structures before67,68, where C16-17 olefin migrates to C13-14, and C18 methyl group 
shifts from C13 to C17. It was speculated that upon Lewis acid coordination with olefin, 
the olefin rearranged to a more stable tetrasubstituted position after a 1,2-methyl shift. 
 Since the TBS group on C-3 seemed to interfere with the cyclization reaction and 
resulted in a complicated mixture of products, it was removed to afford compound 3.10b, 
which was then subjected to the intramolecular hydroalkoxylation condition (entry 5-6, 
Error! Reference source not found.). BF3·Et2O produced the spiro-oxetane 3.11b at a higher y
ield (45%) as compared to AgOTf (17%). The unwanted rearranged sterol 3.13a was 
observed in both cases. This section demonstrated the ability of homoallylic alcohol 3.10 
to undergo cyclization for the formation of E-ring. 
III.3.1.2 Tandem carbonyl ene-hydroalkoxylation reaction 
During the synthesis of OSW-1 aglycon, homoallylic alcohol 3.10 was formed 
through a Lewis acid-mediated carbonyl-ene reaction of (Z)-3β-hydroxyl-5,17(20)-
pregnadiene 3.4 with paraformaldehyde. Since both carbonyl-ene and intramolecular 
hydroalkoxylation reactions involve Lewis-acid, performing these reactions in tandem 
would allow for the rapid assembly of the side chain and formation of the E-ring bridge in 
one operation (Scheme 18).  
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Scheme 18. Tandem carbonyl-ene and hydroalkoxylation reactions 
 
Table 2. Condition screening for tandem carbonyl ene-cyclization reaction 
Entry R R1 
Lewis 
acid 
Solvent Temp. Results 









































 The tandem ene-cyclization reaction was demonstrated successfully with the 
reaction of pregnadiene 3.4 and paraformaldehyde to produce the homoallylic alcohol 3.5 
and spiro-oxetane 3.6 (entry 1, Error! Reference source not found.). The rearrangement of p
regnadiene 3.4 to 3.14 was observed, similar to the rearrangement observed in Section 
III.3.1.1. However, when an aliphatic aldehyde (hexanal, entry 2, Error! Reference source n
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ot found.) was used instead of paraformaldehyde, the reaction resulted in a streaky mixture 
on TLC analysis, and a complicated mixture of products based on 1H NMR. The free 
hydroxyl group on C-3 might have undergone addition to the hexanal under Lewis-acidic 
condition to form a hemiacetal. The streakiness from TLC plate could have resulted from 
the equilibrium of this hemiacetal formation. When the reaction temperature was lowered 
to prevent this hemiacetal formation, only rearranged pregnadiene 3.14 was observed in 
trace amounts (entry 3, Error! Reference source not found.). When the C-3 hydroxyl group 
was protected as a benzyl ether, the reaction afforded homoallylic alcohol 3.4, trace amount 
of spiro-oxetane 3.5 and rearranged pregnadiene 3.14 (entry 4, Error! Reference source not 
found.). Another aliphatic aldehyde (isovaleraldehyde) was examined in this reaction, 
which resulted in a complex mixture of products (entry 5, Error! Reference source not 
found.). The fused-tetrahydrofuran product 3.7 was observed, which suggested the reaction 
might have proceeded through a slightly different mechanism, since the formation of this 
product was unfavored according to Baldwin’s rule (Section III.3.1.1).  
 Section III.3.1 demonstrated that the E-ring bridge can be constructed rapidly from 
two components (pregnadiene and aldehyde) in one operation. Even though a mixture of 
products were observed, the reaction should be tunable with the careful choice of Lewis 
acid reagents and the reaction conditions. The investigation of imino-ene-cyclization is 
underway with another lab member-Cori Malinky. 
III.3.2 Synthesis of OSW-1-related analogs with only E-ring modification 
As the methodology for the two-component approach being developed, it is critical 
to evaluate the effects of E-ring bridge modification on the biological activity of OSW-1. 
Therefore, a set of analogs that are closely related to OSW-1 containing the amine on C-
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22 and N-glycosidic linkage with OSW-1 disaccharide moiety was synthesized. The 
retrosynthesis of these analogs is outlined in Scheme 19. OSW-1 analogs 3.8 and 3.9 can 
be accessed through Lewis acid-mediated cyclization of N-linked glycosylated product 
3.15. Compound 3.15 is a glycosylated product of OSW-1 disaccharide 3.17 and 
homoallylic amine 3.16. Homoallylic amines 3.16 can be converted from homoallylic 
alcohols 3.18, which is the product of carbonyl-ene reaction between pregnadiene 3.14 and 
4-methylpentanal similar to the reaction investigated in Section III.3.1.2. 
 
Scheme 19. Retrosynthesis of OSW-1 analogs with E-ring modification 
 
III.3.2.1 Synthesis of homoallylic alcohols 3.18 
The carbonyl-ene reaction presented in Section III.3.1.2 resulted in a mixture of 
homoallylic alcohols and cyclized products (Scheme 18). For the synthesis of these OSW-
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1 analogs, only homoallylic alcohols were desired, so the reaction condition was optimized 
for the production of only homoallylic alcohols. 
 
Scheme 20. Carbonyl-ene reaction to form homoallylic alcohols 
 
Table 3. Condition screening for carbonyl-ene reaction 









































 The carbonyl-ene reaction was first examined with BF3·Et2O as the Lewis acid in 
the presence of 4Ǻ molecular sieves69, with the pregnadiene 3.4 added to the mixture of 
aldehyde and Lewis acid to lower the rate of pregnadiene rearrangement. Under these 
conditions, the reactions produced only homoallylic alcohols with isovaleraldehyde and 
paraformadedhye in average to good yield (entry 1-2, Error! Reference source not found.), w
ith trace amounts of cyclized products. The benzyl ether protecting group on C-3 hydroxyl 
was replaced with an acetate group for ease of removal later in the synthesis, since 
hydrogenolysis of benzyl ether might also reduce the other olefins in the molecule. A report 
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by Houston et al. demonstrated the carbonyl-ene reaction with a more potent Lewis acid- 
dimethyaluminum chloride (Me2AlCl) at very low temperature.
70 The carbonyl-ene 
reaction of acetylated pregnadiene 3.4 with isovaleraldehyde proceeded smoothly to afford 
the desired homoallylic alcohols 3.5 in great yield (85%), with no cyclized products 
observed (entry 3, Error! Reference source not found.).  
 To synthesize the homoallylic alcohols with the OSW-1 side chain, the aldehyde 
needed was 4-methylpentanal. However, this was not available commercially, so it was 
synthesized in the lab form 4-methylpentanoic acid (Scheme 21A). 4-methylpentanoic acid 
was reduced by lithium aluminum hydride to 4-methylpentanol71, which was selectively 
oxidized to 4-methylpentanal with pyridinium chlorochromate72. 
 
Scheme 21. A) Synthesis of 4-methylpentanal; B) carbonyl-ene reaction with 4-
methylpentanal 
 
The carbonyl-ene reaction was then carried out with 4-methylpentanal to install the 
OSW-1 side chain (entry 4, Error! Reference source not found.). This reaction formed the d
esired homoallylic alcohols 3.20 in good yield (70%), along with a side product 3.21 
(Scheme 21B). The side product had a very similar polarity with the desired homoallylic 
alcohols, so it was first thought to be one of the homoallylic alcohol isomers. After 
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extensive purification (through column chromatography with acetone-hexanes mixture 
eluent, and HPLC), the side product was isolated in 9.7% borsm yield. A full 
characterization through 2D NMR spectroscopy (HSQC, COSY, and HMBC) revealed the 
side product as spiro-oxetane 3.21 (see Experimental section for full characterization 
details-Error! Reference source not found.). This was an unexpected side product. Since t
he carbonyl-ene reaction proceeded very cleanly to afford the desired homoallylic alcohols 
with isovaleraldehyde (entry 3, Error! Reference source not found.), it was hypothesized t
hat the spiro-oxetane side product could have arisen when a contaminant from the synthesis 
of 4-methylpentanal got carried to the carbonyl-ene reaction. This observation started a 
small investigation into the formation of the spiro-oxetane (Section III.3.2.2). 
III.3.2.2 Investigation of pathways to spiro-oxetane product 3.21 
Since 4-methylpentanal (also known as isocaproaldehyde) was not available 
commercially, it was synthesized in our lab. Pyridinium chlorochromate (PCC) oxidized 
the 4-methylpentanol to the desired aldehyde. 1H NMR spectrum of this crude mixture 
showed mainly 4-methylpentanl present, along with a small singlet observed at 11.36 ppm 
(See Chapter appendix). Signals in this region normally correspond to the acidic proton of 
a carboxylic acid. Even though PCC is mainly employed for the controlled oxidation of a 
primary alcohol to an aldehyde, there was a possibility of overoxidation to afford 
carboxylic acid. If water was present, it could react with the aldehyde to form a hydrate 
adduct. PCC reagent can then oxidize the hydrate to carboxylic acid.  
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Scheme 22. Reactions of acetylated pregnadiene 3.19 with 4-methylpentanoic acid or 
acetone 
 
Since a trace amount of carboxylic acid was observed in the 1H NMR spectrum of 
crude aldehyde product, it was hypothesized that the carboxylic acid could play a role in 
the formation of the spiro-oxetane product. Moreover, the spiro-oxetane product was 
essentially a net condensation product of the diene 3.19 and a molecule of acetone. Both 
of these hypotheses were evaluated by treating the diene 3.19 with 4-methylpentanoic or 
acetone (Scheme 22) in the exact conditions that the carbonyl-ene reaction with 4-
methylpentanal was carried out. However, both reactions yielded neither homoallylic 
alcohols nor spiro-oxetane. The diene 3.19 was recovered fully, without any sign of 
rearrangement. This was not very surprising, since ketones and carboxylic acids are more 
electron-rich, due to electron donation from the alkyl and hydroxyl groups, and are 
therefore are not as reactive as aldehydes in the carbonyl-ene reaction. 
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Scheme 23. Formation and fragmentation of 4-hydroxy-4-methylpentanoic acid 
 
Since neither the carboxylic acid nor acetone resulted in spiro-oxetane product, 
another explanation was sought. In the 13C NMR of the crude aldehyde, a small signal at 
around 64 ppm was observed (See Chapter III Appendix, #1434). Signals in this chemical 
shift region are diagnostic for C-O bonds. This signal suggests the possibility that the 
aldehyde or carboxylic acid underwent a hydroxylation reaction at the tertiary carbon 
during the oxidation condition. It has been shown that Cr3+ species, in acidic condition, 
could hydroxylate tertiary carbon hydrocarbons.73,74 If 4-methylpentanoic acid underwent 
chromium-mediated hydroxylation at its tertiary carbon, it would have been converted to 
4-hydroxyl-4-methylpentanoic acid 3.22 (Scheme 23). To provide the equivalent of 
acetone for the formation of the spiro-oxetane 3.21, the hydroxy acid 3.22 could be 
envisioned to undergo fragmentation under the carbonyl-ene reaction condition to afford 
CO2, ethylene, and an equivalent of acetone (Scheme 23). The production of two moles of 
gas is a great driving force for the fragmentation to proceed, even though two carbon-
carbon bonds would be broken. Since the carbonyl-ene reaction of diene 3.19 and acetone 
did not produce the expected spiro-oxetane, the equivalent of acetone could have been 
produced and reacted with the participation of the possible remnant chromium species from 
PCC oxidation. To investigate the role of hydroxy acid in the formation of spiro-oxetane, 
4-hydroxy-4-methylpentanoic acid was desired. 
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Scheme 24. Conversion of dimethyl-γ-butyrolactone to 4-hydroxy-4-methylpentanoic 
acid 
 
4-hydroxy-4-methylpentanoic acid 3.25 (Scheme 24) was not available 
commercially, but dimethyl-γ-butyrolactone 3.23 could be purchased. The lactone 3.23 
was subjected to mild saponification conditions (NaOH in MeOH) to open the lactone 
(Scheme 24). Neutralization of aqueous phase during the work up afforded an off-white 
solid, which was characterized as sodium 4-hydroxy-4-methylpentanoate 3.24.75 Efforts to 
obtain free carboxylic acid from the sodium salt using aqueous hydrochloric acid resulted 
in only lactone 3.23 identified through 1H NMR analysis. Literature suggested that due to 
the Thorpe-Ingold effect 76, where the geminal dimethyl substituents produce a 
compression of the internal angle to facilitate the intramolecular cyclization, the molecule 
was prompted to stay in the cyclized lactone form as compared to the open carboxylic acid 
form. More specifically, it was demonstrated that in acidic aqueous conditions, the 
equilibrium ratio of hydroxy acid: lactone for 4-hydroxy-4-methylpentanoic acid was 
2:98.77 This explained the observation of lactone 3.23 when sodium carboxylate 3.24 was 
neutralized with aqueous HCl. Therefore, anhydrous conditions to convert sodium 
carboxylate salt to carboxylic acid were investigated. The sodium carboxylate salt was 
treated with Dowex resin, or dry silica gel, which is weakly acidic in anhydrous 
tetrahydrofuran (THF). 1H NMR analysis of the resulting mixture from both cases are 
presented in Figure 11. In the 1H NMR spectrum of Dowex treated material, along with 
signals that were corresponded to lactone, a new set of signals was observed with the 
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chemical shifts different from that of lactone 3.23 or sodium carboxylate 3.24. This new 
set of signals was assigned as 4-hydroxy-4-methylpentanoic acid. The 1H NMR spectrum 
of silica treated material showed mainly 4-hydroxy-4-methylpentanoic acid. Therefore, dry 
silica in anhydrous THF seemed to be the best method to convert lactone 3.23 to carboxylic 
acid 3.25.  
 
Figure 11. 1H NMR spectra of lactone 3.23, sodium carboxylate 3.24, and hydroxy acid 
3.25 
 
The role of carboxylate salt 3.24 and carboxylic acid 3.25 in the formation of the 
spiro-oxetane product was then investigated. Diene 3.19 was treated with sodium 
carboxylate 3.24 or carboxylic acid 3.25 in the same condition of the carbonyl-ene reaction 
that was used before. In both cases, no reaction was observed, the diene was recovered 
fully. This result suggested that the hydroxy carboxylic acid 3.25 and its derivative 3.24 
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alone was not responsible for the formation of the spiro-oxetane 3.21. It could be the 
synergistic effect of residual chromium species from PCC oxidation, 4-hydroxy-4-
methylpentanoic acid and dimethylaluminum chloride in the carbonyl-ene reaction 
condition.  
 
Scheme 25. Reactions of diene 3.19 with sodium 4-hydroxy-4-methylpentanoate or 4-
hydroxy-4-methylpentanoic acid 
 
 The investigation into possible pathways of spiro-oxetane formation halted here, 
due to time and resource constraint. The spiro-oxetane side product was observed 
consistently for multiple carbonyl-ene reactions. Later, a better method was employed for 
the work-up of the PCC oxidation reaction. This improved work-up passed the crude 
reaction mixture through a column composed of silica and neutral alumina gel to remove 
remnant chromium species. The NMR analysis of the resulted aldehyde did not show any 
signal for carboxylic acid (1H NMR at 11.36 ppm) or hydroxy carboxylic acid (13C NMR 
at 64 ppm). The carbonyl-ene reaction since then have been proceeded smoothly, with the 
yield of desired homoallylic alcohols near 85%, and no spiro-oxetane was observed. These 
observations also strengthen the hypothesis of chromium species involvement in the 
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formation of spiro-oxetane. Future efforts will be required to develop this potential route 
to a one-step formation of spiro-oxetane. If successful, this spiro-oxetane reaction would 
allow for the formation of a complex motif that is important in medicinal chemistry78 from 
the simple building blocks of olefins and hydroxy carboxylic acid. 
III.3.2.3 Synthesis of steroidal homoallylic amines 
The synthesis of OSW-1 analogs continued with the conversion of homoallylic 
alcohol 3.21 to homoallylic amine 3.28 (Scheme 26). Oxidation of homoallylic alcohol 
3.20 with pyridinium dichlormate afforded C-22 ketone 3.26 in decent yield (60%). Ketone 
3.26 was then transformed to a mixture of oxime isomers 3.27 in good yield (75%), gearing 
up for the reduction to form homoallylic amines 3.28.  
 
Scheme 26. Synthesis of homoallylic amines from C-acetylated homoallylic alcohol 3.20 
 
 The oximes proved to be resistant to reduction conditions. Several metal-mediated 
reduction conditions were screened, but only lithium aluminum hydride (10 equiv) in 
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refluxed tetrahydrofuran produced decent yield of homoallylic amines 3.28. The acetate 
group did not survive the reduction condition.  
Through the results obtained from screening the reduction of oximes, it was clear 
that more robust protection group on C-3 hydroxyl would be required to survive the harsh 
condition of oxime reduction. The acetate group, being an ester, did not survive the LAH 
reduction condition. The deprotection of C-3 hydroxyl group after the oxime reduction 
added complications in the subsequence steps, more specifically, the glycosylation 
reaction. With two competing nucleophiles (C-3 hydroxyl and C-22 amine), the Schmidt 
glycosylation condition seemed to favor the O-glycosidic linkage formation but not the N-
glycosidic bond (Scheme 22, Section III.4.2). Selective protection of the C-3 hydroxyl 
group was possible in the presence of free amine through a silyl ether protecting group, but 
the reaction yield was low (40%) due to difficulties in purification of the desired product. 
Therefore, to reduce the number of reaction steps and increase the overall yield, a p-
methoxybenzyl (PMB) group was chosen for the protection of the C-3 hydroxyl group. 
PMB protecting group is stable towards reduction conditions. Furthermore, the hydroxyl 
groups on the OSW-1 disaccharide moiety were also protected as a PMB ether. This would 




Scheme 27. Synthesis of C-3-PMB protected homoallylic amines 
 
Trans-dehydroandrosterone 3.29 underwent PMB-protection in the presence of 
2,4,6-tris(p-methoxybenzyloxy)-1,3,5-triazine (triBOT-PM) reagent.79 TriBOT-PM can be 
synthesized on large scale from p-methoxybenzyl alcohol and cyanuric chloride with high 
yield (86%) (Scheme 27).79 The PMB protection proceeded smoothly with a catalytic 
amount of trifluoromethanesulfonic acid. The protected product 3.30 was purified through 
recrystallization in isopropanol, which was beneficial as compared to column 
chromatography on gram scale. A Wittig reaction converted ketone 3.30 to diene 3.31, 
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which was also purified through recrystallization in isopropanol. It seems that the presence 
of PMB group allowed the molecule to be recrystallized from isopropanol, because 
attempts to recrystallize the diene 3.19 with acetate protecting group instead of PMB were 
not successful in purifying the desired product. 
Next, the aliphatic side chain was installed through a carbonyl-ene reaction, similar 
to the synthesis of homoallylic alcohols 3.20 described before. Pregnadiene 3.31 (1 equiv.) 
was reacted with 4-methylpentanal (3 equiv., synthesized in the lab) in the presence of 
dimethylaluminum chloride (5 equiv.) at low temperature. The reaction afforded the 
desired mixture of homoallylic alcohols 3.32 in good yield (88%), with no observation of 
the side product spiro-oxetane 3.21. The homoallylic alcohol mixture was oxidized to C-
22 ketone 3.33 in the presence of pyridinium dichromate (PDC). Ketone 3.33, through a 
reductive amination with oximes 3.34 as an intermediate, was converted to a mixture of 
homoallylic amine isomers 3.35. The low yield of oximes reduction was also observed 
before in the C-3 acetate series. The PMB-protecting group on C-3 of the steroidal core, as 
predicted, survived the LAH reduction condition. With C-3 hydroxyl protected, the mixture 
of homoallylic amines proceeded forward to the N-glycosylation reaction with the OSW-
1 disaccharide moiety to form the OSW-1 analog for the validation of the proposed two-
component approach. 
III.3.2.4 N-glycosylation to form OSW-1-related analogs: trials and tribulations 
With the homoallylic amines prepared, the key N-glycosylation reaction between 
the homoallylic amines and the disaccharide moiety to assemble OSW-1 mimetics could 
commence. Although the long-term goal is to replace the OSW-1 disaccharide 
carbohydrates with isosteric replacement units, the first OSW-1 mimetics will include the 
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OSW-1 disaccharide linked through the amine. Evaluating these new amine OSW-1 
mimetics for biological activity and OSBP/ORP4 binding will be important validation for 
this overall approach to new OSW-1 analogs. The O-glycosylation in the synthesis of 
deuterated OSW-1 (Section II.3.4) had proven to be low-yielding and given a complicated 
reaction mixture. Different glycosylation methods were investigated and discussed below.  
 
Scheme 28. Schmidt glycosylation of homoallylic amine 3.28 and disaccharide imidates 
43 afforded O-glycosylated product 
  
First, the Schmidt glycosylation condition that was used to assemble OSW-1 was 
applied for this N-glycosylation transformation. Steroidal acceptor 3.28 with free C-3 
hydroxyl group and C-22-amine was reacted with disaccharide imidates 43 in the presence 
of TMSOTf promoter at low temperature (Scheme 28). This reaction gave a complex 
mixture of products. Purification through pTLC isolated one glycosylated product, along 
with products from disaccharide moiety decomposition. This coupled product, however, 
was characterized as the unwated O-glycosylated product 3.36 through 2D NMR analyses. 
This reaction outcome stressed the importance of a protecting group on the C-3 hydroxy to 
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eliminate the O-glycosylation possibility. Hence, a p-methoxybenzyl (PMB) protecting 
group was installed on C-3 hydroxyl (compound 3.35, Scheme 27) before the LAH oxime 
reduction step. 
 
Scheme 29. N-glycosylation through Schmidt glycosylation method 
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The PMB-protected homoallylic amines were purified through HPLC to afford pure 
isomers for the subsequent optimization of the Schmidt glycosylation reaction. The major 
isomer (the stereochemistry was later determined to be R through X-ray crystallography) 
was subjected to the Schmidt glycosylation reaction. Since the HPLC purification used a 
mild, acidic eluent (0.1% formic acid in water), the purified PMB-protected homoallylic 
amine was characterized as ammonium salt 3.35a (Scheme 29). For the Schmidt 
glycosylation reactions, the neutralization of the this ammonium salt 3.35a to reveal the 
free amine in situ was attempted with bases of different activity: 1) a mild non-nucleophilic 
base-triethyl amine (entry 1 and 2, Error! Reference source not found.) or 2) a strong base-s
odium hydride (entry 3, Error! Reference source not found.). In all entries, the base was 
added to deprotonate the ammonium salt and form the free amine, before the disaccharide 
glycosyl donor 43 and TMSOTf promoter was added. TMSOTf was added in small 
increments (0.1 equiv) at low temperature and the progress of the reaction was monitored 
by TLC analysis. Addition of more TMSOTf (entry 2, Error! Reference source not found.) i
n order to accommodate for the presence of the base or advance a stalled reaction led to 
some decomposition of disaccharide donor 43 based on TLC, and NMR. No desired 
glycosylated product was observed for entries 1-3, but the homoallylic amine 3.35b was 
recovered as the free amine after acid-base work-up of the glycosylation reaction and silica 
gel column chromatography purification. It was possible that the base present in the 
glycosylation reaction mixture complexed with the Lewis acid TMSOTf to interfere with 
the formation of the desired glycosylated product. 
Since the deprotonation of the ammonium salt in situ did not work as expected, the 
Schmidt glycosylation condition was attempted again with the purified homoallylic amine 
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3.35b (Scheme 29) recovered from entries 1-3 (entry 4, Error! Reference source not f
ound.). TLC profile of reaction progress was similar to that of entry 1-3. Once the reaction 
seemed to halt based on TLC analysis, the reaction was stopped. Upon purification, no 
desired glycosylated product was observed, but the disaccharide moiety showed 
decomposition. 
The Schmidt glycosylation method was unsuccessful at producing the desired N-
linked glycosylated product, possibly due to the different reactivity of the free amine as the 
glycosyl acceptor. Amines are normally more Lewis basic than oxygen. In this case, the 
basic primary amine might have acted as a Lewis base rather than nucleophile. The Lewis 
basicity of amine interferes with the glycosylation reaction through amine interaction with 
the strong Lewis acid TMSOTf, which prevented the TMSOTf promoter from catalyzing 
the glycosylation reaction. Searching through literature, there were fewer reports showing 
the successful N-glycosylation through the Schmidt glycosylation method. Alternative 
glycosylation methods were then investigated.  
 
Scheme 30. A) Reported N-glycosylation of indole derivative and chloro sugar80; B) N-
glycosylation of homoallylic amines and bromo-L-arabinopyranoside 
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 A different and simpler glycosyl donor, bromo-L-arabinopyranoside 92, was 
employed for the glycosylation condition with the homoallylic amine 3.35 in the presence 
of sodium hydride (Scheme 30). Bromo monosaccharide 92 was an intermediate in the 
synthesis of the L-arabinose moiety for the total synthesis of the OSW-1 compound 
(Section II.3.1). Li et al. demonstrated successful glycosylation reaction between indole, 
halo sugar in the presence of sodium hydride with high yield (Scheme 30A).80 The 
reactivity between homoallylic amines 3.35 and indole differ in the elevated acidity of the 
indole compared to amine 3.35. The glycosylation reaction produced only recovered 
starting materials. 
 
Scheme 31. Synthesis of N-2-nitrobenzenesulfonyl-protected amines and 2,3,4-triacetyl-
α,β-L-arabinopyranose 
 
 A different method, the Fukuyama-Mitsunobu reaction has been shown to 
successfully form the N-glycosidic bond between N-2-nitrobenzenesulfonyl-protected 
amines (i.e. nosyl amines, Ns-amines) and glycosyl donors in their hemiacetal form under 
mild, near neutral reaction conditions with good yield.81,82 The reaction was considered for 
this N-glycosylation transformation because of its mild conditions and the lack of a strong 
Lewis acid to potentially decompose the disaccharide glycosyl donor as occurred during 
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attempted Schmidt glycosylation. The mixture of homoallylic amines 3.35 were converted 
to mono-nosylate amines 3.39 smoothly with high yield (Scheme 31).83 The N-2-
nitrobenzenesulfonyl (nosyl or Ns)group acts as both a protecting and activating group84. 
The nosyl group increases the acidity of the nitrogen’s proton which in turn facilitates the 
Mitsunobu reaction, since the pronucleophile should have pKa below 11 for a successful 
Mitsunobu reaction.85 The nosyl group can later be removed easily with soft nucleophiles 
(such as thiols) in mild condition to give the corresponding secondary amines.84 The 
saccharide moiety participates in the Fukuyama-Mitsunobu reaction in their hemiacetal 
form, which can be easily accessed from the syntheses of either monosaccharide (one step 
from intermediate 3486, Scheme 7, Section II.3.1) or disaccharide moieties of OSW-1 
(compound 98, Scheme 9 in Section II.3.2).  
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 Further optimizations with Ns-amines 3.39 and monosaccharide 3.40 were carried 
out. Increasing Mitsunobu reagents (triphenylphophine and DIAD) along with more 
equivalents of monosaccharide 3.40 improved the yield slightly (entry 3, Error! Reference s
ource not found.). When diethyl azodicarboxylate (DEAD) was used instead of DIAD, 
desired product was formed in trace amount (entry 4, Error! Reference source not found.). F
inally, when the reaction mixture was heated to 60°C for 24 hours after it had warmed up 
to ambient temperature from -78°C, the desired product was isolated in an acceptable yield 
(47%, entry 5, Error! Reference source not found.). Glycosylated product 3.41 was c
haracterized through X-ray crystallography to confirm the desired β-N-glycosidic linkage 
(See Chapter appendix). Along with the desired product, another coupled product was 
observed in trace amount. This side product could be the α-N-glycosidic linkage, or the 
orthoamide that could form when the Ns-amine trapped the reactive intermediate resulting 
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from the neighboring group participation of C-2 acetate and the anomeric carbon (similar 
to what was observed during the synthesis of compound d-OSW-1-Section II.3.4). 
 
Scheme 33. Fukuyama-Mitsunobu reaction with OSW-1 disaccharide moiety 
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 Using the optimized Fukuyama-Mitsunobu condition from the reaction with the 
monosaccharide, the Mitsunobu reaction was attempted with the disaccharide hemiacetal 
98 (Scheme 33). The desired N-glycosylated product 3.42 was observed, but only in trace 
amount. The equivalency of disaccharide hemiacetal was lowered slightly due to its 
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scarcity. When the reaction was carried out on larger scale (entry 1, Error! Reference source n
ot found.), the desired product was isolated in analytical purity through HPLC in low yield 
(5%). This allowed for the full characterization of 3.42 through 2D NMR spectroscopy 
(See Chapter III Appendix). The stereochemistry at the anomeric center was putatively 
assigned as β-linkage based on the similarity between the chemical shifts of anomeric 
proton and carbon between the glycosylated monosaccharide (compound 3.41) and the 
glycosylated disaccharide (compound 3.42). Attempts at growing crystals for X-ray 
crystallography analysis have not been successful.  
 
Scheme 34. Synthesis of OSW-1 mimetics 
 
 Further optimizations for the Fukuyama-Mitsunobu reaction with the disaccharide 
moiety will be carried out once more starting materials are available. The N-glycosylated 
product will need to go through two deprotection steps: 1) deprotection with 2,3-dichloro-
5,6-dicyano-1,4-benzoquinone (DDQ) to remove PMB protecting groups on C-3 and 
disaccharide moiety; then 2) deprotection with phenylthiol to remove the nosyl protecting 
group on the C-22 nitrogen (Scheme 34). The fully-deprotected compounds can be 
147 
evaluated for its biological activity, or subjected to cyclization condition to produce the 
proposed E-ring for the validation of the two-component approach of OSW-1-related 
analogs.  
III.4 Conclusion 
OSW-1, a natural product with the cellular target of OSBP/ORP4, serves as a good 
starting point for the development of precision cancer therapeutic agent, since ORP4 
protein has recently been validated as a precision cancer therapeutic target for leukemia 
and cervical cancer.34,59 Based on the structure of OSW-1, a concise and convergent two-
component approach to assemble OSW-1-related scaffolds with the E-ring bridge was 
developed. The approach was demonstrated through the formation of the E-ring bridge via 
a tandem carbonyl ene-cyclization reaction of the steroidal core and side chain aldehyde. 
Along the way, an interesting transformation was observed during the carbonyl-ene 
reaction to form an unexpected spiro-oxetane product. Lastly, to examine the effects of the 
new modification on the biological activity of OSW-1, a set of OSW-1-related analogs with 
E-ring are being assembled through an atypical glycosylation methodology- a Fukuyama 
Mitsunobu reaction. The biological evaluations of these analogs will provide information 
to shape the development of future OSW-1 analogs as lead compounds for precision cancer 
therapeutic agents. 
III.5 Experimental section 
III.5.1 General methods 
All reactions were performed in oven-dried glassware under a positive pressure of 
nitrogen unless noted otherwise. Flash column chromatography was performed as 
described by Still et al.55 employing E. Merck silica gel 60 (230-400 mesh ASTM). TLC 
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analyses and preparative TLC (pTLC) purification was performed on 250µm Silica Gel 60 
F254 plates purchased from EM Science and Fluka Analytical. All solvents and chemicals 
were used as purchased without further purification. Solvents used in the reactions were 
collected under nitrogen from a Pure Solv 400-5-MD Solvent Purification System 
(Innovative Technology). Infrared spectra were recorded on a Shimadzu IRAffinity-1 
instrument, or Bruker Tensor 27 spectrometer, and IR spectra peaks are reported in terms 
of frequency of absorption (cm-1). 1H and 13CNMR spectra were recorded on VNMRS 300, 
VNMRS 400, VNMRS 500 or VNMRS 600 MHz-NMR Spectrometer. Chemical shifts for 
proton and carbon resonances are reported in ppm (δ) relative to the residual proton or the 
specified carbon in chloroform (δ 7.26, proton; 77.16, carbon). High-resolution mass 
spectrometry (HRMS) analysis was performed using Agilent 6538 high-mass-resolution 
QTOF mass spectrometer. HPLC purification was performed on Shimadzu LCMS 2020 
system [LC-20AP (pump), SPD-M20A (diode array detector), LCMS-2020 (mass 
spectrometer)]. Semi-preparative HPLC purification was performed using Phenomenex 
Luna C-18(2) column, 5µm particle size (250 mm x 4.6 mm), supported by Phenomenex 
Security Guard cartridge kit C18 (4.0 mm x 3.0 mm); Phenomenex Luna C-8(2) column, 
5µm particle size (250 mm x 4.6 mm), supported by Phenomenex Security Guard cartridge 
kit C8 (4.0 mm x 3.0 mm) and HPLC-grade solvents. 
III.5.2  Compound data 
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Entry 1,Error! Reference source not found.: representative experimental details. Other e
ntries were performed in a similar fashion 
To a 5mL pear-shaped flask was added 3.10a (17mg, 0.0382mmol) and Sc(OTf)3 (1mg, 
0.0020mmol). The flask was sealed, purged with N2, and charged with dry 1,2-
dichloroethane (250µL). The reaction mixture was stirred at RT and the progress was 
monitored by TLC (10% EtOAc/hex). The cloudy, colorless mixture turned to clear, light 
purple after 15 minutes, and to clear, light orange later. After 42h, the reaction mixture was 
filtered through a short pipet silica gel column, packed with DCM. The mixture was then 
diluted in DCM and passed through a short silica pipet column, eluted with DCM (10mL) 
and EtOAc (10mL) which were collected as two separate fractions. Each fraction (DCM 
and EtOAc) was separated further through flash chromatography (EtOAc/hexanes 
gradients) to afford the reported products.  
 
3.11b: 1H NMR (400 MHz, Chloroform-d) δ 5.38 – 5.32 (m, 1H), 3.87 (dd, J = 8.5, 6.4 Hz, 
1H), 3.53 (ddd, J = 15.8, 10.9, 4.6 Hz, 1H), 3.30 (dd, J = 8.5, 7.2 Hz, 1H), 2.35 – 2.27 (m, 
1H), 2.25 – 2.12 (m, 2H), 2.10 – 1.99 (m, 1H), 1.96 – 1.80 (m, 3H), 1.77 – 1.66 (m, 1H), 
1.65 – 1.48 (m, 6H), 1.47 – 1.36 (m, 2H), 1.35 – 1.23 (m, 2H), 1.20 – 1.02 (m, 3H), 0.98 
(s, 3H), 0.96 (s, 3H), 0.91 (d, J = 7.1 Hz, 3H), 0.89 – 0.79 (m, 1H). 13C NMR (101 MHz, 
Chloroform-d) δ 140.89, 121.62, 94.16, 72.09, 71.88, 54.48, 52.32, 45.97, 45.40, 42.15, 
40.54, 37.68, 37.00, 33.15, 32.93, 31.57, 29.92, 27.09, 20.62, 18.93, 18.48, 13.64. The 
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structure of 3.11b was confirmed through 2D NMR analysis. See Chapter appendix for 
1H and 13C NMR spectra, Appendix for 2D NMR spectra. 
 
3.13b: 1H NMR (600 MHz, Chloroform-d) δ 5.44 – 5.40 (m, 1H), 3.80 (dd, J = 10.6, 3.9 
Hz, 1H), 3.57 – 3.51 (m, 1H), 3.40 (dd, J = 10.6, 8.4 Hz, 1H), 2.32 (ddd, J = 12.6, 4.9, 2.3 
Hz, 1H), 2.26 – 2.15 (m, 3H), 2.14 – 2.05 (m, 2H), 2.04 – 1.98 (m, 1H), 1.94 (dt, J = 13.3, 
3.5 Hz, 1H), 1.89 – 1.74 (m, 4H), 1.67 – 1.48 (m, 4H), 1.41 (ddd, J = 13.1, 9.5, 5.4 Hz, 
1H), 1.28 – 1.18 (m, 1H), 1.16 – 1.08 (m, 2H), 1.05 (s, 3H), 0.98 (s, 3H), 0.86 (d, J = 6.8 
Hz, 3H). 13C NMR (151 MHz, Chloroform-d) δ 141.54, 140.05, 137.29, 121.99, 72.16, 
65.76, 51.44, 49.34, 42.58, 42.31, 37.20, 37.08, 33.28, 32.62, 31.72, 31.65, 31.32, 25.20, 
23.38, 23.20, 18.87, 13.05. The structure of 3.13b was confirmed through 2D NMR 
analysis. See Chapter appendix for 1H and 13C NMR spectra, Appendix for 2D NMR 
spectra. 
Entry 1, Error! Reference source not found. 
To a mixture of 4Ǻ MS powder (10mg) in anhydrous DCM (100 µL) was added BF3·Et2O 
(7.4 µL, 0.06mmol). The cloudy mixture was stirred at R.T. for an hour. Then, to this 
mixture was added (Z)-3β-hydroxy-5,17(20)-pregnadiene 3.4 (15mg, 0.050 mmol, 
dissolved in 200 µL anhydrous DCM), and paraformaldehyde (1.5mg, 0.05mmol) 
respectively. The mixture was then cooled to -10°C (mixture of acetone and dry ice). The 
reaction progress was monitored by TLC (30%EtOAc/hexanes, CAM stain). There was a 
new spot with Rf=0.2, consistent with homoallylic alcohol product formed on the TLC 
151 
plate. After 1 hour, the reaction seemed to halt. To the mixture was added more 
paraformaldehyde (1.5mg, 0.05mmol). After 2 hours, to the reaction mixture was added 
more 4Ǻ MS powder (10mg) and BF3·Et2O (6.2 µL, 0.05mmol) at -10°C. After 3 hours, to 
the reaction mixture at -10°C was added BF3·Et2O (6.2 µL, 0.05mmol). After 3h40m, the 
mixture had purple residue on the side of the flask. TLC analysis showed another new spot 
with Rf=0.4. The reaction mixture was stirred at -10°C for another hours, before being 
quenched by addition of saturated NaHCO3 solution. The mixture was filtered through a 
pad of celite and rinsed with DCM (5mL). The purple residue disappeared after filtration. 
The organic layer was washed with saturated NaHCO3 solution (5mL), and DI water (5mL 
x 2). The combined aqueous layer was back extracted with DCM (5mL). The combined 
organic layer was washed with brine, dried over Na2SO4, and filtered. The solvent was 
removed to afford the crude mixture was a white foamy solid (13.8mg). The crude mixture 
was separated by silica gel column chromatography (pipet column, EtOAc/hexanes 
gradient from 10% to 40%) to afford a rearranged pregnadiene 3.14 (1.7mg, 11% yield), a 
mixture of products including spiro-oxatane 3.6 (3.7mg, ~22% yield), and desired 
homoallylic alcohol 3.5 (~2.7mg, 16% yield). 
 
3.14: 1H NMR (400 MHz, Chloroform-d) δ 5.42 (d, J = 4.9 Hz, 1H), 3.54 (tt, J = 10.8, 4.8 
Hz, 1H), 2.38 – 2.28 (m, 1H), 2.27 – 2.01 (m, 4H), 2.02 – 1.90 (m, 2H), 1.90 – 1.69 (m, 
4H), 1.66 – 1.46 (m, 7H), 1.35 – 1.19 (m, 4H), 1.17 – 1.00 (m, 3H), 0.99 (s, 3H), 0.97 – 
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0.95 (m, 3H), 0.75 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, cdcl3) δ 141.47, 140.08, 
136.64, 122.13, 72.20, 49.39, 49.33, 42.31, 37.18, 37.09, 35.58, 33.12, 32.31, 31.76, 31.64, 
30.73, 25.62, 23.20, 22.54, 18.89, 9.20. See Chapter appendix for 1H and 13C NMR 
spectra. 
 
(Z)-5,17(20)-pregnadiene was synthesized as describe previously.70 A bright, orange 
suspension of PPh3EtBr (2.57 g, 6.93 mmol) and t-BuOK (0.778 g, 6.93 mmol) in 
anhydrous THF (10 mL) was stirred at RT under N2 in a 2-neck RBF (fitted with a reflux 
condenser) for 40 minutes. To the mixture was then added trans-dehydroandrosterone 3.29 
solution (500.0 mg, 1.73 mmol, dissolved in 6.0 mL of anhydrous THF). The reaction 
mixture was heated under reflux. The reaction progress was monitored by TLC (30% 
EtOAc/hexanes, UV, CAM stain). After 2.5 hours, the reaction was completed based on 
TLC. The reaction mixture was cooled to RT, quenched with sat’d NH4Cl solution (10 
mL). The reaction mixture was diluted with EtOAc (30 mL). The organic phase was 
washed with sat’d NH4Cl solution (30 mL), DI H2O (30 mL x 2). The combined aqueous 
phase was back extracted with EtOAc (10 mL). The combined organic phase was washed 
with brine, dried over Na2SO4, and filtered. The solvent was removed in vacuo to afford 
crude mixture as a white solid. The crude mixture was purified through flash 
chromatography (EtOAc/hexanes gradient) to afford desired (Z)-5,17(20)-pregnadiene 
(430.8 mg, 82% yield). 1H NMR (400 MHz, Chloroform-d) δ 5.36 (d, J = 5.0 Hz, 1H), 5.19 
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– 5.09 (m, 1H), 3.58 – 3.48 (m, 1H), 2.43 – 2.13 (m, 5H), 2.09 – 1.98 (m, 1H), 1.90 – 1.81 
(m, 3H), 1.66 (dt, J = 7.1, 2.0 Hz, 3H), 1.64 – 1.57 (m, 2H), 1.57 – 1.45 (m, 6H), 1.30 – 
1.04 (m, 3H), 1.02 (s, 3H), 1.01 – 0.93 (m, 1H), 0.90 (s, 3H). See Chapter appendix for 
1H and 13C NMR spectra. 
 
4-methylpentanol was synthesized with an adapted procedure.71 To a suspension of 
LiAlH4 (980.2 mg, 25.8 mmol) in anhydrous THF (24 mL) at 0°C was added 4-
methylpentanoic acid solution (2.2 mL dissolved in 10 mL THF) slow dropwise. The 
reaction mixture was stirred at RT for 2 hours, then cooled to 0°C and quenched by addition 
of EtOAc(10 mL). To the reaction mixture was added a saturated solution of sodium 
potassium tartrate (200 mL) and Et2O (100 mL). The mixture was stirred vigorously at RT 
for 30 minutes. The two phases were then separated. The aqueous phase was extracted with 
Et2O (50 mL x 2). The combined organic phase was washed with brine, dried over Na2SO4. 
The solve was removed to afford crude product as a yellow liquid, which was purified 
through vacuum distillation (T ~ 95°C under house vacuum) to afford desired 4-
methylpentanol. The NMR data agreed with the published reference. 1H NMR (400 MHz, 
DMSO-d6) δ 4.33 (t, J = 5.2 Hz, 1H), 3.36 (td, J = 6.7, 5.2 Hz, 2H), 1.50 (dp, J = 13.3, 6.7 
Hz, 1H), 1.44 – 1.36 (m, 2H), 1.19 – 1.11 (m, 2H), 0.85 (d, J = 6.6 Hz, 6H). 13C NMR (101 
MHz, DMSO-d6) δ 61.06, 34.83, 30.43, 27.38, 22.52. See Appendix for NMR spectra. 
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4-methylpentanal was synthesized with an adapted procedure.72 To a suspension of PCC 
(2.95 g, 13.7 mmol), anhydrous NaOAc (94.7 mg, 1.37 mmol) and neutral alumina (6.2 g, 
to aid with work up) in anhydrous DCM (27.4 mL, 0.25M) at 0°C under N2 atmosphere 
was added 4-methyl-1-pentanol fast dropwise. The reaction mixture’s color changed from 
light yellow to dark brown within 5 minutes. The reaction mixture was then stirred at RT, 
and reaction progress was monitored by TLC (5%MeOH/DCM, KMnO4 stain). The 
reaction was completed after 1.5h. The brown solid was removed by filtration through a 
short silica gel column, rinsed with DCM (100 mL). The filtrate was then condensed in 
vacuo (water bath temperature around 15°C) to the final volume of 5 mL, light yellow 
solution. The crude product was used in the subsequent reaction without further 
purification. 1H NMR (500 MHz, Chloroform-d) δ 9.76 (t, J = 1.9 Hz, 1H), 2.44 – 2.39 (m, 
2H), 1.58 (ddt, J = 12.8, 7.6, 6.4 Hz, 1H), 1.54 – 1.49 (m, 2H), 0.90 (d, J = 6.5 Hz, 6H).13C 
NMR (126 MHz, cdcl3) δ 203.08, 53.57, 42.11, 30.90, 27.79, 22.37. See Chapter 
appendix for NMR spectra. 
 
Compound 3.20 was synthesized with an adapted procedure. 70 A solution of anhydrous 
DCM (10 mL) and 4-methylpentanal (~438 mg, 4.38 mmol, dissolved in 5mL DCM) was 
stirred under N2 atmosphere at -78°C for 10 minutes. The mixture was then observed to be 
cloudy, which might indicate presence of water, so 4ÅMS powder (~200mg) was added. 
After 10 minutes stirring at -78°C, Me2AlCl solution (1M solution, 8.8 mL, 8.8 mmol) was 
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added dropwise over 5 minutes. The mixture was stirred at -78°C for another 10 minutes 
before acetate-protected pregnadiene 3.19 (511.3 mg, 1.49 mmol, dissolved in 10 mL 
anhydrous DCM) was added fast dropwise. The reaction mixture was stirred in the cold 
bath, without additional dry ice added to allow slow warm-up. The reaction progress was 
monitored by TLC (10% EtOAc/hexanes, UV, CAM stain). After 2.5h, the reaction was 
warmed up to RT. The reaction was mostly completed based on TLC after 3.5h. The 
reaction was then quenched by mixture of MeOH: DI H2O (1:1, 10 mL) at -78°C. The 
reaction mixture was diluted with DI H2O (30 mL), extracted with DCM (40 mL x3). The 
combined organic phase was washed with 1N HCl (50 mL), saturated solution of NaHCO3 
(50 mL), DI H2O (50 mL x2). The combined aqueous phase was back extracted with DCM 
(15 mL). The combined organic phase was washed with brine, dried over Na2SO4. The 
solvent was removed to afford crude mixture was a yellow gel (720 mg). The crude mixture 
was then separated through silica gel column (60g Si-gel, 5% acetone/hex (400 mL); 10% 
acetone/hex (400 mL); 9mL fractions). Some acetate-pregnadiene 3.19 (48.3 mg, 9.4%) 
was recovered. A mixture of homoallylic alcohols 3.20 was obtained (F31-52, 445.8 mg, 
67%, 75% borsm yield). A side product was isolated and identified as spiro-oxetane 3.21 
(F22-27, 52.7 mg, 9.7% borsm yield). The NMR data of 3.20 agreed with published 
reference.70 
3.20: 1H NMR (500 MHz, Chloroform-d) δ 5.51 – 5.48 (m, 1H), 5.41 – 5.37 (m, 1H), 4.61 
(tdd, J = 10.4, 6.2, 4.3 Hz, 1H), 3.63 (dtd, J = 8.0, 4.7, 3.3 Hz, 1H, H-22 of major isomer), 
3.57 (tt, J = 8.7, 2.1 Hz, 1H, H-22 of minor isomer), 2.39 – 2.25 (m, 4H), 2.19 – 2.06 (m, 
2H), 2.06 – 1.96 (m, 5H), 1.95 – 1.83 (m, 4H), 1.82 – 1.74 (m, 1H), 1.75 – 1.59 (m, 3H), 
1.59 – 1.48 (m, 4H), 1.49 – 1.41 (m, 2H), 1.41 – 1.31 (m, 3H), 1.31 – 1.24 (m, 1H), 1.23 – 
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1.16 (m, 1H), 1.15 – 1.10 (m, 1H), 1.08 – 1.05 (m, 4H), 1.02 (dd, J = 7.0, 1.7 Hz, 3H), 1.01 
– 0.98 (m, 1H), 0.92 – 0.87 (m, 13H). See Chapter appendix for NMR spectra. 
Characterization of spiro-oxetane 3.21 
F22-27 that contained 3.21 was purified by HPLC before characterization was carried out. 
At the beginning, the 1H and 13C NMR of 3.21 were puzzling. According to the 1H NMR, 
there were only one alkene-proton, and there were no doublets that correspond to the iso-
moiety at the end of the side chain. 13C NMR only showed 23 carbons, instead of the 
expected 26 carbons. The NMR was analyzed in both CDCl3 and benzene-D6 to eliminate 
the possibility of signals hidden under the solvent peaks. In the 13C NMR spectrum, two 
alkene carbons that corresponded to one double bond eliminated the hypothesis of 
rearrangement of pregnadiene. There was a 13C signal at 93 ppm, which suggested a 
quaternary C-O that could either be an anomeric carbon, or strained carbon scaffold. Full 
2D NMR spectra (COSY, HSQC, HMBC) of 3.21 suggested the structure of spiro-oxetane. 
With C17 being the carbon at the spiro center, it agreed with the chemical shift of 93 ppm. 
The stereochemistry of the spiro-oxetane moiety has not been assigned. Attempts at 
growing crystals for X-ray crystallography did not yield crystals with good quality. HRMS 
did not resulted in the expected molecular weight, which could be low ionization of the 
molecule. See Appendix for 2D NMR spectra. 
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Table 7. 2D NMR assignment of spiro-
oxetane 3.21 
Atom Chemical 
Shift COSY HSQC HMBC 
1 C 36.80  1', 1'' 18, 9 
H' 1.58  1 3, 10 
H'' 0.89  1  
2 C 28.08  2', 2'' 4' 
H' 1.84 4', 3 2  
H'' 1.55 3 2 3 
3 C 73.96  3 1', 2'', 4' 
H 4.82 2', 2'', 4', 
4'' 3 25 
4 C 38.49  4', 4'' 6 
H' 2.48 2', 3 4 3, 2, 5, 6, 10 
H'' 2.32 3, 6 4 5 
5 C 139.58   4'', 4', 7', 7'', 
18 
6 C 122.91  6 4', 7'' 
H 5.27 4'', 7', 7'' 6 4, 7, 8, 10 
7 C 33.82  7', 7'' 6 
H' 2.05 6, 8 7 5 
H'' 1.49 6, 8 7 5, 6 
8 C 32.62  8 6, 15', 15'', 9 
H 1.19 7', 7'' 8  
9 C 46.81  9 18, 11', 11'' 
H 1.06  9 1, 8, 11, 12, 
10 
10 C 37.74   1', 4', 6, 9, 18 
11 C 33.28  11', 
11'' 9 
H' 1.84  11 9, 12 
H'' 1.65  11 9, 12 
12 C 21.82  12', 
12'' 9, 11', 11'' 
H' 1.71  12  
H'' 1.19  12  
 
Atom Chemical 
Shift COSY HSQC HMBC 
13 C 53.61   15'', 19, 20 
14 C 55.34  14 15', 15'' 
H 1.78  14 17 
15 C 25.59  15', 
15'' 
 
H' 1.90  15 8, 14 
H'' 1.32  15 8, 13, 14 
16 C 41.95  16', 
16'' 19, 20 
H' 1.38  16 17 
H'' 1.26  16 19, 17 
17 C 93.00   19, 16', 16'', 14 
18 C 18.41  18  
H3 0.82  18 1, 5, 9, 10 
19 C 20.06  19 16'', 20 
H3 0.96  19 13, 20, 16, 17 
20 C 54.22  20 19, 23, 24 
H 1.69  20 22, 21, 16, 19, 
23, 24, 13 
21 C 10.93  21 20 
H3 0.67  21 22 
22 C 81.31   21, 23, 24, 20 
23 C 24.85  23 24, 20 
H3 1.04  23 22, 20, 24 
24 C 29.89  24 23, 20 
H3 1.23  24 22, 20, 23 
25 C 169.57   3, 26 
26 C 21.11  26  




Compound 3.26 was synthesized with procedure adapted from Deng et al.35 To a solution 
of homoallylic alcohols 3.20 (333.0 mg, 0.777 mmol) in anhydrous DCM (3.9 mL) and 
DMF (0.9 mL) at RT under N2 was added 4Ǻ MS powder (700 mg), PDC (584.5 mg, 1.55 
mmol). The brown suspension was stirred at RT, and the reaction progress was monitored 
by TLC (10% EtOAc/hexanes, UV, CAM stain). After 17h, TLC still showed presence of 
3.20. To the reaction mixture was added more PDC (292.0 mg, 0.77 mmol) and neutral 
alumna (500 mg). The reaction mixture was stirred at RT for another 24h, when TLC 
showed the reaction almost completed (~80% conversion). The reaction mixture was 
filtered through a silica plug, washed with DCM (15 mL). The solvent was removed in 
vacuo. The resulting residue was resuspended in Et2O (15 mL), washed with DI H2O (10 
mL x 3), brine, dried over Na2SO4, and filtered. The solvent was removed in vacuo to afford 
crude mixture, which was purified by flash chromatography (EtOAc/hexanes gradient from 
5% to 15%) to afford desired C-22 ketone 3.26 (188.8 mg, 56% yield). The diagnostic 
NMR data agreed with published reference35. 1H NMR (400 MHz, Chloroform-d) δ 5.42 – 
5.32 (m, 2H), 4.59 (tdd, J = 10.6, 6.3, 4.2 Hz, 1H), 3.18 (q, J = 6.8 Hz, 1H), 2.47 (dt, J = 
15.8, 7.8 Hz, 1H), 2.41 – 2.25 (m, 3H), 2.08 (ddd, J = 15.1, 6.6, 3.2 Hz, 1H), 2.05 – 1.95 
(m, 4H), 1.92 – 1.75 (m, 3H), 1.69 – 1.46 (m, 4H), 1.45 – 1.29 (m, 4H), 1.29 – 1.18 (m, 
1H), 1.14 (d, J = 7.0 Hz, 3H), 1.09 – 0.97 (m, 4H), 0.91 – 0.81 (m, 9H). 13C NMR (101 
159 
MHz, Chloroform-d) δ 211.73, 170.63, 154.37, 140.03, 125.28, 122.48, 73.95, 57.12, 
50.59, 47.41, 45.81, 38.35, 38.22, 37.02, 36.91, 34.68, 33.15, 31.60, 31.33, 30.64, 27.84, 
27.71, 22.62, 22.36, 21.55, 20.78, 19.34, 16.95, 16.38. See Chapter appendix for NMR 
spectra. 
 
To a mixture of C-22 ketone 3.26 (56.2 mg, 0.127 mmol) in 200-proof EtOH (1.28 mL) 
was added hydroxyl amine hydrochloride NH2OH·HCl (35.5 mg, 0.51 mmol) and sodium 
acetate trihydrates NaOAc·3H2O (104.1 mg, 0.76 mmol). The resulting slurry was heated 
under reflux. The reaction progress was monitored by TLC (20% EtOAc/hexanes, UV, 
CAM stain). After 18 hours, the reaction was completed based on TLC. The reaction 
mixture was diluted with DI H2O (5 mL). The aqueous phase was extracted with DCM (5 
mL x 4). The combined organic phase was washed with brine, dried over Na2SO4, and 
filtered. The solvent was removed in vacuo to afford crude mixture as a white solid (58.2 
mg). The crude mixture was purified by flash chromatography (EtOAc/hexanes gradient 
from 5% to 30%) to afford the desired mixture of oxime isomers 3.27 as a white solid (40.0 
mg, 70%). Oximes 3.27 were characterized by 2D NMR and HRMS. 1H NMR (500 MHz, 
Chloroform-d) δ 5.46 (dt, J = 2.9, 1.4 Hz, 1H), 5.42 – 5.37 (m, 1H), 4.65 – 4.55 (m, 1H), 
3.12 – 3.07 (m, 1H), 2.37 – 2.29 (m, 2H), 2.29 – 2.23 (m, 1H), 2.17 – 2.05 (m, 2H), 2.03 
(s, 3H), 2.00 – 1.96 (m, 1H), 1.91 – 1.82 (m, 4H), 1.72 – 1.44 (m, 7H), 1.42 – 1.23 (m, 3H), 
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1.20 (d, J = 7.1 Hz, 3H), 1.18 – 1.09 (m, 1H), 1.07 – 0.99 (m, 4H), 0.90 (dd, J = 6.5, 1.8 
Hz, 6H), 0.78 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 170.68, 164.06, 156.16, 
140.11, 125.02, 122.59, 74.07, 57.60, 50.68, 47.02, 38.31, 37.08, 36.97, 35.39, 34.70, 
31.70, 31.25, 30.60, 28.90, 27.92, 25.21, 22.55, 22.45, 21.59, 20.83, 19.38, 17.79, 16.27. 
HRMS: calculated for C29H45NO3 + H
+ -[M+H]+: 456.3478, measured: 456.3469. See 
Chapter appendix for 1H and 13C NMR spectra, Appendix for 2D NMR spectra. 
 
 
To a solution of oximes 3.27 (125.0 mg, 0.274 mmol) in anhydrous THF (2.0 mL) at 0°C 
under N2 was added a suspension of LiAlH4 (104.1 mg, 2.74 mmol, in 2.7 mL THF) 
dropwise. The gray suspension was then heated under reflux. The reaction progress was 
monitored by TLC (5% MeOH/DCM, UV, CAM stain). After 48 hours, TLC showed 
absence of oximes 3.27. The reaction was quenched with DI H2O at 0°C. The reaction 
mixture was transferred to an Erlenmeyer flask. To it was added 15% NaOH solution (20 
mL) and EtOAc (10 mL). The mixture was stirred at RT for 10 minutes. The aqueous phase 
was extracted with EtOAc (10 mL x 3). The combined organic phase was washed with 
brine, dried over Na2SO4, and filtered. The solvent was removed in vacuo to afford crude 
mixture as a white foamy solid (118.0 mg). The crude mixture was purified by flash 
chromatography (MeOH/DCM gradient from 0% to 15%) to afford the mixture of 
161 
homoallylic amine isomers 3.28 (32.5 mg, 30%). 1H NMR (500 MHz, Chloroform-d) δ 
5.40 (dd, J = 3.0, 1.4 Hz, 1H), 5.36 (dt, J = 5.2, 2.0 Hz, 1H), 3.57 – 3.48 (m, 1H), 2.80 (ddt, 
J = 11.5, 8.9, 5.0 Hz, 1H, H-22 of major isomer), 2.67 – 2.58 (m, 1H, H-22 of minor 
isomer), 2.30 (ddd, J = 13.1, 5.1, 2.0 Hz, 1H), 2.24 (ddq, J = 15.7, 11.1, 2.6 Hz, 1H), 2.13 
– 2.05 (m, 1H), 2.06 – 1.98 (m, 1H), 1.95 – 1.76 (m, 3H), 1.72 – 1.58 (m, 4H), 1.58 – 1.47 
(m, 2H), 1.48 – 1.38 (m, 1H), 1.38 – 1.27 (m, 2H), 1.24 – 1.13 (m, 1H), 1.13 – 1.06 (m, 
1H), 1.04 (s, 3H), 0.98 (d, J = 6.9 Hz, 3H), 0.93 – 0.86 (m, 6H), 0.83 (s, 3H). See Chapter 
appendix for 1H and 13C NMR spectra. 
 
The mixture of homoallylic amine isomers were purified through HPLC (C8-Phenomenex 
column, MeOH/0.1% formic acid gradient) to afford the pure major isomer of homoallylic 
amine in the form of ammonium formate salt. The structure of homoallylic amine 3.28 was 
confirmed through 2D NMR. However, the absolute stereochemistry at C-22 has been 
assigned as (R), through the X-ray crystallography of compound 3.41. 1H NMR (500 MHz, 
Methanol-d4) δ 8.55 (s, 1H), 5.59 (dd, J = 3.1, 1.5 Hz, 1H), 5.37 (dd, J = 4.9, 2.5 Hz, 1H), 
3.40 (tt, J = 10.5, 4.9 Hz, 1H), 3.28 (dt, J = 8.2, 4.1 Hz, 1H), 2.45 (p, J = 7.0 Hz, 1H), 2.30 
– 2.18 (m, 2H), 2.15 (ddd, J = 15.0, 6.6, 3.3 Hz, 1H), 2.08 – 2.01 (m, 1H), 2.01 – 1.94 (m, 
1H), 1.90 – 1.83 (m, 1H), 1.83 – 1.75 (m, 1H), 1.74 – 1.66 (m, 2H), 1.66 – 1.60 (m, 1H), 
1.60 – 1.50 (m, 3H), 1.50 – 1.43 (m, 2H), 1.43 – 1.33 (m, 2H), 1.32 – 1.20 (m, 1H), 1.10 
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(d, J = 6.9 Hz, 3H), 1.09 – 1.00 (m, 4H), 0.95 (dd, J = 6.6, 1.6 Hz, 6H), 0.90 (s, 3H). 13C 
NMR (126 MHz, Methanol-d4) δ 157.01, 142.58, 126.44, 122.21, 72.38, 59.08, 55.94, 
52.23, 48.12, 43.04, 38.49, 37.92, 37.12, 35.97, 35.12, 32.64, 32.29, 32.20, 31.87, 29.41, 
28.25, 22.94, 22.60, 21.88, 19.78, 16.70. See Chapter appendix for 1H and 13C NMR 
spectra, Appendix for 2D NMR spectra. 
 
TriBOT-PM was synthesized as described previously. 79 To a suspension of NaH (3.9 g, 
97.6 mmol, 60% dispersion in mineral oil) in anhydrous THF (50 mL) at 0°C was added 
PMB-OH solution (12.34 g, 89.48 mmol, dissolved in 20 mL anhydrous THF) fast 
dropwise. The gray reaction mixture was stirred at 0°C for 15 minutes, then at RT. After 
50 minutes, the reaction mixture was cooled to 0°C, then cyanuric chloride solution (5.0 g, 
27.11 mmol, dissolved in 50 mL THF) was added fast dropwise. The reaction mixture was 
stirred at 0°C for 15 minutes, then a RT for 3 hours. The reaction mixture was then poured 
slowly to an Erlenmeyer flask containing DI H2O (100 mL) to quench excess NaH. This 
mixture was then cooled in an ice bath, which resulted in two layers, not much 
precipitation. The reaction mixture was filtered through vacuum filtration. During this 
process, the off-white solid started to form. The filtrated was re-filtered a couple times to 
collect all of the precipitation. The solid was washed with chilled DI H2O (100 mL x 2), 
hexanes (50 mL x 2) and DI H2O (50 mL). The solid was transferred to a pre-weighted vial 
and dried on hi-vac to afford desired product at a white powder (11.4 g, 85.9%). 1H NMR 
(500 MHz, Chloroform-d) δ 7.37 (d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 5.38 (s, 2H), 
163 
3.81 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 173.11, 159.93, 130.37, 127.61, 
114.06, 69.86, 55.44. See Chapter appendix for NMR spectra. 
 
Compound 3.30 was synthesized with procedure adapted from Yamada et al.79 To a clear, 
colorless solution of trans-dehydroandrosterone 3.29 (2.0 g, 6.93 mmol) in anhydrous THF 
(17.4 mL, 0.4M) at RT under N2 atmosphere was added trifluoromethanesulfonic acid 
solution (18.4 µL, 0.208 mmol dissolved in 100 µL THF). The reaction mixture was stirred 
at RT for 5 minutes, then TriBOT-PM solution (2.03 g, 4.16 mmol dissolved in 21 mL 
THF) was added in portions over 40 minutes (~5 mL every 10 minutes). The reaction 
progress was monitored by TLC every 10 minutes (30% EtOAc/hex, UV, CAM stain). The 
light yellow, clear reaction mixture was stirred at RT for additional 30 minutes, when TLC 
profile remained the same. The reaction was quenched by saturated NaHCO3 solution (10 
mL). The reaction mixture was diluted with EtOAc (40 mL), washed with saturated 
NaHCO3 (30 mL), DI H2O (30 mL x 2). The combined aqueous phase was back extracted 
with EtOAc (10 mL). The combined organic phase was washed with brine, dried over 
Na2SO4, and filtered. The solvent was removed in vacuo to afford crude mixture was a 
white solid. The pure desired product 3.30 was obtained after two rounds of 
recrystallization in isopropanol as a white, crystalline powder (2.11 g, 74 % yield). 1H 
NMR (400 MHz, Chloroform-d) δ 7.30 – 7.24 (m, 3H), 6.90 – 6.85 (m, 2H), 5.37 (dd, J = 
4.7, 2.5 Hz, 1H), 4.49 (s, 2H), 3.80 (s, 3H), 3.26 (tt, J = 11.2, 4.5 Hz, 1H), 2.51 – 2.39 (m, 
2H), 2.33 – 2.23 (m, 1H), 2.17 – 2.03 (m, 2H), 2.00 – 1.82 (m, 4H), 1.73 – 1.58 (m, 2H), 
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1.58 – 1.43 (m, 3H), 1.34 – 1.22 (m, 2H), 1.10 – 0.95 (m, 5H), 0.89 (s, 3H). 13C NMR (101 
MHz, Chloroform-d) δ 221.27, 159.22, 141.44, 131.23, 129.29, 120.90, 113.94, 78.21, 
69.77, 55.44, 51.95, 50.46, 47.70, 39.32, 37.35, 37.19, 36.00, 31.66, 31.61, 30.98, 28.52, 
22.03, 20.51, 19.57, 13.71. See Chapter appendix for 1H and 13C NMR spectra. 
 
Compound 3.31 was synthesized with procedure adapted from Houston et al.70 A bright, 
orange suspension of PPh3EtBr (6.25 g, 16.83 mmol) and t-BuOK (1.89 g, 16.83 mmol) in 
anhydrous THF (38 mL) was stirred at RT under N2 in a 2-neck RBF (fitted with a reflux 
condenser) for 40 minutes. To the mixture was then added PMB-protected 
dehydroandrosterone 3.30 solution (1.72 g, 4.21 mmol, dissolved in 12 mL of anhydrous 
THF). The reaction mixture was heated under reflux. The reaction progress was monitored 
by TLC (10% EtOAc/hexanes, UV, CAM stain). After 3.5 hours, the reaction was 
completed based on TLC. The reaction mixture was cooled to RT, quenched with sat’d 
NH4Cl solution (20 mL). The reaction mixture was diluted with EtOAc (30 mL). The 
organic phase was washed with sat’d NH4Cl solution (30 mL), DI H2O (30 mL x 2). The 
combined aqueous phase was back extracted with EtOAc (10 mL). The combined organic 
phase was washed with brine, dried over Na2SO4, and filtered. The solvent was removed 
in vacuo to afford crude mixture as a white solid. The pure desired product 3.31 was 
obtained after two rounds of recrystallization in isopropanol as a white, crystalline powder 
(1.35 g, 76 % yield). The diagnostic NRM data agreed with published reference70. 1H NMR 
(500 MHz, Chloroform-d) δ 7.30 – 7.25 (m, 2H), 6.90 – 6.85 (m, 2H), 5.35 (dt, J = 5.5, 1.9 
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Hz, 1H), 5.17 – 5.10 (m, 1H), 4.53 – 4.45 (m, 2H), 3.80 (s, 3H), 3.26 (tt, J = 11.3, 4.5 Hz, 
1H), 2.44 – 2.34 (m, 2H), 2.34 – 2.23 (m, 2H), 2.23 – 2.14 (m, 1H), 2.07 – 1.98 (m, 1H), 
1.98 – 1.91 (m, 1H), 1.87 (dt, J = 13.5, 3.6 Hz, 1H), 1.66 (dt, J = 7.2, 2.0 Hz, 3H), 1.65 – 
1.60 (m, 1H), 1.59 – 1.47 (m, 5H), 1.28 – 1.18 (m, 1H), 1.18 – 1.10 (m, 1H), 1.08 – 1.00 
(m, 4H), 0.96 (td, J = 10.9, 4.8 Hz, 1H), 0.90 (s, 3H). 13C NMR (126 MHz, cdcl3) δ 159.19, 
150.42, 141.21, 131.30, 129.29, 121.53, 113.92, 113.61, 78.36, 69.72, 56.70, 55.43, 50.36, 
44.20, 39.32, 37.36, 37.14, 37.11, 31.91, 31.60, 31.56, 28.59, 24.62, 21.37, 19.51, 16.77, 
13.28. See Chapter appendix for 1H and 13C NMR spectra. 
 
Compound 3.32 was synthesized with procedure adapted from Houston et al.70 To a 
solution of 4-methylpentanal (357.2 mg, 3.57 mmol) in anhydrous DCM (15 mL) at -78°C 
was added dimethylaluminum chloride solution (1M solution, 5.94 mL, 5.94 mmol). The 
mixture was stirred at -78°C for 15 minutes, then PMB-pregnadiene 3.31 solution (500.0 
mg, 1.19 mmol, dissolved in 10 mL anhydrous DCM) was added dropwise. The reaction 
mixture was stirred in the cold bath, without additional dry ice added to allow slow warm-
up. The reaction progress was monitored by TLC (10% EtOAc/hexanes, UV, CAM stain). 
After 2.5h, the reaction was warmed up to RT. The reaction was mostly completed based 
on TLC after 4h. The reaction was then quenched by mixture of MeOH: DI H2O (1:1, 20 
mL) at -78°C. The reaction mixture was diluted with DI H2O (30 mL), extracted with DCM 
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(15 mL x3). The combined organic phase was washed with 1N HCl (20 mL), saturated 
solution of NaHCO3 (20 mL), DI H2O (20 mL x2). The combined aqueous phase was back 
extracted with DCM (10 mL). The combined organic phase was washed with brine, dried 
over Na2SO4, and filtered. The solvent was removed to afford crude mixture was a white 
solid (903.8 mg). The crude mixture was then separated through silica gel column (60g Si-
gel, Et2O/hexanes gradient from 5% to 35%) to afford the desired mixture of homoallylic 
alcohol isomers 3.32 (545.9 mg, 88%). 1H NMR (500 MHz, Chloroform-d) δ 7.30 – 7.23 
(m, 2H), 6.90 – 6.84 (m, 2H), 5.49 (dt, J = 3.1, 1.5 Hz, 1H), 5.36 (dd, J = 3.6, 1.9 Hz, 1H), 
4.53 – 4.44 (m, 2H), 3.80 (s, 3H), 3.66 – 3.61 (m, 1H,H-22 of major isomer), 3.59 – 3.54 
(m, 1H, H-22 of minor isomer), 3.26 (tt, J = 11.2, 4.5 Hz, 1H), 2.42 (ddd, J = 13.3, 4.8, 2.3 
Hz, 1H), 2.32 – 2.23 (m, 2H), 2.21 – 2.14 (m, 1H), 2.10 (dddd, J = 15.3, 12.6, 6.5, 3.2 Hz, 
1H), 2.02 (ddt, J = 16.9, 5.0, 2.4 Hz, 1H), 1.98 – 1.88 (m, 2H), 1.85 (dt, J = 13.2, 3.7 Hz, 
1H), 1.78 (ddd, J = 11.9, 4.6, 2.6 Hz, 1H), 1.72 – 1.59 (m, 3H), 1.59 – 1.46 (m, 3H), 1.47 
– 1.38 (m, 1H), 1.38 – 1.24 (m, 3H), 1.24 – 1.13 (m, 1H), 1.05 (d, J = 1.1 Hz, 4H), 1.02 (d, 
J = 7.0 Hz, 3H), 0.99 (d, J = 6.9 Hz, 2H), 0.92 – 0.86 (m, 9H), 0.83 (s, 1H). See Chapter 
appendix for 1H and 13C NMR spectra. 
 
Compound 3.33 was synthesized with procedure adapted from Deng et al.35 To a 
suspension of 4Ǻ MS powder (170 mg), PDC (114.1 mg, 0.303 mmol) in anhydrous DCM 
167 
(0.160 mL) and DMF (0.170 mL) at RT was added a solution of homoallylic alcohols 3.32 
(79.0 mg, 0.151 mmol, dissolved in 1.0 mL DCM). The brown suspension was stirred at 
RT, and the reaction progress was monitored by TLC (10% EtOAc/hexanes, UV, CAM 
stain). After 24 hours, the reaction mixture was filtered through a silica plug, washed with 
DCM (15 mL). The solvent was removed in vacuo. The resulting residue was resuspended 
in Et2O (7 mL), washed with DI H2O (3 mL x 3), brine, dried over Na2SO4, and filtered. 
The solvent was removed in vacuo to afford crude mixture, which was purified by flash 
chromatography (EtOAc/hexanes gradient from 5% to 15%) to afford desired C-22 ketone 
3.33 (75.7 mg, 76% yield). 1H NMR (500 MHz, Chloroform-d) δ 7.28 (d, J = 8.5 Hz, 2H), 
6.91 – 6.84 (m, 2H), 5.40 – 5.34 (m, 2H), 4.50 (s, 2H), 3.81 (s, 3H), 3.27 (tt, J = 11.2, 4.5 
Hz, 1H), 3.20 (q, J = 6.8 Hz, 1H), 2.54 – 2.46 (m, 1H), 2.46 – 2.40 (m, 1H), 2.40 – 2.32 
(m, 1H), 2.32 – 2.24 (m, 1H), 2.10 (ddd, J = 15.0, 6.5, 3.2 Hz, 1H), 2.06 – 1.99 (m, 1H), 
1.99 – 1.93 (m, 1H), 1.92 – 1.83 (m, 2H), 1.81 (ddd, J = 12.1, 4.6, 2.5 Hz, 1H), 1.73 – 1.59 
(m, 3H), 1.56 – 1.41 (m, 5H), 1.35 (tt, J = 11.1, 5.4 Hz, 2H), 1.16 (d, J = 6.9 Hz, 3H), 1.09 
– 0.98 (m, 5H), 0.93 – 0.82 (m, 9H). See Chapter appendix for 1H and 13C NMR spectra. 
 
To a mixture of C-22 ketone 3.33 (270 mg, 0.52 mmol) in 200-proof EtOH (6.0 mL) was 
added hydroxyl amine hydrochloride NH2OH·HCl (144.7 mg, 2.08 mmol) and sodium 
acetate trihydrates NaOAc·3H2O (424.9 mg, 3.12 mmol). The resulting slurry was heated 
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under reflux. The reaction progress was monitored by TLC (20% EtOAc/hexanes, UV, 
CAM stain). After 5 hours, the reaction was completed based on TLC. The reaction mixture 
was diluted with DI H2O (10 mL). The aqueous phase was extracted with DCM (5 mL x 
4). The combined organic phase was washed with brine, dried over Na2SO4, and filtered. 
The solvent was removed in vacuo to afford a mixture of C-22-oxime isomers 3.34 as a 
white solid (260.0 mg, 93%). The product was used without further purification. 1H NMR 
(400 MHz, Chloroform-d) δ 7.27 (d, J = 8.1 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 5.48 – 5.43 
(m, 1H), 5.35 (d, J = 5.1 Hz, 1H), 4.49 (s, 2H), 3.80 (s, 3H), 3.25 (td, J = 11.2, 5.5 Hz, 1H), 
3.09 (q, J = 7.0 Hz, 1H), 2.41 (dd, J = 13.2, 4.5 Hz, 1H), 2.32 – 2.20 (m, 2H), 2.17 – 2.01 
(m, 3H), 2.01 – 1.91 (m, 1H), 1.91 – 1.80 (m, 3H), 1.73 – 1.42 (m, 4H), 1.41 – 1.24 (m, 
4H), 1.20 (d, J = 7.0 Hz, 3H), 1.16 (d, J = 7.1 Hz, 1H), 1.03 (d, J = 3.3 Hz, 5H), 0.95 – 0.86 
(m, 7H), 0.77 (s, 3H). 13C NMR (101 MHz, Chloroform-d) δ 164.33, 159.20, 156.11, 
141.50, 131.29, 129.30, 125.08, 121.44, 113.93, 78.36, 69.73, 57.68, 55.44, 50.83, 47.03, 
39.35, 38.28, 37.34, 37.28, 35.35, 34.74, 31.75, 31.26, 30.63, 28.89, 28.59, 25.35, 22.53, 
22.43, 20.87, 19.45, 17.78, 16.27. See Chapter appendix for 1H and 13C NMR spectra. 
 
To a solution of oximes 3.34 (260.0 mg, 0.487 mmol) in anhydrous THF (3.6 mL) at 0°C 
under N2 was added a suspension of LiAlH4 (185.0 mg, 4.87 mmol, in 4.9 mL THF) 
dropwise. The gray suspension was then heated under reflux. The reaction progress was 
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monitored by TLC (5% MeOH/DCM, UV, CAM stain). After 48 hours, TLC showed 
absence of oximes 3.34. The reaction was quenched with DI H2O at 0°C. The reaction 
mixture was transferred to an Erlenmeyer flask. To it was added 15% NaOH solution (20 
mL) and EtOAc (10 mL). The mixture was stirred at RT for 10 minutes. The aqueous phase 
was extracted with EtOAc (10 mL x 3). The combined organic phase was washed with 
brine, dried over Na2SO4, and filtered. The solvent was removed in vacuo to afford crude 
mixture as a white foamy solid (200 mg). The crude mixture was purified by flash 
chromatography (MeOH/DCM gradient from 0% to 10%) to afford the mixture of 
homoallylic amine isomers 3.35 (100.0 mg, 39%). The ratio between the two isomers were 
~ 2:1. 1H NMR (500 MHz, Chloroform-d) δ 7.27 (d, J = 8.7 Hz, 2H), 6.89 – 6.85 (m, 2H), 
5.40 (dd, J = 2.8, 1.5 Hz, 1H), 5.36 (dt, J = 5.4, 2.0 Hz, 1H), 4.54 – 4.45 (m, 2H), 3.80 (s, 
3H), 3.26 (tt, J = 11.2, 4.5 Hz, 1H), 2.80 (t, J = 8.5 Hz, 1H, H-22 of major isomer), 2.74 – 
2.57 (m, 0H-H-22 of minor isomer), 2.42 (ddd, J = 13.2, 4.8, 2.3 Hz, 1H), 2.27 (ddq, J = 
16.0, 11.4, 2.7 Hz, 1H), 2.09 (ddd, J = 14.8, 6.6, 3.1 Hz, 1H), 2.02 (dtd, J = 12.5, 4.7, 4.3, 
2.2 Hz, 1H), 1.98 – 1.82 (m, 3H), 1.79 (ddd, J = 12.0, 4.4, 2.6 Hz, 1H), 1.73 – 1.57 (m, 
3H), 1.57 – 1.47 (m, 3H), 1.46 – 1.24 (m, 4H), 1.24 – 1.12 (m, 2H), 1.08 – 1.01 (m, 4H), 
0.98 (d, J = 6.9 Hz, 3H), 0.93 – 0.86 (m, 6H), 0.83 (s, 3H). See Chapter appendix for 1H 
and 13C NMR spectra. 
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The mixture of homoallylic amine isomers were purified through HPLC (C8-Phenomenex 
column, MeOH/0.1% formic acid gradient) to afford the pure major isomer of homoallylic 
amine in the form of ammonium formate salt. The absolute stereochemistry at C-22 has 
been assigned as (R), through the X-ray crystallography of compound 3.41. 1H NMR (500 
MHz, Chloroform-d) δ 7.26 (s, 3H), 6.87 (d, J = 8.6 Hz, 2H), 5.50 (s, 1H), 5.35 (d, J = 5.0 
Hz, 1H), 4.49 (s, 2H), 3.79 (s, 3H), 3.25 (td, J = 11.1, 5.5 Hz, 1H), 3.09 (s, 1H), 2.44 (dd, 
J = 19.1, 10.6 Hz, 2H), 2.26 (t, J = 12.5 Hz, 1H), 2.11 (dd, J = 12.6, 6.2 Hz, 1H), 2.05 – 
1.87 (m, 3H), 1.82 (t, J = 14.8 Hz, 1H), 1.72 (d, J = 12.7 Hz, 1H), 1.69 – 1.58 (m, 2H), 1.58 
– 1.46 (m, 2H), 1.45 – 1.30 (m, 2H), 1.29 – 1.20 (m, 1H), 1.07 (d, J = 6.8 Hz, 3H), 1.03 (s, 
3H), 1.02 – 0.96 (m, 1H), 0.89 (dd, J = 6.6, 4.4 Hz, 6H), 0.84 (s, 3H). 13C NMR (126 MHz, 
Chloroform-d) δ 159.18, 156.90, 141.43, 131.23, 129.30, 124.62, 121.37, 113.92, 78.31, 
69.73, 57.71, 55.43, 54.72, 50.78, 47.20, 39.32, 37.30, 37.24, 36.79, 34.75, 34.51, 31.69, 
31.42, 30.64, 28.57, 28.19, 27.82, 22.78, 22.35, 20.84, 19.41, 16.42. See Chapter 




Scheme 28: To a mixture of amine 3.28 (10 mg, 0.0224 mmol) and 4Ǻ MS powder (170 
mg) at RT was added dry DCM (1.2 mL) under N2 atmosphere. To the reaction mixture 
was then added disaccharide imidates 43 (21.61 mg, 0.0224 mmol, dissolved in 0.4 mL of 
dry DCM total). The mixture was stirred at RT for 30 minutes. The flask was sonicated in 
attempt to solubilized small amount of white precipitation observed. After 30 minutes at 
RT, the reaction mixture was cooled down to -45°C (acetonitrile/dry ice bath). To the 
reaction mixture was added TMSOTf in portions, while the reaction progress was 
monitored with TLC (7.5% MeOH/DCM, UV, CAM stain). The reaction temperature was 
kept within -30°C to -45°C. TMSOTf (0.4 µL, 2.24 µmol) was added at T=0, 15, and 43 
minutes. At T=140 minutes, no further progress was observed, so the reaction was 
quenched by addition of saturated NaHCO3 solution at -30°C. The reaction mixture was 
then allowed to warm up to RT and stirred for 10 minutes. The aqueous phase was extracted 
with DCM (5 mL x 3). The combined organic phase was washed with sat’d NaHCO3, DI 
H2O, brine, and dried over Na2SO4. The solvent was removed to afford crude mixture as a 
tan, foamy solid (24.8 mg). The crude mixture was separated by pTLC (1 plate, 7.5% 
MeOH/CHCl3, 3 elutions) to afford 6 bands. Amongst the bands, some unreacted amine 
3.28 (2.2 mg), and disaccharide 43 (11.1 mg) were recovered. The most promising band 
was B4 (1.8 mg 5.6%), which seemed to be the O-glycosylated product 3.26 (HMBC 
spectrum showed correlation of the anomeric proton of arabinose and a 13C signal at 73 
ppm; if it were N-glycosylated product, it should have been correlated to 13C signal at lower 
than 70 ppm).  
3.26: 
1H NMR (500 MHz, Chloroform-d) δ 7.93 (d, J = 8.8 Hz, 2H), 7.30 – 7.22 (m, 4H), 
7.11 (d, J = 8.5 Hz, 2H), 6.87 (dd, J = 8.7, 3.8 Hz, 4H), 6.81 (d, J = 8.5 Hz, 2H), 6.68 (d, J 
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= 8.6 Hz, 2H), 5.42 (bs, 1H), 5.27 (s, 1H), 5.20 – 5.15 (m, 1H), 5.13 – 5.08 (m, 1H), 4.71 
(d, J = 6.1 Hz, 1H), 4.67 (d, J = 11.9 Hz, 1H), 4.63 (s, 2H), 4.62 – 4.57 (m, 2H), 4.53 (d, J 
= 11.3 Hz, 1H), 4.35 (d, J = 6.4 Hz, 1H), 3.96 (dd, J = 11.8, 4.4 Hz, 1H), 3.90 (dd, J = 12.3, 
4.0 Hz, 1H), 3.85 (s, 3H), 3.81 (s, 3H), 3.79 (s, 3H), 3.78 – 3.74 (m, 1H), 3.73 – 3.69 (m, 
5H), 3.68 – 3.62 (m, 1H), 3.40 – 3.29 (m, 3H), 2.40 – 2.23 (m, 2H), 2.20 – 1.84 (m, 7H), 
1.81 (s, 3H), 1.78 – 1.68 (m, 4H), 1.66 – 1.42 (m, 5H), 1.42 – 1.14 (m, 4H), 1.09 – 0.97 
(m, 3H), 0.94 (s, 3H), 0.93 – 0.86 (m, 9H), 0.87 – 0.80 (m, 6H). See Chapter appendix 
for 1H and 13C NMR spectra, Appendix for 2D NMR spectra. 
Entry 1, Error! Reference source not found.: homoallylic ammonium salt 3.35a was n
eutralized with NEt3 at RT. Order of addition: homoallylic amine + TMSOTf, then 
disaccharide imidates 43; TMSOTf was added more after the reaction started. 0.4 eqv of 
TMSOTf was used total. 
To a solution of ammonium salt 3.35a (10 mg, 16.6 µmol) in anhydrous DCM (300 µL) 
was added triethylamine (4 µL, 28.7 µmol). The yellow solution was stirred at RT for 10 
minutes, then the solvent was removed. The residue was azeotroped with benzene two 
times, then dried on hi-vac for one hour. In a 5mL conical flask, a mixture of homoallylic 
amine, 4Å MS powder (100 mg) in anhydrous DCM (200 µL) was stirred at RT for 5 
minutes, then at -35°C for 10 minutes while a solution of TMSOTf was prepared (2.4 µL 
TMSOTf was dissolved in 97.6 µL of DCM; 10 µL solution contained 0.1 eqv of 
TMSOTf). To the reaction mixture containing homoallylic amine at -35°C was added 
TMSOTf (10 µL solution, 0.1 eqv). After 5 minutes, disaccharide imidates 2 (14.9 mg, 
15.5 µmol, dissolved in 100 µL DCM). The reaction progress was monitored by TLC (7.5% 
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MeOH/DCM, UV, CAM stain). The reaction temperature was maintained between -35°C 
and -20°C. TMSOTf additions are summarized in the table below: 
Reagent added Time Temperature 
TMSOTf (10 µL solution, 0.1 eqv) T = 0m -35°C 
TMSOTf (10 µL solution, 0.1 eqv) T = 35m -35°C 
Fire alarm T = 50m to 1h20m -20°C (freezer) 
TMSOTf (10 µL solution, 0.1 eqv) T = 1h40m -35°C 
TMSOTf (10 µL fresh solution, 0.1 eqv) T = 1h50m -35°C 
 
After the last addition of TMSOTf, the TLC profile changed significantly. The reaction 
was quenched by addition of saturated NaHCO3 solution (3 mL) at -30°C. The reaction 
mixture was then stirred at RT for 10 minutes. The aqueous phase was extracted with DCM 
(3 mL x 3). The combined organic phase was washed with DI H2O, brine, and dried over 
anhydrous Na2SO4. The solvent was removed to afford crude mixture as a sticky residue 
(19.1 mg). The crude mixture was separated by pTLC (3/4 plate, 4% MeOH/DCM, 1 
elution). The bands were scraped from the plate in order of increasing Rf value. The silica 
gel was rinsed with 10% MeOH/DCM. The solvent was removed to afford residue, which 
was dried on hi-vac and analyzed by 1H NMR. 1H NMR spectra of the bands are shown 
below. From the pTLC results, no glycosylated product was observed. Most of the pTLC 
bands showed signals of derivative of disaccharide moiety, except for B1, which was the 





Entry 2, Error! Reference source not found.: used TEA to neutralize ammonium salt at RT; o
rder of addition: disaccharide 43 with TMSOTf, then amine 3.35a was added; 1.4 eqv 
TMSOTf used total 
To a solution of ammonium salt 1 (7.3 mg, 12.9 µmol) in anhydrous DCM (292 µL) was 
added triethylamine (2.7 µL, 19.4 µmol). The yellow solution was stirred at RT for 10 
minutes, then the solvent was removed. The residue was azeotroped with benzene two 
times, then dried on hi-vac for one hour. In a 5mL conical flask, a mixture of disaccharide 
imidates 2 (15.4 mg, 16 µmol) and 4Å MS powder (76 mg) in anhydrous DCM (200 µL) 
was stirred at RT for 5 minutes, then at -40°C for 10 minutes, while a solution of TMSOTf 
was prepared (9.3 µL TMSOTf was dissolved in 190.5 µL of DCM). To the reaction flask 
with disaccharide mixture at -40°C was added TMSOTf (5 µL solution, 0.1 eqv). After 5 
minutes, to the reaction flask was added a solution of homoallylic amine 3.35a (dissolved 
in 150 µL of anhydrous DCM). The reaction progress was monitored by TLC (7.5% 
MeOH/DCM, UV, CAM stain). TMSOTf additions are summarized in the table below: 
Reagent added Time Temperature 
TMSOTf (5 µL solution, 0.1 eqv) T = 33m -40°C 
TMSOTf (5 µL solution, 0.1 eqv) T = 45m -40°C 
TMSOTf (5 µL solution, 0.1 eqv) T = 60m -40°C 
TMSOTf (5 µL solution, 0.1 eqv) T = 1h14m -25°C 
TMSOTf (5 µL solution, 0.1 eqv) T = 1h34m -20°C 
TMSOTf (5 µL fresh solution, 0.1 eqv) T = 1h53m -20°C 
TMSOTf (5 µL fresh solution, 0.1 eqv) T = 2h7m -18°C 
TMSOTf (5 µL fresh solution, 0.1 eqv) T = 2h23m -18°C 
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TMSOTf (0.2 µL neat, 0.1 eqv) T = 2h42m -30°C 
Disaccharide imidates 43 T = 3h -20°C 
TMSOTf (0.5 µL neat, 0.25 eqv) T = 4h4m -30°C 
TMSOTf (0.5 µL neat, 0.25 eqv) T = 4h47m -35°C 
 
At 5h30m, the reaction was quenched by addition of saturated NaHCO3 solution (3 mL) at 
-30°C. The reaction mixture was then stirred at RT for 10 minutes. The aqueous phsase 
was extracted with DCM (3 mL x 3). The combined organic phase was washed with DI 
H2O, brine, and dried over anhydrous Na2SO4. The solvent was removed to afford crude 
mixture as a tan, foamy solid (23 mg). The crude mixture was separated by pTLC (1 plate, 
6% MeOH/DCM, 2 elutions). The bands were scraped from the plate in order of increasing 
Rf value. The silica gel was rinsed with 10% MeOH/DCM. The solvent was removed to 





From these NMR spectra, it seems that B4 and B5 might contain some glycosylated 
product, but it cannot be confirmed, since the NMR spectra looked messy and might 
contain more than one compound. During the reaction progress, after the last TMSOTf 
addition (1.4 eqv total), the TLC profile changed significantly. It is possible that too much 
TMSOTf could degrade the products formed. The TLC of the reaction mixture with 
disaccharide imidates 43 and TMSOTF showed new spots, but it was not clear if this was 
the oxonium ion formed once the imidate group left. 
Entry 3, Error! Reference source not found.: used NaH to neutralize the ammonium salt at R
T; 0.4 eqv of TMSOTf used total. 
To the solution of ammonium salt 3.35a (7 mg, 12.4 µmol) in anhydrous DCM (150 µL) 
at RT was added NaH (1.5 mg, 37.2 µmol, 60% suspended in mineral oil). Upon NaH 
addition, gas evolution was observed. The mixture was stirred at RT for 5 minutes, then 
disaccharide imidates 43 solution (14.9 mg, 15.5 µmol, dissolved in 150 µL dry DCM) was 
added fast dropwise at RT. The reaction mixture was stirred at RT, reaction progress was 
monitored by TLC (8% MeOH/DCM, UV, CAM stain). After 1h15m, 4ÅMS powder (79 
mg) was added. At 1h45m, the reaction mixture was cooled down to -40°C, then TMSOTf 
(0.25 µL, 1.24 µmol) was added every 7 minutes for the total of 1µL of TMSOTf (0.4 eqv). 
The reaction mixture was analyzed by TLC after each TMSOTf addition. Not much 
progress was observed, so at 2h30m, the reaction was quenched by addition of saturated 
NaHCO3 solution (3 mL) at -30°C. The reaction mixture was then stirred at RT for 10 
minutes. The aqueous phase was extracted with DCM (3 mL x 3). The combined organic 
phase was washed with DI H2O, brine, and dried over anhydrous Na2SO4. The solvent was 
removed to afford crude mixture as a tan, foamy solid (16 mg). The crude mixture was 
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separated by pTLC (3/4 plate, 3% MeOH/DCM, 2 elutions). The seven bands were scraped 
from the plate in order of increasing Rf value. The silica gel was rinsed with 10% 
MeOH/DCM. The solvent was removed to afford residue, which was dried on hi-vac and 
analyzed by 1H NMR. B1 (2.9 mg), B2 (1.3 mg), B3 (2.5 mg), B4 (1 mg), B5 (0.8 mg), B6 
(1.5 mg), B7 (5.1 mg). 
Analysis: Out of seven bands obtained from pTLC, only 2 bands (B1 and B7) had NMR 
signals corresponded to steroidal moiety. The rest of the bands had NMR spectra 
suggestive of derivatives of disaccharide moiety. This could be explained by the stability 
of disaccharide imidates. With the excess NaH in the mixture, disaccharide imidates could 
have been degraded.  
B1’s NMR spectrum showed the recovered unreacted homoallylic amine. B7’s NMR 
showed signals for both disaccharide and homoallylic amine, along with new signals in 
2.2-2.6 ppm region, which could belong to the area around the glycosydic bond if it were 
formed. LCMS analysis of B7 showed the desired m/z value for the glycosylated product 
(1320-1321).  
B7 material was subjected to a second round of pTLC (1/2 plate, 35% EtOAc/hex, 1 
elution). The result of this is showed below. It appeared that no glycosylated product was 
present. B7-1 through B7-6 showed disaccharide derivatives, while B7-7 and B7-8 showed 







Entry 4, Error! Reference source not found.: used homoallylic amine recovered from entry 1
-3; 0.6 eqv TMSOTf used total 
To the solution of homoallylic amine 3.35b (5.1 mg, 9.81 µmol) in anhydrous DCM (100 
µL) and 4ÅMS powder (30 mg) at RT was added disaccharide imidates 43 solution (11.9 
mg, 12.4 µmol, dissolved in 150 µL dry DCM. The reaction mixture was stirred at RT for 
30 minutes, then cooled to -40°C. A solution of TMSOTf was prepared (7 µL TMSOTf 
was dissolved in 193 µL of DCM; 5µL solution contained 0.1 eqv). The reaction progress 
was monitored by TLC (7.5% MeOH/DCM, UV, CAM stain). TMSOTf additions are 
summarized in the table below: 
Reagent added Time Temperature 
TMSOTf (5 µL solution, 0.1 eqv) T = 28m -40°C 
TMSOTf (5 µL solution, 0.1 eqv) T = 38m -40°C 
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TMSOTf (5 µL solution, 0.1 eqv) T = 48m -40°C 
TMSOTf (0.2 µL neat, 0.11 eqv) T = 1h8m -40°C 
TMSOTf (0.2 µL neat, 0.11 eqv) T = 1h20m -30°C 
TMSOTf (0.2 µL neat, 0.11 eqv) T = 1h31m -30°C 
 
After the last addition of TMSOTf, the reaction mixture color changed to light purple, and 
the TLC profile changed significantly. The reaction was quenched by addition of saturated 
NaHCO3 solution (3 mL) at -30°C. The reaction mixture was then stirred at RT for 10 
minutes. The aqueous phase was extracted with DCM (3 mL x 3). The combined organic 
phase was washed with DI H2O, brine, and dried over anhydrous Na2SO4. The solvent was 
removed to afford crude mixture as a tan, foamy solid (13 mg). The crude mixture was 
separated by pTLC (1/2 plate, 6% MeOH/DCM, 1 elution). The bands were scraped from 
the plate in order of increasing Rf value. The silica gel was rinsed with 10% MeOH/DCM. 
The solvent was removed to afford residue, which was dried on hi-vac and analyzed by 1H 
NMR. All the bands yielded less than 1 mg of material, except B10 (3 mg). The 1H NMR 






To a solution of homoallylic amines 3.35 (15.0 mg, 0.00288 mmol) in anhydrous 
acetonitrile (0.2 mL) and DCM (0.1 mL, to help with solubility of amine 3.35) was added 
NaH (8.9 mg, 0.217 mmol). The reaction mixture was stirred at RT for 10 minutes, then to 
it was added compound 92 (14.7 mg, 0.0433 mmol, dissolved in 110 µL anhydrous 
acetonitrile). The reaction mixture was stirred at RT, and the reaction progress was 
monitored by TLC (5% MeOH/DCM, UV, CAM stain). After 24h, no changes were 
observed by TLC. The reaction mixture was neutralized with 1M HCl solution, extracted 
with EtOAc (5 mL x 3). The combined organic phase was washed with brine, dried over 
Na2SO4, and filtered. The solvent was removed in vacuo to afford crude mixture as a tan 




To a solution of homoallylic amine 3.35 (33.0 mg, 0.0634 mmol) in anhydrous DCM (0.32 
mL) was added NEt3 (8.9 µL, 0.0634 mmol). The reaction mixture was cooled to 0°C in 
an ice bath. To the reaction mixture was then added 2-nitrobenzenesulfonyl chloride 
solution (14.1 mg, 0.0634 mmol, dissolved in 70 µL DCM) dropwise. The reaction mixture 
was stirred at 0°C for 15 minutes, then allowed to warmed up to RT. The reaction progress 
was monitored by TLC (2.5 % MeOH/DCM/, UV, CAM stain). After 1 hour 10 minutes, 
TLC showed the reaction was almost completed. The reaction was quenched with 1N HCl 
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solution (3 mL). The aqueous phase was extracted with DCM (3 mL x 3). The combined 
organic phase was washed with brine, dried over anhydrous Na2SO4. The solvent was 
removed in vacuo to afford crude mixture as a white, foamy solid, which was purified 
through silica gel column chromatography (eluted with DCM/hexanes gradient from 50% 
to 100%) to afford the desired Ns-amines 3.39 was a white, foamy solid (38.8 mg, 87% 
yield). 1H NMR (500 MHz, Chloroform-d) δ 8.18 – 8.08 (m, 0H), 7.91 – 7.85 (m, 0H), 
7.72 (pd, J = 7.5, 1.7 Hz, 1H), 5.41 – 5.38 (m, 0H), 5.35 (dd, J = 4.7, 2.7 Hz, 0H), 3.80 (d, 
J = 1.3 Hz, 1H), 3.26 (tt, J = 10.4, 4.1 Hz, 0H), 2.47 – 2.37 (m, 1H), 2.27 (t, J = 11.5 Hz, 
0H), 1.04 (s, 1H), 0.97 (d, J = 7.0 Hz, 1H), 0.79 (s, 1H), 0.72 (dd, J = 17.1, 6.6 Hz, 1H). 
13C NMR (101 MHz, Chloroform-d) δ 159.20, 156.76, 147.85, 141.47, 135.70, 133.30, 
132.93, 131.27, 130.53, 129.29, 125.43, 125.09, 121.41, 113.93, 78.32, 77.36, 69.73, 
58.63, 58.04, 55.43, 50.75, 46.88, 39.34, 37.73, 37.35, 37.26, 34.89, 34.74, 31.68, 31.32, 
30.54, 28.58, 27.87, 27.83, 22.74, 22.42, 20.85, 19.44, 16.90, 14.72. Compound 3.39 was 
characterized fully through 2D NMR. See Chapter appendix for 1H and 13C NMR spectra, 
Appendix for 2D NMR spectra. 
 
To a solution of compound 34 (1.0 g, 3.14 mmol) in anhydrous THF (10 mL) under N2 at 
RT was added benzyl amine (515.0 µL, 4.71 mmol). The reaction mixture was stirred at 
RT, and the reaction progress was monitored by TLC (5% MeOH/DCM, UV, KMnO4 
stain). After 14h, TLC showed the reaction was almost completed. The reaction mixture 
was diluted with DCM (10 mL), washed with cold 0.2M HCl (10 mL x 2), then saturated 
NaHCO3 solution (10 mL), DI H2O (10 mL), and brine. The organic phase was dried over 
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anhydrous Na2SO4, and filtered. The solvent was removed to afford crude mixture, which 
was then purified through silica gel column chromatography (eluted with EtOAc/hexanes 
gradient) to afford desired product 3.40 as a mixture of both anomer (550.0 mg, 63% yield). 
1H NMR (500 MHz, Chloroform-d) δ 6.27 (d, J = 3.8 Hz, 1H), 5.48 (s, 1H), 5.41 (dd, J = 
10.5, 3.5 Hz, 1H), 5.34 (dt, J = 3.7, 1.9 Hz, 1H), 5.33 – 5.31 (m, 1H), 5.28 (q, J = 2.7, 2.1 
Hz, 1H), 5.20 (dd, J = 10.5, 3.5 Hz, 1H), 5.09 – 5.07 (m, 1H), 4.62 (s, 1H), 4.23 – 4.17 (m, 
1H), 4.03 (dd, J = 13.4, 2.5 Hz, 1H), 3.99 (d, J = 13.3 Hz, 1H), 3.80 (dd, J = 13.2, 2.1 Hz, 
1H), 3.71 (dd, J = 13.0, 2.3 Hz, 1H), 3.69 – 3.65 (m, 1H), 3.54 (d, J = 9.0 Hz, 1H), 2.90 (s, 
1H), 2.15 (s, 1H), 2.14 (s, 3H), 2.11 (s, 1H), 2.10 (s, 3H), 2.03 (s, 1H), 2.02 (s, 3H). 13C 
NMR (126 MHz, Chloroform-d) δ 170.53, 170.48, 170.20, 170.14, 96.34, 91.15, 71.46, 
70.11, 69.16, 68.76, 68.74, 68.06, 66.98, 64.27, 60.59, 21.19, 21.09, 21.05, 20.98, 20.87, 
20.78, 14.33. Compound 3.40 was characterized fully through 2D NMR. See Chapter 
appendix for 1H and 13C NMR spectra, Appendix for 2D NMR spectra. 
Entry 5, Error! Reference source not found. (ATL-VII-059) 
 
To a clear, colorless solution of PPh3 (37.2 mg, 142 µmol) in anhydrous THF (100 µL) at 
-78°C under N2 atmosphere was added DIAD solution (28 µL DIAD dissolved in 28 µL 
anhydrous THF, 142 µmol) dropwise slowly. The bright, clear yellow solution was stirred 
at -78°C for 40 minutes after which the solution turned cloudy and pale yellow and very 
thick, then the mixture was allowed to warm up to -40°C. To the reaction mixture was 
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added L-arabinose hemiacetal 3.40 solution (23.5 mg, 85 µmol, dissolved in 46 µL of 
THF). The reaction mixture was stirred for 15 minutes at -40°C, then the mixture of 
homoallylic nosyl amine isomers 3.39 (20.0 mg, 28.4 µmol dissolved in 150 µL THF) was 
added dropwise. The reaction mixture was stirred at -30°C and allowed to slowly warmed 
up in the cold bath to RT (the reaction temperature reached 0°C after 2 hours, then up to 
RT overnight). After 26 hours, the reaction was heated to 50°C for 3 hours, then to 60°C 
for 11 hours. The reaction mixture was then cooled to RT, the solvent was removed in 
vacuo to afford crude mixture as a tan, sticky gel (101.5 mg). During the reaction time (~60 
hours), the reaction progress was monitored by TLC (30% EtOAc, 25% DCM/hexanes, 
UV, CAM stain).  
Purification: The crude mixture was purified through silica gel column chromatography 
(with EtOAc/hexanes step gradient from 20% to 40%) to afford recovered homoallylic 
nosyl amines 3.39 (6.0 mg, 30%), a mixture of glycosylated products (13.0 mg, 47%). The 
mixture of glycosylate products was further purified through HPLC (C8(2) Phenomenex 
semiprep column, acetonitrile: 0.1% formic acid in water gradient from 65% to 100% 
acetonitrile. Two main glycosylated products were isolated in small amount. The HPLC 
sample (prepared in methanol) resulted in crystals that was then analyzed through X-ray 
crystallography to confirm the product’s identity (See Chapter appendix). 
3.41: 1H NMR (500 MHz, Chloroform-d) δ 8.25 (bs, 1H), 7.68 – 7.57 (m, 2H), 7.41 (bs, 
1H), 7.31 – 7.23 (m, 2H), 6.91 – 6.82 (m, 2H), 6.41 (bs, 1H), 5.44 – 5.32 (m, 2H), 5.27 (s, 
1H), 4.97 (bs, 1H), 4.62 (bs, 1H), 4.49 (s, 3H), 4.07 (d, J = 11.9 Hz, 1H), 3.98 (bs, 1H), 
3.80 (s, 3H), 3.59 (bs, J = 13.1 Hz, 1H), 3.26 (td, J = 11.2, 5.6 Hz, 1H), 2.51 (bs, 1H), 2.45 
– 2.38 (m, 1H), 2.32 – 2.21 (m, 5H), 2.12 – 2.05 (m, 5H), 2.03 (s, 5H), 2.01 – 1.98 (m, 1H), 
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1.98 – 1.89 (m, 2H), 1.85 (d, J = 13.3 Hz, 1H), 1.79 (d, J = 11.8 Hz, 1H), 1.69 (s, 1H), 1.64 
– 1.47 (m, 3H), 1.38 – 1.28 (m, 1H), 1.28 – 1.18 (m, 3H), 1.12 (d, J = 7.0 Hz, 3H), 1.05 (s, 
3H), 1.03 – 0.93 (m, 2H), 0.87 (s, 3H), 0.67 – 0.55 (m, 6H). See Chapter appendix for 1H 
and 13C NMR spectra, Appendix for 2D NMR spectra. 
 
Entry 3, Error! Reference source not found.  
 
To a clear, colorless solution of PPh3 (59.5 mg, 227 µmol) in anhydrous THF (1.0 mL) at 
-78°C under N2 atmosphere was added DIAD solution (44.4 µL DIAD dissolved in 55.6 
µL anhydrous THF, 227 µmol) dropwise slowly. The bright, clear yellow solution was 
stirred at -78°C for 40 minutes after which the solution turned cloudy and pale yellow and 
very thick. To the reaction mixture a mixture of disaccharide hemiacetal 98 (116.2 mg, 141 
µmol) and the mixture of homoallylic nosyl amine isomers 3.39 solution (40.0 mg, 56.7 
µmol, dissolved in 800 µL THF) was added dropwise slowly. The reaction mixture was 
stirred at -78°C for 2 hours, then allowed to slowly warmed up in the cold bath to RT (the 
reaction temperature reached 0°C after 5 hours, then up to RT overnight). The reaction 
temperature was maintained at RT for 15.5 hours before being heated to 60°C for another 
48h. The reaction mixture was then cooled to RT, the solvent was removed in vacuo to 
afford crude mixture as a tan, sticky gel (270 mg). During the reaction time (~74 hours), 
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the reaction progress was monitored by TLC (30% EtOAc, 25% DCM/hexanes, UV, CAM 
stain).  
Purification: The crude mixture was purified through silica gel column chromatography 
(with EtOAc/hexanes step gradient from 20% to 100%) to afford recovered homoallylic 
nosyl amines 3.39 (31.8 mg, 79%), a mixture of glycosylated products (16.4 mg, 19%) and 
some derivative of disaccharide moiety (75.5 mg). The mixture of glycosylate products 
was further purified through HPLC (C8(2) Phenomenex semiprep column, acetonitrile: 
0.1% formic acid in water gradient from 65% to 100% acetonitrile. Three glycosylated 
products were isolated (F3-3.9 mg; F4-1.3 mg, F5-1.2 mg). F3 was characterized as the 
desired glycosylated product 3.42 through HRMS, and 2D NMR (5% yield). The other 
products have not been definitively characterized due to the small amount of material. 
3.42: 1H NMR (500 MHz, Acetonitrile-d3) δ 8.31 (d, J = 8.0 Hz, 1H), 7.98 – 7.92 (m, 2H), 
7.74 – 7.63 (m, 2H), 7.48 (d, J = 7.9 Hz, 1H), 7.40 (d, J = 8.2 Hz, 2H), 7.34 – 7.28 (m, 2H), 
7.25 (d, J = 8.6 Hz, 1H), 7.03 – 6.97 (m, 4H), 6.94 – 6.86 (m, 5H), 6.67 (d, J = 8.7 Hz, 1H), 
6.07 (d, J = 10.0 Hz, 1H), 5.36 (d, J = 5.0 Hz, 1H), 5.02 (dd, J = 8.7, 7.3 Hz, 1H), 4.71 – 
4.61 (m, 4H), 4.60 (s, 2H), 4.53 (d, J = 9.2 Hz, 1H), 4.49 (d, J = 10.9 Hz, 1H), 4.45 (s, 2H), 
4.03 – 3.96 (m, 2H), 3.87 (s, 4H), 3.79 – 3.77 (m, 4H), 3.74 – 3.70 (m, 1H), 3.69 (s, 3H), 
3.68 – 3.62 (m, 1H), 3.48 (d, J = 12.9 Hz, 1H), 3.32 (dd, J = 11.8, 8.7 Hz, 1H), 3.18 (td, J 
= 11.2, 5.5 Hz, 1H), 2.38 (dd, J = 12.6, 4.3 Hz, 1H), 2.25 (s, 1H), 2.22 – 2.17 (m, 1H), 2.17 
– 2.09 (m, 1H), 2.08 – 2.00 (m, 1H), 1.92 – 1.82 (m, 3H), 1.72 – 1.60 (m, 5H), 1.59 – 1.52 
(m, 2H), 1.44 (dd, J = 24.8, 11.6 Hz, 3H), 1.30 – 1.23 (m, 1H), 1.20 (t, J = 7.1 Hz, 3H), 
1.04 (s, 3H), 1.02 – 0.92 (m, 4H), 0.75 (s, 3H), 0.60 (d, J = 6.6 Hz, 3H), 0.57 (d, J = 6.6 
Hz, 3H), 0.37 (s, 1H). HRMS calcd for C85H104N2O20S + H
+- [M+H]+: 1505.6976; found 
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X-Ray Crystallography Experimental (Dr. Douglas Powell): 
A colorless, plate-shaped crystal of dimensions 0.064 x 0.226 x 0.284 mm was 
selected for structural analysis. Intensity data for this compound were collected using a 
D8 Quest diffractometer with a Bruker Photon II ccd area detector (1) and an Incoatec 
Ims microfocus Mo Ka source (λ = 0.71073 Å). The sample was cooled to 100(2) K. Cell 
parameters were determined from a least-squares fit of 9979 peaks in the range 2.39 < θ 
< 27.84°. A total of 80283 data were measured in the range 2.276 < θ < 27.914° using ϕ 
and ω oscillation frames. The data were corrected for absorption by the empirical method 
(2) giving minimum and maximum transmission factors of 0.7095 and 0.7456. The data 
were merged to form a set of 12494 independent data with R(int) = 0.0473 and a coverage 
of 99.9 %. 
The orthorhombic space group P212121 was determined by systematic absences 
and statistical tests and verified by subsequent refinement. The structure was solved by 
direct methods and refined by full-matrix least-squares methods on F2 (3). The 
positions of hydrogens bonded to carbons were initially determined by geometry and 
were refined using a riding model. The hydrogen bonded to O1S was located on a 
difference map, and its position was refined using a riding model. Non-hydrogen atoms 
were refined with anisotropic displacement parameters. Hydrogen atom displacement 
parameters were set to 1.2 (1.5 for methyl) times the isotropic equivalent displacement 
parameters of the bonded atoms. A total of 631 parameters were refined against 12494 
data to give wR(F2) = 0.0961 and S = 1.010 for weights of  
w = 1/[σ2 (F2) + (0.0550 P)2 + 1.2500 P], where P = [Fo
2 + 2Fc
2] / 3. The final R(F) 
was 0.0355 for the 11704 observed, [F > 4σ(F)], data. The largest shift/s.u. was 0.001 
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in the final refinement cycle. The final difference map had maxima and minima of 0.242 
and -0.302 e/Å3, respectively. The absolute structure was determined by refinement of 
the Flack parameter (4). 
Table 1. Crystal data and structure refinement for 3.41 
 
Empirical formula (C52 H70 N2 O13 S)  (C 
H4 O) C53 H74 N2 O14 S 
Formula weight 995.20 
Crystal system orthorhombic 
Space group P212121 
Unit cell dimensions a = 11.8174(6) Å = 90° 
b = 12.3469(6) Å = 90° 
c = 35.8006(18) Å = 90° 
Volume 5223.6(5) Å3 
Z, Z' 4, 1 
Density (calculated) 1.265 Mg/m3 
Wavelength 0.71073 Å 
Temperature 100(2) K 
F(000) 2136 
Absorption coefficient 0.129 mm-1 
Absorption correction semi-empirical from equivalents 
Max. and min. transmission 0.7456 and 
0.7095 Theta range for data collection 2.276 to 
27.914° Reflections collected 80283 
Independent reflections 12494 [R(int) = 0.0473] 
Data / restraints / parameters 12494 / 0 / 631 
wR(F2 all data) wR2 = 0.0961 
R(F obsd data) R1 = 0.0355 
Goodness-of-fit on F2 1.010 
Observed data [I > 2(I)] 11704 
Absolute structure parameter 0.00(2) 
Largest and mean shift / s.u .................. 0.001 and 0.000 
Largest diff. peak and hole 0.242 and -0.302 e/Å3 
---------- 
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wR2 = {  [w(Fo
2 - Fc
2)2] /  [w(Fo 
2)2] }1/2 
R1 =  ||Fo| - |Fc|| /  |Fo| 
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Table 2. Atomic coordinates and equivalent isotropic displacement 
parameters for compound 3.41 U(eq) is defined as one third of the trace of 
the orthogonalized Uij tensor. 
 
x y z U(eq) 
 
 
S(1) 0.02706(4) 0.57714(4) 0.55595(2) 0.01713(11) 
O(1) 0.94094(14) 0.03776(14) 0.69218(4) 0.0239(3) 
O(2) 1.42529(14) -0.17240(14) 0.70177(5) 0.0259(4) 
O(3) 0.10633(13) 0.48961(13) 0.55418(5) 0.0225(3) 
O(4) 0.02244(15) 0.65427(14) 0.52632(4) 0.0245(3) 
O(5) -0.00385(15) 0.30476(15) 0.59435(5) 0.0306(4) 
O(6) -0.00878(16) 0.28213(15) 0.53403(5) 0.0321(4) 
O(7) -0.06980(13) 0.79590(12) 0.59391(4) 0.0193(3) 
O(8) 0.23310(13) 0.78610(13) 0.57478(5) 0.0224(3) 
O(9) 0.25102(16) 0.75440(17) 0.51299(5) 0.0366(4) 
O(10) 0.17811(14) 1.00586(13) 0.55614(4) 0.0218(3) 
O(11) 0.31351(18) 1.03681(18) 0.59914(5) 0.0406(5) 
O(12) -0.04678(14) 0.98600(13) 0.54445(4) 0.0209(3) 
O(13) -0.17844(15) 1.10728(14) 0.56193(5) 0.0280(4) 
N(1) 0.04734(15) 0.64249(14) 0.59483(5) 0.0166(4) 
N(2) -0.03915(17) 0.32575(16) 0.56293(6) 0.0228(4) 
C(1) 0.74503(18) 0.25580(18) 0.66042(6) 0.0187(4) 
C(2) 0.84644(18) 0.1791(2) 0.66097(6) 0.0214(4) 
C(3) 0.84562(19) 0.10911(19) 0.69564(6) 0.0206(4) 
C(4) 0.7349(2) 0.04696(18) 0.69901(6) 0.0217(4) 
C(5) 0.63193(19) 0.11964(17) 0.69626(6) 0.0181(4) 
C(6) 0.54783(19) 0.11225(18) 0.72079(6) 0.0198(4) 
C(7) 0.44006(19) 0.17628(18) 0.71937(6) 0.0198(4) 
C(8) 0.42239(18) 0.23250(17) 0.68170(6) 0.0165(4) 
C(9) 0.53610(17) 0.28426(16) 0.66968(6) 0.0152(4) 
C(10) 0.62899(18) 0.19831(17) 0.66315(6) 0.0166(4) 
C(11) 0.52525(19) 0.36350(18) 0.63646(6) 0.0199(4) 
C(12) 0.42898(18) 0.44608(18) 0.64082(6) 0.0200(4) 
C(13) 0.31813(18) 0.38733(17) 0.64838(6) 0.0164(4) 
C(14) 0.33289(18) 0.32103(17) 0.68453(6) 0.0176(4) 
C(15) 0.21074(19) 0.29599(19) 0.69637(7) 0.0229(5) 
C(16) 0.15193(19) 0.39811(18) 0.68339(6) 0.0214(4) 
C(17) 0.21269(18) 0.45307(17) 0.65844(6) 0.0171(4) 
C(18) 0.60776(19) 0.13274(19) 0.62701(6) 0.0209(4) 
C(19) 0.2842(2) 0.3172(2) 0.61445(6) 0.0226(4) 
C(20) 0.18891(17) 0.55871(17) 0.63828(6) 0.0172(4) 
 
C(21) 0.2409(2) 0.65337(18) 0.66010(7) 0.0237(5) 
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C(22) 0.06141(17) 0.57345(17) 0.62923(6) 0.0153(4) 
C(23) -0.01101(18) 0.61490(18) 0.66170(6) 0.0176(4) 
C(24) -0.13642(18) 0.58900(19) 0.65736(6) 0.0203(4) 
C(25) -0.21099(19) 0.63232(18) 0.68884(6) 0.0203(4) 
C(26) -0.2111(2) 0.7564(2) 0.68942(8) 0.0270(5) 
C(27) -0.3315(2) 0.5893(2) 0.68428(7) 0.0277(5) 
C(28) 0.9862(2) -0.0005(2) 0.72621(6) 0.0247(5) 
C(29) 1.10280(19) -0.04599(19) 0.71884(6) 0.0208(4) 
C(30) 1.1659(2) -0.01233(18) 0.68821(6) 0.0216(4) 
C(31) 1.27411(19) -0.05222(18) 0.68176(6) 0.0210(4) 
C(32) 1.32106(19) -0.12639(18) 0.70629(6) 0.0204(4) 
C(33) 1.2595(2) -0.16034(19) 0.73727(6) 0.0229(5) 
C(34) 1.1512(2) -0.1207(2) 0.74334(6) 0.0244(5) 
C(35) 1.4842(2) -0.1470(2) 0.66814(8) 0.0299(5) 
C(36) -0.10990(18) 0.51798(18) 0.55853(6) 0.0181(4) 
C(37) -0.13021(18) 0.40723(18) 0.56013(6) 0.0197(4) 
C(38) -0.2391(2) 0.3657(2) 0.55819(6) 0.0237(5) 
C(39) -0.3286(2) 0.4368(2) 0.55452(7) 0.0290(5) 
C(40) -0.3104(2) 0.5472(2) 0.55300(7) 0.0292(5) 
C(41) -0.20155(19) 0.5885(2) 0.55499(7) 0.0234(4) 
C(42) 0.04340(18) 0.75948(17) 0.59759(6) 0.0169(4) 
C(43) 0.11839(18) 0.82316(18) 0.57019(6) 0.0177(4) 
C(44) 0.11373(18) 0.94141(17) 0.58200(6) 0.0182(4) 
C(45) -0.00776(19) 0.98233(18) 0.58275(6) 0.0198(4) 
C(46) -0.08097(19) 0.90644(18) 0.60588(6) 0.0210(4) 
C(47) 0.2893(2) 0.7513(2) 0.54391(7) 0.0265(5) 
C(48) 0.4028(2) 0.7074(3) 0.55425(10) 0.0425(7) 
C(49) 0.2763(2) 1.0496(2) 0.56835(6) 0.0252(5) 
C(50) 0.3308(3) 1.1142(3) 0.53815(7) 0.0370(6) 
C(51) -0.1336(2) 1.05463(19) 0.53794(7) 0.0233(5) 
C(52) -0.1639(3) 1.0563(2) 0.49746(8) 0.0357(6) 
O(1S) 0.1579(3) 0.6496(3) 0.44607(9) 0.0829(10) 




Table 3. Bond lengths [Å] and angles [°] for ATL-VII-059-F20-24. 
 
 
S(1)-O(4) 1.4266(17) C(7)-H(7AB) 0.9900 
S(1)-O(3) 1.4316(17) C(8)-C(14) 1.524(3) 
S(1)-N(1) 1.6266(18) C(8)-C(9) 1.549(3) 
S(1)-C(36) 1.778(2) C(8)-H(8) 1.0000 
O(1)-C(28) 1.412(3) C(9)-C(10) 1.545(3) 
O(1)-C(3) 1.435(3) C(9)-C(11) 1.545(3) 
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O(2)-C(32) 1.366(3) C(9)-H(9) 1.0000 
O(2)-C(35) 1.426(3) C(10)-C(18) 1.547(3) 
O(5)-N(2) 1.228(3) C(11)-C(12) 1.536(3) 
O(6)-N(2) 1.220(3) C(11)-H(11A) 0.9900 
O(7)-C(42) 1.417(3) C(11)-H(11B) 0.9900 
O(7)-C(46) 1.437(3) C(12)-C(13) 1.522(3) 
O(8)-C(47) 1.359(3) C(12)-H(12A) 0.9900 
O(8)-C(43) 1.440(3) C(12)-H(12B) 0.9900 
O(9)-C(47) 1.196(3) C(13)-C(17) 1.530(3) 
O(10)-C(49) 1.353(3) C(13)-C(14) 1.541(3) 
O(10)-C(44) 1.439(3) C(13)-C(19) 1.545(3) 
O(11)-C(49) 1.197(3) C(14)-C(15) 1.536(3) 
O(12)-C(51) 1.351(3) C(14)-H(14) 1.0000 
O(12)-C(45) 1.447(3) C(15)-C(16) 1.513(3) 
O(13)-C(51) 1.200(3) C(15)-H(15A) 0.9900 
N(1)-C(42) 1.449(3) C(15)-H(15B) 0.9900 
N(1)-C(22) 1.507(3) C(16)-C(17) 1.332(3) 
N(2)-C(37) 1.476(3) C(16)-H(16) 0.9500 
C(1)-C(2) 1.528(3) C(17)-C(20) 1.517(3) 
C(1)-C(10) 1.547(3) C(18)-H(18A) 0.9803 
C(1)-H(1A) 0.9900 C(18)-H(18B) 0.9799 
C(1)-H(1AB) 0.9900 C(18)-H(18C) 0.9799 
C(2)-C(3) 1.512(3) C(19)-H(19A) 0.9802 
C(2)-H(2A) 0.9900 C(19)-H(19B) 0.9800 
C(2)-H(2AB) 0.9900 C(19)-H(19C) 0.9800 
C(3)-C(4) 1.521(3) C(20)-C(21) 1.534(3) 
C(3)-H(3) 1.0000 C(20)-C(22) 1.552(3) 
C(4)-C(5) 1.515(3) C(20)-H(20) 1.0000 
C(4)-H(4A) 0.9900 C(21)-H(21A) 0.9800 
C(4)-H(4AB) 0.9900 C(21)-H(21B) 0.9800 
C(5)-C(6) 1.330(3) C(21)-H(21C) 0.9801 
C(5)-C(10) 1.533(3) C(22)-C(23) 1.531(3) 
C(6)-C(7) 1.500(3) C(22)-H(22) 1.0000 
C(6)-H(6) 0.9500 C(23)-C(24) 1.524(3) 
C(7)-C(8) 1.531(3) C(23)-H(23A) 0.9900 
C(7)-H(7A) 0.9900 C(23)-H(23B) 0.9900 
 
C(24)-C(25) 1.527(3) C(39)-C(40) 1.381(4) 
C(24)-H(24A) 0.9900 C(39)-H(39) 0.9500 
C(24)-H(24B) 0.9900 C(40)-C(41) 1.386(3) 
C(25)-C(27) 1.528(3) C(40)-H(40) 0.9500 
C(25)-C(26) 1.532(3) C(41)-H(41) 0.9500 
C(25)-H(25) 1.0000 C(42)-C(43) 1.538(3) 
C(26)-H(26A) 0.9799 C(42)-H(42) 1.0000 
C(26)-H(26B) 0.9799 C(43)-C(44) 1.521(3) 
C(26)-H(26C) 0.9802 C(43)-H(43) 1.0000 
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C(27)-H(27A) 0.9801 C(44)-C(45) 1.522(3) 
C(27)-H(27B) 0.9801 C(44)-H(44) 1.0000 
C(27)-H(27C) 0.9799 C(45)-C(46) 1.521(3) 
C(28)-C(29) 1.511(3) C(45)-H(45) 1.0000 
C(28)-H(28A) 0.9900 C(46)-H(46A) 0.9900 
C(28)-H(28B) 0.9900 C(46)-H(46B) 0.9900 
C(29)-C(30) 1.389(3) C(47)-C(48) 1.493(4) 
C(29)-C(34) 1.396(3) C(48)-H(48A) 0.9799 
C(30)-C(31) 1.390(3) C(48)-H(48B) 0.9800 
C(30)-H(30) 0.9500 C(48)-H(48C) 0.9800 
C(31)-C(32) 1.385(3) C(49)-C(50) 1.490(3) 
C(31)-H(31) 0.9500 C(50)-H(50A) 0.9800 
C(32)-C(33) 1.391(3) C(50)-H(50B) 0.9800 
C(33)-C(34) 1.388(3) C(50)-H(50C) 0.9799 
C(33)-H(33) 0.9500 C(51)-C(52) 1.493(4) 
C(34)-H(34) 0.9500 C(52)-H(52A) 0.9801 
C(35)-H(35A) 0.9801 C(52)-H(52B) 0.9800 
C(35)-H(35B) 0.9800 C(52)-H(52C) 0.9800 
C(35)-H(35C) 0.9800 O(1S)-C(1S) 1.404(5) 
C(36)-C(37) 1.390(3) O(1S)-H(1S) 0.9402 
C(36)-C(41) 1.395(3) C(1S)-H(1SA) 0.9799 
C(37)-C(38) 1.387(3) C(1S)-H(1SB) 0.9799 
C(38)-C(39) 1.381(3) C(1S)-H(1SC) 0.9800 
C(38)-H(38) 0.9500   
O(4)-S(1)-N(1) 108.11(10) C(42)-N(1)-C(22) 120.78(17) 
O(3)-S(1)-N(1) 108.41(10) C(42)-N(1)-S(1) 123.25(15) 
O(4)-S(1)-C(36) 106.14(10) C(22)-N(1)-S(1) 115.79(14) 
O(3)-S(1)-C(36) 106.73(10) O(6)-N(2)-O(5)  125.7(2) 
N(1)-S(1)-C(36) 107.06(10) O(6)-N(2)-C(37) 117.22(19) 
C(28)-O(1)-C(3) 115.38(17) O(5)-N(2)-C(37) 116.99(19) 
C(32)-O(2)-C(35) 116.65(19) C(2)-C(1)-C(10) 114.21(18) 
C(42)-O(7)-C(46) 111.12(16) C(2)-C(1)-H(1A)  108.7 
C(47)-O(8)-C(43) 117.89(19) C(10)-C(1)-H(1A)  108.7 
C(49)-O(10)-C(44) 117.81(18) C(2)-C(1)-H(1AB)  108.7 
C(10)-C(1)-H(1AB) 108.7 C(5)-C(10)-C(18) 108.59(17) 
H(1A)-C(1)-H(1AB) 107.6 C(9)-C(10)-C(18) 111.78(17) 
C(3)-C(2)-C(1) 111.08(18) C(5)-C(10)-C(1) 108.63(17) 
C(3)-C(2)-H(2A) 109.4 C(9)-C(10)-C(1) 108.92(17) 
C(1)-C(2)-H(2A) 109.4 C(18)-C(10)-C(1) 109.33(17) 
C(3)-C(2)-H(2AB) 109.4 C(12)-C(11)-C(9) 113.80(17) 
C(1)-C(2)-H(2AB) 109.4 C(12)-C(11)-H(11A) 108.8 
H(2A)-C(2)-H(2AB) 108.0 C(9)-C(11)-H(11A) 108.8 
O(1)-C(3)-C(2) 105.96(18) C(12)-C(11)-H(11B) 108.8 
O(1)-C(3)-C(4) 111.84(18) C(9)-C(11)-H(11B) 108.8 
C(2)-C(3)-C(4) 111.03(18) H(11A)-C(11)-H(11B) 107.7 
O(1)-C(3)-H(3) 109.3 C(13)-C(12)-C(11) 109.84(18) 
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C(2)-C(3)-H(3) 109.3 C(13)-C(12)-H(12A) 109.7 
C(4)-C(3)-H(3) 109.3 C(11)-C(12)-H(12A) 109.7 
C(5)-C(4)-C(3) 112.75(18) C(13)-C(12)-H(12B) 109.7 
C(5)-C(4)-H(4A) 109.0 C(11)-C(12)-H(12B) 109.7 
C(3)-C(4)-H(4A) 109.0 H(12A)-C(12)-H(12B) 108.2 
C(5)-C(4)-H(4AB) 109.0 C(12)-C(13)-C(17) 119.34(18) 
C(3)-C(4)-H(4AB) 109.0 C(12)-C(13)-C(14) 107.77(17) 
H(4A)-C(4)-H(4AB) 107.8 C(17)-C(13)-C(14) 100.16(16) 
C(6)-C(5)-C(4) 121.1(2) C(12)-C(13)-C(19) 110.54(18) 
C(6)-C(5)-C(10) 122.51(19) C(17)-C(13)-C(19) 105.73(17) 
C(4)-C(5)-C(10) 116.35(19) C(14)-C(13)-C(19) 113.07(18) 
C(5)-C(6)-C(7) 125.2(2) C(8)-C(14)-C(15) 121.74(18) 
C(5)-C(6)-H(6) 117.4 C(8)-C(14)-C(13) 113.80(17) 
C(7)-C(6)-H(6) 117.4 C(15)-C(14)-C(13) 103.43(17) 
C(6)-C(7)-C(8) 112.62(18) C(8)-C(14)-H(14) 105.5 
C(6)-C(7)-H(7A) 109.1 C(15)-C(14)-H(14) 105.5 
C(8)-C(7)-H(7A) 109.1 C(13)-C(14)-H(14) 105.5 
C(6)-C(7)-H(7AB) 109.1 C(16)-C(15)-C(14) 100.33(18) 
C(8)-C(7)-H(7AB) 109.1 C(16)-C(15)-H(15A) 111.7 
H(7A)-C(7)-H(7AB) 107.8 C(14)-C(15)-H(15A) 111.7 
C(14)-C(8)-C(7) 111.17(17) C(16)-C(15)-H(15B) 111.7 
C(14)-C(8)-C(9) 108.94(16) C(14)-C(15)-H(15B) 111.7 
C(7)-C(8)-C(9) 108.26(17) H(15A)-C(15)-H(15B) 109.5 
C(14)-C(8)-H(8) 109.5 C(17)-C(16)-C(15) 112.5(2) 
C(7)-C(8)-H(8) 109.5 C(17)-C(16)-H(16) 123.7 
C(9)-C(8)-H(8) 109.5 C(15)-C(16)-H(16) 123.7 
C(10)-C(9)-C(11) 112.17(17) C(16)-C(17)-C(20) 131.1(2) 
C(10)-C(9)-C(8) 112.03(17) C(16)-C(17)-C(13) 109.06(18) 
C(11)-C(9)-C(8) 113.76(17) C(20)-C(17)-C(13) 119.67(18) 
C(10)-C(9)-H(9) 106.1 C(10)-C(18)-H(18A) 109.5 
C(11)-C(9)-H(9) 106.1 C(10)-C(18)-H(18B) 109.5 
C(8)-C(9)-H(9) 106.1 H(18A)-C(18)-H(18B) 109.5 
C(5)-C(10)-C(9) 109.53(17) C(10)-C(18)-H(18C) 109.5 
H(18A)-C(18)-H(18C) 109.5 C(25)-C(26)-H(26B) 109.5 
H(18B)-C(18)-H(18C) 109.5 H(26A)-C(26)-H(26B) 109.5 
C(13)-C(19)-H(19A) 109.5 C(25)-C(26)-H(26C) 109.5 
C(13)-C(19)-H(19B) 109.5 H(26A)-C(26)-H(26C) 109.5 
H(19A)-C(19)-H(19B) 109.5 H(26B)-C(26)-H(26C) 109.5 
C(13)-C(19)-H(19C) 109.5 C(25)-C(27)-H(27A) 109.5 
H(19A)-C(19)-H(19C) 109.5 C(25)-C(27)-H(27B) 109.5 
H(19B)-C(19)-H(19C) 109.5 H(27A)-C(27)-H(27B) 109.5 
C(17)-C(20)-C(21) 109.78(17) C(25)-C(27)-H(27C) 109.5 
C(17)-C(20)-C(22) 112.33(17) H(27A)-C(27)-H(27C) 109.5 
C(21)-C(20)-C(22) 113.94(18) H(27B)-C(27)-H(27C) 109.5 
C(17)-C(20)-H(20) 106.8 O(1)-C(28)-C(29) 108.62(18) 
C(21)-C(20)-H(20) 106.8 O(1)-C(28)-H(28A) 110.0 
C(22)-C(20)-H(20) 106.8 C(29)-C(28)-H(28A) 110.0 
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C(20)-C(21)-H(21A) 109.5 O(1)-C(28)-H(28B) 110.0 
C(20)-C(21)-H(21B) 109.5 C(29)-C(28)-H(28B) 110.0 
H(21A)-C(21)-H(21B) 109.5 H(28A)-C(28)-H(28B) 108.3 
C(20)-C(21)-H(21C) 109.5 C(30)-C(29)-C(34) 118.3(2) 
H(21A)-C(21)-H(21C) 109.5 C(30)-C(29)-C(28) 121.1(2) 
H(21B)-C(21)-H(21C) 109.5 C(34)-C(29)-C(28) 120.6(2) 
N(1)-C(22)-C(23) 111.69(16) C(29)-C(30)-C(31) 121.3(2) 
N(1)-C(22)-C(20) 110.12(16) C(29)-C(30)-H(30) 119.4 
C(23)-C(22)-C(20) 115.05(17) C(31)-C(30)-H(30) 119.4 
N(1)-C(22)-H(22) 106.5 C(32)-C(31)-C(30) 119.8(2) 
C(23)-C(22)-H(22) 106.5 C(32)-C(31)-H(31) 120.1 
C(20)-C(22)-H(22) 106.5 C(30)-C(31)-H(31) 120.1 
C(24)-C(23)-C(22) 113.33(17) O(2)-C(32)-C(31) 124.1(2) 
C(24)-C(23)-H(23A) 108.9 O(2)-C(32)-C(33) 116.1(2) 
C(22)-C(23)-H(23A) 108.9 C(31)-C(32)-C(33) 119.7(2) 
C(24)-C(23)-H(23B) 108.9 C(34)-C(33)-C(32) 120.1(2) 
C(22)-C(23)-H(23B) 108.9 C(34)-C(33)-H(33) 120.0 
H(23A)-C(23)-H(23B) 107.7 C(32)-C(33)-H(33) 120.0 
C(23)-C(24)-C(25) 114.35(18) C(33)-C(34)-C(29) 120.8(2) 
C(23)-C(24)-H(24A) 108.7 C(33)-C(34)-H(34) 119.6 
C(25)-C(24)-H(24A) 108.7 C(29)-C(34)-H(34) 119.6 
C(23)-C(24)-H(24B) 108.7 O(2)-C(35)-H(35A) 109.5 
C(25)-C(24)-H(24B) 108.7 O(2)-C(35)-H(35B) 109.5 
H(24A)-C(24)-H(24B) 107.6 H(35A)-C(35)-H(35B) 109.5 
C(24)-C(25)-C(27) 109.70(18) O(2)-C(35)-H(35C) 109.5 
C(24)-C(25)-C(26) 111.14(19) H(35A)-C(35)-H(35C) 109.5 
C(27)-C(25)-C(26) 110.4(2) H(35B)-C(35)-H(35C) 109.5 
C(24)-C(25)-H(25) 108.5 C(37)-C(36)-C(41) 118.9(2) 
C(27)-C(25)-H(25) 108.5 C(37)-C(36)-S(1) 124.31(17) 
C(26)-C(25)-H(25) 108.5 C(41)-C(36)-S(1) 116.45(17) 
C(25)-C(26)-H(26A) 109.5 C(38)-C(37)-C(36) 121.5(2) 
C(38)-C(37)-N(2) 115.3(2) O(7)-C(46)-H(46A 109.3 
C(36)-C(37)-N(2) 123.19(19) C(45)-C(46)-H(4A) 109.3 
C(39)-C(38)-C(37) 118.7(2) O(7)-C(46)-H(4B) 109.3 
C(39)-C(38)-H(38) 120.6 C(45)-C(46)-H(46B) 109.3 
C(37)-C(38)-H(38) 120.6 H(46A)-C(46)-H(46B) 107.9 
C(40)-C(39)-C(38) 120.8(2) O(9)-C(47)-O(8) 123.9(2) 
C(40)-C(39)-H(39) 119.6 O(9)-C(47)-C(48) 125.5(2) 
C(38)-C(39)-H(39) 119.6 O(8)-C(47)-C(48) 110.6(2) 
C(39)-C(40)-C(41) 120.4(2) C(47)-C(48)-H(48A) 109.5 
C(39)-C(40)-H(40) 119.8 C(47)-C(48)-H(48B) 109.5 
C(41)-C(40)-H(40) 119.8 H(48A)-C(48)-H(48B) 109.5 
C(40)-C(41)-C(36) 119.7(2) C(47)-C(48)-H(48C) 109.4 
C(40)-C(41)-H(41) 120.1 H(48A)-C(48)-H(48C) 109.5 
C(36)-C(41)-H(41) 120.1 H(48B)-C(48)-H(48C) 109.5 
O(7)-C(42)-N(1) 109.90(17) O(11)-C(49)-O(10) 124.1(2) 
O(7)-C(42)-C(43) 108.80(16) O(11)-C(49)-C(50) 125.5(2) 
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N(1)-C(42)-C(43) 116.59(18) O(10)-C(49)-C(50) 110.5(2) 
O(7)-C(42)-H(42) 107.0 C(49)-C(50)-H(50A) 109.5 
N(1)-C(42)-H(42) 107.0 C(49)-C(50)-H(50B) 109.5 
C(43)-C(42)-H(42) 107.0 H(50A)-C(50)-H(50B) 109.5 
O(8)-C(43)-C(44) 107.91(17) C(49)-C(50)-H(50C) 109.5 
O(8)-C(43)-C(42) 107.90(17) H(50A)-C(50)-H(50C) 109.5 
C(44)-C(43)-C(42) 107.01(17) H(50B)-C(50)-H(50C) 109.5 
O(8)-C(43)-H(43) 111.3 O(13)-C(51)-O(12) 123.5(2) 
C(44)-C(43)-H(43) 111.3 O(13)-C(51)-C(52) 125.5(2) 
C(42)-C(43)-H(43) 111.3 O(12)-C(51)-C(52) 111.0(2) 
O(10)-C(44)-C(43) 109.45(17) C(51)-C(52)-H(52A) 109.5 
O(10)-C(44)-C(45) 109.06(17) C(51)-C(52)-H(52B) 109.5 
C(43)-C(44)-C(45) 110.96(18) H(52A)-C(52)-H(52B) 109.5 
O(10)-C(44)-H(44) 109.1 C(51)-C(52)-H(52C) 109.5 
C(43)-C(44)-H(44) 109.1 H(52A)-C(52)-H(52C) 109.5 
C(45)-C(44)-H(44) 109.1 H(52B)-C(52)-H(52C) 109.5 
O(12)-C(45)-C(46) 110.73(18) C(1S)-O(1S)-H(1S) 112.0 
O(12)-C(45)-C(44) 107.11(17) O(1S)-C(1S)-H(1SA) 109.6 
C(46)-C(45)-C(44) 109.98(18) O(1S)-C(1S)-H(1SB) 109.5 
O(12)-C(45)-H(45) 109.7 H(1SA)-C(1S)-H(1SB) 109.5 
C(46)-C(45)-H(45) 109.7 O(1S)-C(1S)-H(1SC) 109.3 
C(44)-C(45)-H(45) 109.7 H(1SA)-C(1S)-H(1SC) 109.5 
























































































































































































































Chapter IV : Synthesis, Characterization and Evaluation of Stable-
isotopically Labeled Anti-cancer Compounds for Precision Medicine 
Abstract 
 Personalized cancer medicine has emerged as a targeted and tailored treatment 
approach to maximize the treatment efficacy and reduce toxicity for individual patients. 
Great advances in sequencing of cancer genomes and characterization of cancer biomarkers 
allowed for a more targeted cancer treatment 58. However, patient-tailored administration 
of chemotherapeutic agents is still in its infancy due to the limitations in robust 
bioanalytical methods for therapeutic drug monitoring 87. Here, the synthesis and 
characterization of stable-isotopically labeled anti-cancer compounds (OSW-1, 
gemcitabine, and cisplatin) allowed for absolute quantification of the compounds in single, 
living cells through the development of Single-probe quantitative Single Cell Mass 
Spectrometry (qSCMS). Utilizing the stable-isotopically labeled anti-cancer compounds, 
Single-probe qSCMS methodology successfully measured the concentration of the 
therapeutic agents inside both adherent and suspension cell lines. Based on the success of 
these in vitro cell line experiments, the qSCMS methodology was successfully used to 
quantify the intracellular gemcitabine drug levels in bladder cancer cells isolated from 
patients undergoing chemotherapy. This is perhaps the first instance of using SCMS to 
quantify the intracellular drug level in a patient cancer cell. The success of the Single-probe 
qSCMS method will advance personalized cancer medicine forward with a more 
customizable chemotherapeutic treatment course.  
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IV.1 Introduction 
IV.1.1 Personalized medicine in cancer therapy 
Recent advances of personalized cancer medicine entail not only targeted therapy 
but also focus on personalized and responsive course of treatments with interpatient 
differences taken into account.44 Targeted cancer treatments have made great progress with 
high-throughput sequencing of cancer genomes, along with identification and 
characterization of cancer biomarkers.58 However, personalized cancer medicine must also 
extend to development of a patient-tailored chemotherapy regimen. The conventional 
method for cancer treatment does not allow for patient-customized therapeutic process, 
mainly due to the restraint of the bioanalytical capabilities to provide informative patient 
analyses in a timely manner. Physicians typically determine drug-dosage for patients using 
mainly their physical characteristics, such as weight or body surface area88, rather than 
biological or cancer-specific criteria. The prescribed chemotherapeutic agents are then 
administered following a pre-established schedule, usually without any real-time 
bioanalytical method to examine patient’s response to the drugs or the efficacy of the 
treatment. At the end of the treatment course (weeks or months after the first medication 
administration), physicians conduct end-point analysis, such as an imaging study, to 
determine the efficacy of the treatment. By this time, patients may have endured an 
extended period of chemotherapy treatment along with the associated serious side effects, 
to only then learn that the treatment was not effective. 
 Therapeutic drug monitoring (TDM) emerged as a method that allows physician to 
measure the therapeutic agent concentration in biological samples such as serum 
throughout the course of treatment.87 TDM provides feedback for the adjustment of the 
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following dosage to maintain a constant concentration of specific drugs in the patient’s 
bloodstream.89 Even though TDM enables a more customized dosage for the patient, it 
suffers the drawback results from inter-individual pharmacokinetic/pharmacodynamics 
where the amount of drug present in the patient serum might not reflect the amount of drug 
present at the tumor site.87 Alternatively, TDM can be performed on tumor biopsies 
obtained from accessible tumors sites. This would involve invasive methods, and 
furthermore, the concentration of drugs at the tumor site doesn’t necessarily give true 
validation of therapeutically-relevant concentration of the drug inside of the cancer cells.  
 The observation of heterogeneity in cancer biology has led the cancer research and 
anti-cancer therapeutic development to focus on biology at the single cell level. Recent 
advances in investigation of intratumor-heterogeneity90, development of cancer stem 
cells91, and identification of circulating tumor cells92,93 have elevated cancer research to a 
more focused single-cell-level. These developments require methodologies to perform 
meaningful bioanalysis of patient-isolated cancer cells, which often cannot be easily 
propagated. A clinical bioanalytical method that allows the concentration of 
chemotherapeutic agents to be measured from inside of a patient’s individual cancer cells 
would improve therapeutic drug monitoring significantly. This will help physicians to 
establish optimal dosing regimens that maximize the therapeutic effects while minimize 
the toxicities. Furthermore, performing single cell analysis on cancer cells isolated from 
patients undergoing chemotherapy would provide real-time relevant information about the 
therapeutic efficacy.  
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IV.1.2 Single Cell Mass Spectrometry and its application in personalized cancer 
medicine 
Within the past two decades, Single Cell Analysis (SCA) has grown exponentially 
as a new approach that allows the investigation of biology in the individual cells.94 SCA 
techniques can now detect and analyze many different classes of biomolecules, including 
genes, transcripts, proteins and metabolites.94 Mass spectrometry (MS) has become an 
important methodology for single cell proteomics and metabolomics with its sensitive 
ability to simultaneously analyze a large number of molecules.95 To improve the 
application of single cell mass spectrometry (SCMS) in biological research, recent 
advances have been focused on increasing detection sensitivity and mass resolution with 
novel sampling and ionization techniques.94 The laboratory of Dr. Zhibo Yang at the 
University of Oklahoma (OU) has developed a novel SCMS sampling technology named 
the Single-probe.45 The Single-probe can sample the intracellular constituents of live single 
eukaryotic cells for real-time MS analysis under ambient conditions without sample 
preparation.45 The fabricated single probe consists of one fused silica capillary that carries 
solvent, and one nano-ESI emitter embedded in a laser-pulled dual-bore quartz needle 
(Figure 12).45 For real-time MS analysis, the single-probe is inserted into a live and 
unaltered cell in order to sample the cell contents and ionize the intracellular components. 
The analytes are then delivered directly into a Thermo LTQ Orbitrap XL mass spectrometer 
through the nano-ESI emitter for high-resolution mass spectrometry analysis. 
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Figure 12. Set up schematic of a single cell MS analysis.  
Figure is adapted from Pan et al. 45 
 
The Single-probe MS technique has been used successfully to analyze individual 
cervical cancer HeLa cells.45 Multiple cellular metabolites and lipids were detected and 
identified in both negative and positive modes including ATP, ADP, AMP, 
phosphatidylcholines, and sphingomyleins.45,95 When HeLa cells were treated with 
anticancer compounds such as Doxorubicin (Adriamycin), paclitaxel (Taxol), and OSW-
1, the compounds and their metabolites can be detected inside the single cells 45. 
Furthermore, the anti-cancer drugs inside of the single cancer cells can potentially be 
absolutely quantified with quantitative single cell mass spectrometry (qSCMS). The 
Single-probe qSCMS methodology can be utilized to determine the concentration of drugs 
inside the single cancer cells, including those from patient-isolated bladder cancer cells. 
Bladder cancer is an ideal candidate for development of Single-probe qSCMS. Bladder 
cancer cells are excreted in the urine and can be positively identified from no-cancerous 
cells based on overall morphology. Moreover, Single-probe qSCMS could also be applied 
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for other disease states in which the patient’s cells can be easily accessed. With the ability 
to quantify the amounts of small molecules inside the single cells, Single-probe qSCMS 
will improve therapeutic drug monitoring (TDM) application for physicians and patients, 
and it will also be a powerful bioanalytical tool in basic biomedical research, especially for 
hard-to-propagate primary and patient-isolated cell populations. 
IV.1.3 Anti-cancer compounds used in qSCMS studies 
The experimental protocols for qSCMS methodology can be first established in 
vitro using the Single-probe technology on bladder cancer cell lines treated with anti-
cancer compounds cisplatin96, gemcitabine97 and OSW-110 (Figure 13). Cisplatin and 
gemcitabine are well-established anti-cancer drugs used in treatment of bladder cancer.97 
Both of these drugs work through inducing DNA damage in cells. OSW-1 is a cytotoxic 
natural product with a unique mechanism of action.10 By using these structurally diverse 
compounds, the generality of Single-probe qSCMS application to analyze small molecules 
will be evaluated.  
Absolute quantification of a compound through mass spectrometry (MS) is only 
possible with the use of an internal standard compound. The ideal MS internal standards 
are stable-isotopically labeled (deuterated, carbon-13, or nitrogen-15) analogs of the 
compound of interest (Figure 13), which should possess the similar ionization 
characteristics with a different molecular weight. During the Single-probe qSCMS 
experiment, the isotopically labeled internal standard compounds will be added at a fixed 
concentration to the sampling solvent that goes through the Single-probe and carried the 
analytes from the single cell (Figure 12). The MS signal that corresponds to the internal 
standard will be used to calculate the concentration of the analyte present.  
254 
 
Figure 13. Anti-cancer compounds in qSCMS studies and their stable-isotopically 
labeled analogs 
 
IV.2 Results and discussion 
Isotopically-labeled OSW-1, gemcitabine, and cisplatin were synthesized 
following the established total synthesis of each compound, with adaptations to incorporate 
the isotopic labels.98,99 Once the compounds were successfully synthesized, the labeled 
compounds underwent full characterization (2D NMR, IR, HR-MS, and biological assays) 
to validate the presence of stable isotopes at the desired location, and that incorporation of 
the stable isotopes did not change the bioactivity of the anti-cancer compounds. Then, the 
labeled compounds were employed as internal standard in Single-probe quantitative Single 
Cell Mass Spectrometry in Dr. Yang’s Lab. Here, the syntheses and characterization of the 
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stable-isotopically labeled anti-cancer compounds will be described in detail, and their 
application in Single-probe qSCMS will be highlighted. 
IV.2.1  Syntheses of stable-isotopically labeled anti-cancer compounds 
IV.2.1.1 Synthesis and characterization of d-OSW-1 
The synthesis and characterization of deuterated OSW-1 has been presented in 
detail in Chapter II (Section II.3.1 to Section II.3.4).  
IV.2.1.2 Synthesis and characterization of 15N,13C-labeled Gemcitabine 
Stable-isotopically labeled gemcitabine was accessed through a short sequence of 
reactions following the synthetic route that scientists at Eli Lily published in 1991 98. The 
starting material 3,5-di-O-benzoate-2-deoxy-2,2-difluoro-D-ribofuranose 4.3 (Scheme 35) 
was purchased commercially as a mixture of both anomers. The hemiacetal mixture was 
then activated as glycosyl donor by conversion of the free hydroxyl group to a mesyl group 
in 4.4 with good yield (82%). The glycosyl acceptor was prepared from commercially 
available 2-13C, 1,3-15N2 cytosine 4.5 (Scheme 35). Glycosyl acceptor 4.6 was prepared in 
situ from heating the mixture of cytosine 4.5 and hexamethyldisilane to reflux in presence 
of ammonium sulfate for 45 minutes. Utilizing the Vorbrueggen glycosylation method, the 
mesylated glycosyl donor 4.4 was reacted with silylated glycosyl acceptor 4.6 and 
trimethylsilyl trifluoromethanesulfonate as the activator in refluxing 1,2-dichloroethane for 
48 hours. This reaction produced a mixture of protected isotopically labeled gemcitabine 
4.7 (76% yield). The glycosylation reaction was presumed to proceed through an SN1 
pathway involving an oxonium ion intermediate, which resulted in a mixture of nucleoside 
anomers with the ratio of α : β being 1.3 : 1  as measured through 1H NMR. 
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Scheme 35. Synthesis of stable-isotopically labeled Gemcitabine 
 
 Treating the mixture 4.7 with ammonia in anhydrous methanol effectively removed 
both benzoyl protecting groups. The anomeric mixture of deprotected nucleoside were 
successfully separated through semi-preparative reverse-phase HPLC to afford desired β-
anomer (4.8 in 34% yield) and α-anomer (4.9 in 4.0% yield). The desired β-nucleoside 4.8 
was then converted to the hydrochloride salt of gemcitabine 4.10 in the presence of 
equimolar HCl in isopropanol. The molecular weight of the stable-isotopically labeled 
gemcitabine 4.10 was confirmed through high resolution mass spectrometry.  
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Figure 14. 1H NMR spectra of non-labeled gemcitabine (top) and labeled gemcitabine 
(bottom) 
 
Since both 15N and 13C are NMR active, the differences observed in the NMR 
spectra of labeled gemcitabine 4.10 and non-labeled gemcitabine can be used to confirm 
the presence and placement of the stable isotopes (Figure 14). As shown in Figure 14, the 
1H NMR signals of labeled gemcitabine matched up perfectly with the signals of non-
labeled gemcitabine. The differences lie in the splitting patterns of the signals, especially 
the ones in proximity of 15N and 13C. The most downfield signal (at 8.02 ppm) was assigned 
to the proton on C-9. In the spectrum of non-labeled gemcitabine, this signal appears as a 
doublet, since the proton on C-9 can be split by proton on C-8. The signal at 8.02 ppm in 
the labeled-gemcitabine spectrum displays a different splitting pattern. C-9 in the labeled 
gemcitabine is adjacent to 15N, which is NMR active. The coupling between proton on C-
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9 and this 15N resulted in the more complex splitting pattern observed. Similar patterns can 
be observed at around 6.28 ppm where two signals corresponding to C-1 and C-8 protons. 
In the non-labeled gemcitabine spectrum, the signal for C-1 proton appears as a clear 
doublet, while the signal for C-1 proton of the 15N-labeled-gemcitabine shows a much more 
complicated multiplicity. The splitting pattern observed in the NMR, along with the HRMS 
and IR confirmed the structure of stable-isotopically labeled gemcitabine 4.10. 
 
Figure 15. Cytotoxicity assay of non-labeled gemcitabine (Gem) and stable-isotopically 
labeled Gemcitabine (Labeled Gem) on T-24 cell line 
 
The stable-isotopically labeled gemcitabine was evaluated, along with non-labeled 
gemcitabine, for their cytotoxicity in the adherent T-24 (bladder cancer) cell line (Figure 
15). The IC50 value obtained for stable-isotopically labeled gemcitabine was 22.3 ± 5.9 
nM, while that of non-labeled gemcitabine was 27.5 ± 6.6 nM. These identical values 
indicate that the presence of stable isotopes of nitrogen and carbon did not alter the 
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bioactivity of gemcitabine. The Single-probe qSCMS studies utilizing stable-isotopically 
labeled gemcitabine as the internal standard are underway. 
IV.2.1.3 Synthesis and characterization of 15N-labeled Cisplatin 
 
Scheme 36. Synthesis of 15N-labeled cisplatin 
 
 The cis-dichlorodiamineplatinum(II) (cisplatin) complex was synthesized 
following the rapid and facile one-step synthesis adapted from Lebedinsky’s method 99 
(Scheme 36). The 15N-label was incorporated through the use of 15N-labeled ammonium 
acetate. Potassium tetrachloroplatinate(II) (K2PtCl4) was heated in water to reflux in the 
presence of 15N-labeled ammonium acetate and potassium chloride for 2 hours. After quick 
filtration of the hot reaction mixture, the desired cisplatin crystallized from the reaction 
mixture upon cooling. Pure cisplatin was obtained through recrystallization of crude 
product from 0.1M aqueous HCl in 25% yield. The incorporation of 15N-labeled was 
confirmed through high resolution mass spectrometry (See IV.4.2. Compound data).  
 The presence of 15N-label can also be observed through 1H NMR (Figure 16). In 
the 1H NMR spectrum of non-label cisplatin, the -NH3 moiety shows up as a broad singlet 
at 4.17 ppm, since protons on nitrogen are exchangeable. For the 15N-labeled cisplatin, the 
signal for -NH3 group shows up as a doublet at 4.17 ppm with coupling constant of 72.30 
Hz. This coupling constant is within range of the reported J(15N-1H) 100. The chemical shift 
of 4.17 ppm was reported to be from cisplatin, since 1H signal for trans-platin would be 
observed at 3.74 ppm 101. Both non-labeled and 15N-labeled cisplatin were analyzed by 2D 
NMR (15N – 1H HSQC experiment) to show they have essentially the same chemical shifts 
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for both proton and nitrogen-15 (See IV.5.Chapter Appendix). X-ray crystallography 
analysis was attempted on 15N-labeled cisplatin, but the crystals could not be grown to the 
sufficient size for the analysis.  
 
Figure 16. 1H NMR spectra of 15N-labeled cisplatin (top) and non-labeled cisplatin 
(bottom) 
 Cisplatin can undergo modifications inside of cells to form other platinum 
complexes through substitution of the chlorine with water or DMSO.102 This interferes with 
the ability to use 15N-labeled cisplatin as internal standard in qSCMS. Therefore, different 
technologies to detect and quantify platinum are being investigated and developed for 
qSCMS 
IV.2.2 Application of stable-isotopically labeled anti-cancer compounds in qSCMS 
Both deuterated OSW-1 and labeled gemcitabine were employed as the internal 
standards for the development and application of Single-probe qSCMS technology. As 
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demonstrated in Figure 17, a fixed 
concentration of the internal standard is added to 
the sampling solvent that goes through the 
Single-probe to then carry the cellular contents, 
along with the internal standard, to the mass 
spectrometry inlet for detection and analysis. 
The absolute concentration of the compound of 
interest was calculated based on the average cell 
volume, the sampling solvent flow rate and the concentration of the internal standard.  
Deuterated OSW-1 was used for the development and validation of the Single-
probe qSCMS technique. Figure 18 shows a representative mass spectrum of a single cell 
analysis utilizing the internal standard d-OSW-1. T-24 (bladder cancer) cells were treated 
for two hours with 1 µM OSW-1. Then the cells underwent single cell analysis with the 
Single-probe, with 100 nM of d-OSW-1 internal standard in the sampling solvent. In the 
mass spectrum of cellular contents (Figure 18), OSW-1 and the internal standard d-OSW-
1 were clearly observed. The intensity of the peaks was then used to calculate the moles of 
OSW-1 present inside the cells.  
Using the Single-probe qSCMS technology, the pharmacokinetic and 
pharmacodynamic properties of compounds of interest can be determined. The 
concentration of the molecule can be determined immediately at various time points after 
drug treatment through qSCMS, with minimal sample preparation. This shows a big 
advantage over the traditional methods of cellular analysis, which includes the preparation 
Figure 17. Schematic of real-time 
SCMS sampling with the Single-
probe (courtesy of Shawna Standke) 
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of cell lysate from the samples and analysis through Liquid Chromatography-Mass 
Spectrometry (LCMS).  
 
Figure 18. SCMS spectrum of T-24 (bladder cancer) cells after 2 hours treatment of 1µM 
OSW-1 with 100nM d-OSW-1 in the sampling solvent (courtesy of Shawna Standke and 
Ryan Bensen) 
 
 Similar to d-OSW-1, stable-isotopically labeled gemcitabine was employed as the 
internal standard for Single-probe qSCMS analysis. Figure 19 presents the mass spectrum 
of a T-24 cell following a one-hour treatment with 0.1 µM gemcitabine, with 100 nM of 
labeled gemcitabine in the sampling solvent. The peaks for both gemcitabine and the 
internal standard are clearly observed in the spectrum, and their intensities can be used to 
calculate the moles of gemcitabine present inside the cell after treatment. With the 
collaboration between Burgett’s and Yang’s labs, the methodology has been optimized for 
both adherent cell lines (i.e. T-24 and SW-780-bladder cancer cell lines ) and suspension 
cell lines (i.e. K562-human chronic myeloid leukemia).  
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Figure 19. SCMS spectrum of T-24 (bladder cancer) cells after 1-hour treatment of 
0.1µM gemcitabine with 100nM labeled gemcitabine in the sampling solvent (courtesy of 
Shawna Standke and Ryan Bensen) 
 
 Gemcitabine is an FDA-approved anti-cancer drug that is used currently in treating 
bladder cancer 97. This presents the opportunity to apply Single-probe qSCMS technology 
to the clinical settings, which could later be adapted for personalized cancer medicine. 
Urine samples were collected from patients following infusion of gemcitabine as part of 
standard of care chemotherapy. Cells from patient urine were isolated, and the bladder 
cancer cells were identified via examination of morphology during the Single-probe 
analysis. Intracellular gemcitabine was quantified the Single-probe qSCMS method 
(example result, see Figure 20). This could mark the first reported time intracellular 
chemotherapy drug levels have been measured inside of single cancer cell isolated from a 
patient. The next stage of research will be to tract the intracellular levels of gemcitabine in 
bladder cancer cells of patient undergoing active chemotherapy. In the future, physicians 
could conceivable use the intracellular drug concentrations in a patient’s individual cancer 
cells to adjust and optimize chemotherapy dosage to maximize the treatment efficacy. 
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Figure 20. Mass spectrum of gemcitabine and 15N-labeled-gemcitabine (1 µM) from an 
individual cell isolated from the urine of a bladder cancer patient (courtesy of Shawna 
Standke and Ryan Bensen) 
 
IV.3 Conclusion 
The development of personalized cancer medicine needs to extend beyond patient-
matched-targeted treatment to include a more-tailored, and responsive chemotherapeutic 
administration that will maximize the benefit to the individual patient. The Single-probe 
quantitative Single Cell Mass Spectrometry emerged as a robust bioanalytical method that 
allows for the real-time analysis to measure the absolute concentration of therapeutic agent 
inside the single cells with minimal sample preparation. The synthesis and characterization 
of stable-isotopically labeled analogs of the anti-cancer compounds (OSW-1, gemcitabine 
and cisplatin) enabled the absolute quantification of the drugs through the Single-probe 
methodology. This method has been applied successfully to quantify the amount of drug 
in both adherent and suspension cell lines. Furthermore, Single-probe qSCMS effectively 
measured the concentration of gemcitabine, using the produced isotopically-labeled 
gemcitabine, in bladder cancer cells isolated from patients. This advancement could 
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develop into powerful too in cancer medicine to provide personalized, adaptable 
chemotherapy treatments.  
IV.4 Experimental section 
IV.4.1 General methods 
All reactions were performed in oven-dried glassware under a positive pressure of nitrogen 
unless noted otherwise. Flash column chromatography was performed as described by Still 
et al.55 employing E. Merck silica gel 60 (230-400 mesh ASTM). TLC analyses and 
preparative TLC (pTLC) purification was performed on 250µm Silica Gel 60 F254 plates 
purchased from EM Science and Fluka Analytical. All solvents and chemicals were used 
as purchased without further purification. Solvents used in the reactions were collected 
under nitrogen from a Pure Solv 400-5-MD Solvent Purification System (Innovative 
Technology). Infrared spectra were recorded on a Shimadzu IRAffinity-1 instrument, or 
Bruker Tensor 27 spectrometer, and IR spectra peaks are reported in terms of frequency of 
absorption (cm-1). 1H and 13CNMR spectra were recorded on VNMRS 300, VNMRS 400, 
VNMRS 500 or VNMRS 600 MHz-NMR Spectrometer. Chemical shifts for proton and 
carbon resonances are reported in ppm (δ) relative to the residual proton or the specified 
carbon in chloroform (δ 7.26, proton; 77.16, carbon). High-resolution mass spectrometry 
(HRMS) analysis was performed using Agilent 6538 high-mass-resolution QTOF mass 
spectrometer. HPLC purification was performed on Shimadzu LCMS 2020 system [LC-
20AP (pump), SPD-M20A (diode array detector), LCMS-2020 (mass spectrometer)]. 
Semi-preparative HPLC purification was performed using Phenomenex Luna C-18(2) 
column, 5µm particle size (250 mm x 4.6 mm), supported by Phenomenex Security Guard 
cartridge kit C18 (4.0 mm x 3.0 mm); Phenomenex Luna C-8(2) column, 5µm particle size 
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(250 mm x 4.6 mm), supported by Phenomenex Security Guard cartridge kit C8 (4.0 mm 
x 3.0 mm) and HPLC-grade solvents. 
IV.4.2 Compound data 
 
Compounds 4.4 was synthesized as previously describe.98 To a solution of 2-Deoxy-2,2-
difluoro-D-ribofuranose-3,5-dibenzoate (200.0 mg, 0.529 mmol) in anhydrous DCM (2 
mL, 0.26 M) at 0°C was added triethylamine (103 µL, 0.74 mmol), followed by 
methanesulfonyl chloride (49 µL, 0.634 mmol). The reaction mixture was stirred at RT for 
4h15m, when it was completed base on TLC analysis. The reaction mixture was diluted 
with DCM (20 mL), washed with 1N HCl (15 mL), 5% NaHCO3 solution (15 mL), DI H2O 
(15 mL), and brine. The organic phase was dried over Na2SO4, and filtered. The solvent 
was removed in vacuo to afford mixture of products (α:β = 1.3:1) as a sticky yellow gel 
(200 mg, 82% yield). Products 4.4 was used in the next step without further purification. 
1H NMR (400 MHz, Chloroform-d) δ 8.07 (dt, J = 8.5, 1.5 Hz, 5H), 8.05 – 8.02 (m, 2H), 
7.66 – 7.61 (m, 2H), 7.58 (td, J = 7.5, 1.4 Hz, 2H), 7.46 (dtd, J = 15.6, 7.7, 2.4 Hz, 9H), 
6.13 (d, J = 6.3 Hz, 1H), 6.03 (d, J = 6.5 Hz, 0H), 5.93 (dd, J = 15.0, 6.8 Hz, 1H), 5.57 (dd, 
J = 16.4, 4.3 Hz, 1H), 4.85 (q, J = 4.1 Hz, 1H), 4.79 – 4.70 (m, 2H), 4.70 – 4.57 (m, 3H), 
3.17 (s, 3H), 3.02 (s, 3H). 13C NMR (101 MHz, Chloroform-d) δ 166.01, 165.92, 165.09, 
164.95, 134.35, 134.29, 133.74, 133.60, 130.26, 130.19, 129.86, 129.23, 129.16, 128.85, 
128.82, 128.79, 128.64, 128.14, 127.98, 123.49, 123.13, 121.01, 120.74, 120.61, 120.45, 
118.26, 117.93, 99.99, 99.74, 99.52, 99.28, 99.21, 98.96, 98.79, 98.54, 82.83, 82.80, 82.77, 
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79.84, 79.76, 71.34, 71.17, 70.98, 70.81, 69.75, 69.60, 69.49, 69.34, 63.06, 62.55, 40.42, 
40.30. See Chapter appendix for NMR spectra. 
 
Compounds 4.7 were synthesized with procedure adapted from Chou et al.98 A suspension 
of isotopically labeled cytosine 4.5 (25.0 mg, 0.219 mmol), ammonium sulfate (1.2 mg, 
0.009 mmol) in hexamethyldisilazane (300 µL, 1.4 mmol) was heated under reflux (130°C) 
for 45 minutes. The reaction mixture was then cooled to RT. Under N2 atmosphere, to this 
reaction mixture was added 1,2-dichloroethane (0.75 mL, 0.3 M) and trimethylsilyl 
trifluoromethanesulfonate (40 µL, 0.144 mmol). The clear, colorless solution was stirred 
at RT for 45 minutes. To the reaction mixture was then added SM (66 mg, 0.144 mmol, 
dissolved in 0.66 mL 1,2-dichloroethane). The reaction mixture was heated under reflux 
(90°C). The reaction progress was monitored by TLC (5% MeOH/CHCl3, UV). 1,2-DCE 
was added periodically to keep the same reaction concentration. After 72 hours, the 
reaction was completed based on TLC analysis. The reaction mixture was cooled to RT, 
the solvent was removed in vacuo to afford a thick gel, which was dissolved in EtOAc (40 
mL), washed with DI H2O (5 mL x 3), 5% NaHCO3 solution (5 mL). The organic phased 
was dried over Na2SO4 and filtered. The solvent was removed in vacuo to afford crude 
mixture (64.8 mg), which was purified through silica gel column chromatography (eluted 
with MeOH/CHCl3 gradient, 2% to 10% MeOH) to afford desired products 4.7 as a white 
powder (52.7 mg, 76% yield). 1H NMR (500 MHz, Chloroform-d) δ 8.10 – 8.03 (m, 6H), 
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8.03 – 7.99 (m, 2H), 7.67 – 7.56 (m, 4H), 7.51 – 7.41 (m, 10H), 6.68 (t, J = 7.0 Hz, 1H), 
6.56 (bs, 1H), 5.83 (dd, J = 7.6, 3.6 Hz, 1H), 5.78 (dt, J = 10.3, 5.2 Hz, 1H), 5.70 (dd, J = 
7.6, 3.7 Hz, 1H), 5.64 (d, J = 13.1 Hz, 1H), 4.86 – 4.75 (m, 2H), 4.68 (dd, J = 12.4, 4.6 Hz, 
1H), 4.64 (d, J = 5.0 Hz, 2H), 4.55 (td, J = 4.7, 3.3 Hz, 1H). See Chapter appendix for 
NMR spectra. 
 
Compounds 4.8 and 4.9 were synthesized with procedure adapted from Chou et al.98 To a 
suspension of 4.7 (47.6 mg, 0.10 mmol) in anhydrous MeOH (2 mL) at RT was added NH3 
solution in MeOH (100 µL, 7M solution). The reaction mixture was stirred at RT and the 
reaction progress was monitored by TLC (10% MeOH/CHCl3, UV). The reaction was 
completed after 16h by TLC. The solvent was removed in vacuo to afford an oily residue, 
which was resuspended in DI H2O (10 mL) and EtOAc (5 mL). The aqueous phase was 
extracted with EtOAc (5 mL) while the organic phase was washed with DI H2O (5 mL). 
The combined aqueous phase was concentrated in vacuo to afford crude product as a clear 
gel (25 mg, 94%). The crude mixture was purified through LCMS (C18 column, condition) 
to afford 4.9 (α-anomer-10.5 mg, 39.5%) and 4.8 (β-anomer-9.0 mg, 33.9%).  
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Compounds 4.10 were synthesized with procedure adapted from Chou et al.98 Compound 
4.8 (9.0 mg) was dissolved in DI H2O (0.5 mL) and isopropanol (0.5 mL), then HCl 
solution (6 µL of 6N solution) was added. The mixture was mixed for 5 minutes, then the 
solvent was removed in vacuo to afford 4.10 as a white solid (10.1 mg). 
1H NMR (400 MHz, Deuterium Oxide) δ 8.06 – 7.98 (m, 1H), 6.33 – 6.22 (m, 2H), 4.40 
(td, J = 11.7, 8.3 Hz, 1H), 4.18 – 4.09 (m, 1H), 4.04 (d, J = 12.3 Hz, 1H), 3.89 (dd, J = 13.1, 
4.4 Hz, 1H). 13C NMR (101 MHz, Deuterium Oxide) δ 160.58 (d, J = 14.2 Hz), 144.62 (d, 
J = 12.6 Hz), 121.62 (t, J = 260.5 Hz), 96.44 (d, J = 3.7 Hz), 86.30 – 84.66 (m), 81.81 (d, J 
= 7.7 Hz), 71.46 – 68.07 (m), 60.12. 19F NMR (376 MHz, Deuterium Oxide) δ -116.75 (dd, 
J = 13.0, 5.5 Hz), -117.39 (dd, J = 12.9, 5.4 Hz), -118.00, -118.64. IR (cm-1) 3392.64 (N-




+- [M+H]+: 267.0765; found 267.0730. See Chapter appendix 
for NMR, IR and HRMS spectra. 
 
cis-dichlorodiammineplatinum(II) was synthesized with procedure adapted from 
Kukushkin et al.99 A suspension of K2PtCl4 (100mg, 0.241 mmol), 
15NH4OAc (80.9 mg, 
1.04 mmol) and KCl (100.6 mg, 1.35 mmol) in DI H2O (1.5 mL) was heated under reflux 
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(115°C) for 2 hours. During this period, the color of the reaction mixture changed from red 
to orange/brown (after 30 minutes), and then green-ish yellow (after 1 hour). After 2 hours, 
the hot reaction mixture was filtered through a cotton plug. The yellow filtrate was cooled 
in an ice bath and then stored at 4°C for 2 hours. The yellow precipitate was collected by 
centrifugation. The solid was washed with chilled DI H2O (3 mL x 3). The solid was then 
dried on hi-vac to afford crude product (58.6 mg). The crude product was purified through 
recrystallization in hot 0.1N HCl. The crude product was dissolved in sufficient amount of 
hot 0.1N HCl (~3.7 mL) to obtain a clear, yellow solution. The solution was immediately 
centrifuged for 30 seconds to separate any undissolved materials. The yellow supernatant 
was removed, then cooled in an ice bath for 15 minutes. To the mixture was added cold 
200-proof EtOH (~12 mL). The yellow solid was collected by centrifugation, washed with 
cold EtOH (3 mL x 2), dried on hi-vac to afford the labeled cisplatin 4.2 (36.5 mg, 25% 
yield). 
The NMR data (both 1H and 15N) matched perfectly with the commercially available 
cisplatin. In 1H NMR spectrum of labeled cisplatin, a doublet with J-value of 72.3 Hz was 
observed, in comparison with a broad doublet in commercial cisplatin. This is due to N-15 
being NMR active, therefore it splits the 1H-NMR signal correspond to -NH3 groups. 
1H NMR (500 MHz, DMF-d7) δ 4.16 (d, J = 72.3 Hz, 6H).15N NMR (51 MHz, DMF-d7) 
δ -45.72. IR (cm-1) 3278.39, 3200.45, 1618.74, 1536.15, 1307.72, 1292.16, 792.50. HRMS 
calcd for Cl2H6
15N2Pt + H
+ [M+H]+: 301.9569, found: 301.9534 
IV.4.3 Cell cytotoxicity assay 
T24 cell lines were grown in McCoy’s medium supplemented with 10% synthetic fetal 
bovine serum and 1% penicillin-streptomycin. All cells were maintained in an incubator at 
271 
37°C under 5% CO2, and they were passaged around 75% confluency. To avoid mutations, 
only cells under passage number 25 that were in culture less than 2 months were utilized 
in the experiments. 
Cells (5000 cells/well) were plated into 96-well plates in 75 μl of medium. After 24 h, a 
time-zero plate was produced by adding 25 μL of medium and 20 μL of CellTiter-Blue 
(Promega) to the wells and then incubating the plates at 37 °C for 90 min. Fluorescence 
(560 nm excitation; 590 nm emission) was detected using a Tecan Infinite M200 to 
establish cell viability at time of dosing. Then, compounds were serially diluted in medium 
and delivered to the cells as 4× solutions in 25 μl of medium. At either 48 h or 72 h, 
CellTiter-Blue was added, and the fluorescence was recorded as described above. Growth 
relative to untreated cells was calculated, and this data was fitted to a four-parameter dose-




































































































































































































































































































































































































































































Chapter V : Synthesis, Characterization and Evaluation of α,α-
Dichloro-all-trans-retinone (DAR) as a Selective Inhibitor for 
Retinaldehyde Dehydrogenase Enzymes 
Abstract 
The retinaldehyde dehydrogenase (RALDH) enzyme subfamily (which includes 
RALDH1, RALDH2, and RALDH3) catalyzes the irreversible oxidation of all-trans-
retinaldehyde to all-trans-retinoic acid (atRA). Despite the importance of the RALDH 
enzymes in embryonic development and their association with different syndromes and 
diseases, no commercially available inhibitors that selectively target these enzymes are 
available. Utilizing a structure-based design strategy, α,α-dichloro-all-trans-retinone 
(DAR) was synthesized and characterized as a small molecule inhibitor that exhibited 
selectivity for RALDH1, 2, and 3, but not mitochondrial ALDH2. These results encourage 
the further development of DAR as a specific inhibitor for RALDH enzymes for use in 
experimental applications, and asvpotential therapeutic agents for many diseases.  
V.1 Introduction and background  
The aldehyde dehydrogenases (ALDHs) are a superfamily of proteins that catalyze the 
NAD(P)+ dependent, irreversible oxidation of aldehydes to their respective carboxylic 
acids.46 ALDH proteins have been shown to participate in a wide variety of physiological 
processes including aldehyde detoxification, alcohol metabolism, vision and 
neurotransmission.103 Mutations in ALDH genes have been connected with various 
diseases such as brain, breast, and lung cancer 104,105, late-onset Alzheimer’s disease 106, 
and alcohol flushing syndrome 107.   
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The retinaldehyde dehydrogenase (RALDH, also known as ALDH1A) subfamily 
consists of three members, RALDH1 (ALDH1A1), RALDH 2 (ALDH1A2) and RALDH 
3 (ALDH1A3), which catalyze the oxidation of all-trans-retinoic acid (atRA) from 
retinaldehyde (both all-trans-retinaldehyde or 9-cis-retinaldehyde).46 RALDH proteins are 
essential for regulating retinoic acid signaling prenatally and postnatally. In embryonic 
development, each RALDH is selectively expressed in targeted tissue to mediate 
organogenesis of the eye, brain, heart, kidney, lung, and reproductive organs.108 
Postnatally, RALDH proteins are involved in spermatogenesis109, maintenance of lens 
transparency110, and stem cell differentiation111. The RALDH subfamily has also been 
associated with a variety of diseases through the modulation of all-trans-retinaldehyde and 
all-trans-retinoic acid concentrations. RALDH1 has been linked to obesity 112 and 
inflammation113, while RALDH2 has been associated with abnormal ocular growth 
(myopia)114,115. Therefore, RALDH 2 is a potential therapeutic target for the development 
of an effective therapy to slow or prevent the development of myopia.  
Regardless the involvement of various ALDH family members in numerous diseases, 
pharmacological selective inhibitors have been developed for only two of the ALDH 
isozymes: ALDH1A1 (CM026, CM037) and ALDH3A1 (CB29) for treatment of 
oxazophosphorine resistant cancers.116,117 Due to the similarities in protein structure, many 
inhibitors (reversible and irreversible) have been found to be non-specifically inhibit a 
range of ALDH family members.117 Thus, studies utilizing these non-specific inhibitors to 
gain insights into the physiologic roles of ALDH isoenzyme activity may be complicated 
by inhibition of multiple proteins leading to off-target effects.  
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Recently, bisdichloroacetyldiamine (WIN 18446, commercially known as 
Fertilysin, (Figure 21) was shown to effectively and reversibly inhibit testicular all-trans-
retinoic acid biosynthesis via the testes-specific enzyme RALDH2.118,119 These findings 
led to WIN 18446 being employed as a male contraception in a number of mammals 119–
121 and was tested for its potential as a male contraceptive in human volunteers 122. Even 
though WIN 18446 was a promising candidate for male contraceptive, it was not 
introduced for the general public use because the disulfiram ethanol reaction (i.e. blurred 
vision, nausea, and flushing of the face) was observed upon patient consumption of alcohol 
while the compound was administered.118 This observation indicated that WIN 18446 did 
not only interact with RALDH2, but also inhibited ALDH2 and possibly other ALDH 
enzymes, which was later confirmed in vitro .119 These results demonstrate the importance 
of developing small molecule inhibitors that are specific and selective for the RALDH 
isozymes for treatment of diseases without unwanted and serious side effects. This chapter 
details the design, synthesis and evaluation of a novel inhibitor, [(3E,5E,7E,9E)-1,1-
dichloro-4,8-dimethyl-10-(2,6,6-trimethylcyclohex-1-en-1-yl)deca-3,5,7,9-tetraene-2-
one; “α,α-dichloro-all-trans-retinone” or DAR- Figure 21], for the retinaldehyde 
dehydrogenase (RALDH or ALDH1A) subfamily that is specific for RALDH1, RALDH2, 
and RALDH3, but has no activity on human mitochondrial ALDH2. This work resulted 
from a successful collaboration the Burgett’s laboratory and the research group of Prof. 
Jody Summers’ at OUHSC. 
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V.2 Results and discussion 
V.2.1 Structure-based design of DAR 
 
Figure 21. Structures of WIN 18446, all-trans-retinaldehyde, and DAR 
 
α,α-dichloro-all-trans-retinone (DAR) was designed based on two results: 1) the 
covalent interaction of WIN 18446 with RALDH2; 2) the conformational differences in 
protein structure between the binding sites of RALDH enzymes and the other ALDH 
enzymes.123 WIN 18446 has been shown to inhibit RALDH1, 2, and 3, as well as ALDH2 
and other proteins of the ALDH superfamily.122 WIN 18446 irreversibly binds to RALDH2 
through a covalent modification as illustrated in the crystal structure of RALDH2 – WIN 
18446 complex (Figure 22) 123. The thiol group on residue cysteine 320  was proposed to 
undergo a SN
2 reaction to displace a chloride from WIN 18446 dichloro moiety to form the 
covalent adduct.123 Furthermore, the substrate entrance tunnel for the RALDH enzymes are 
relatively larger than that of the other ALDH enzymes, as determined for ALDH2.124 This 
difference in entrance tunnels size likely accounts for the specificity of retinaldehyde to the 
RALDH enzymes.124 This research results suggests that a successful RALDH selective 
inhibitor could be a hybrid of the WIN 18446 and retinaldehyde. The DAR compound is 
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designed to contain the dichloromethyl moiety from WIN 18446 for irreversible interaction 
with the protein, and the large, rigid structure of retinaldehyde. 
 
Figure 22. Crystal structure of the covalent adduct between Cys 320 and WIN 18446; 
proposed mechanism of adduct formation. Figure is adapted from Chen et al. 123 
 
V.2.2 Synthesis and characterization of DAR 
 
Scheme 37. Synthesis of α,α-dichloro-all-trans-retinone DAR 
 
 α,α-dichloro-all-trans-retinone (DAR) was synthesized in a one-step transformation 
of ethyl ester of retinoic acid 5.4 (Scheme 37). Since the availability of ethyl retinoate 5.4 
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was rather limited commercially, it was synthesized in lab over two steps starting from 
commercially available retinyl acetate 5.1. The all-trans-retinyl moiety, with the extended 
conjugation system, isomerizes very easily in light and acidic reaction conditions. All the 
reactions were carried out in a darkened fume hood, with reaction flasks wrapped in 
aluminum foil to limit the exposure of the compounds to ambient light. Reaction conditions 
were chosen carefully to lower the possibility of isomerization.  
 Saponification of retinyl acetate with a catalytic amount of potassium carbonate 
afforded retinol 5.2 in quantitative yield (Scheme 37). Retinol 5.2 was then oxidized to 
ethyl retinoate 5.4 through two steps.125,126 First, oxidation of retinol 5.2 with manganese 
dioxide afforded all-trans-retinaldehyde 5.3125. This reaction proceeded smoothly with 
excellent yield (94%). Retinaldehyde 5.3 was subjected to another oxidation condition with 
manganese dioxide in presence of cyanide ion to obtain ethyl retinoate 5.4. In this process, 
retinaldehyde is converted to the cyanohydrin with the cyanide ion, which is susceptible to 
further oxidation by manganese dioxide to an acyl cyanide. Esterification of the acyl 
cyanide with the ethanol solvent produced ethyl ester 5.4 126.  
 With ethyl retinoate prepared, the synthesis of α,α-dichloro-all-trans-retinone 
(DAR) was attempted. Dichloromethyllithium, generated in situ from a reaction of lithium 
diisopropylamide and dichloromethane, performed a nucleophilic addition to the carbonyl 
carbon of ethyl retinoate .127 The adduct then underwent hydrolysis to afford the desired 
product DAR in fairly low yield (10%). A small amount of the starting ethyl retinoate was 
recovered, with the remaining mass balance of this reaction being comprised of a complex 
mixture of unidentified isomeric byproducts. Extensive purification, including preparative 
TLC and semi-preparative HPLC, produced analytically pure DAR, free from any 
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contaminating byproducts. The low yield of this reaction was not surprising given the 
combination of the inherent reactivity of the extended conjugated system in DAR and the 
highly reactive dichloromethyllithium species. DAR was characterized fully through HR-
MS, 2D NMR spectroscopy and IR.  
 DAR is prone to photoisomerization, therefore was protected from ambient light at 
all times. DAR was dissolved in dimethylsulfoxide (DMSO) to produce 10 mM solution 
for biological testing. These stock solutions were protected from light and stored frozen at 
-20°C. Multiple small aliquots of DAR (10mM) were prepared and used for biological 
testing to prevent refreezing of sample as DAR will degrade upon frequent freeze/thaw 
cycles. 
V.2.3 Biological evaluation of DAR 
After DAR had been fully purified and characterized, evaluation of the compound 
commenced to determine its activity in biological systems. Dr. Angelica Harper (from Dr. 
Summers’ lab) performed the majority of the biological assays. The concentration of all-
trans-retinoic acid isolated from biological samples was measured and quantified using 
LCMS methods developed and optimized in Burgett lab.  
V.2.3.1 Effects of DAR on aldehyde dehydrogenase activity 
DAR was tested on recombinant chicken RALDH1, RALDH2, RALDH3, human 
RALDH2 (hRALDH2) and recombinant human mitochondrial ALDH2 (hALDH2) to 
examine the effects of DAR on aldehyde dehydrogenase activity (Figure 23). RALDH1, 
2, 3, and hRALDH2 were pre-incubated with DAR (0 – 10 µM) for 20 minutes at 37°C, 
after which retinaldehyde (RAL, 250 µM) was added to the reaction mixture to initiate all-
trans-retinoic acid (atRA) and NADH production. RALDH activity in the presence and 
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absence of DAR was measured by quantifying the synthesis of NADH, as both NADH and 
atRA are produced in equimolar amounts during the oxidation of all-trans-retinaldehyde.46 
DAR inhibited chicken RALDH1, 2, and 3 with IC50 values of 434.70 ± 99.70 nM, 55.00 
± 10.71 nM and 161.27 ± 16.57 nM, respectively, as well as human RALDH2 (hRALDH2, 
IC50 = 191.32 ± 36.77 nM) (Figure 23A-D). Using propionaldehyde as the substrate (5 
mM) for human aldehyde dehydrogenase 2 (hALDH2), DAR (0 – 100 µM, 1 hour pre-
incubation) did not have an inhibitory effect on hALDH2 (Figure 23E), while WIN 18446 
inhibited hALDH2 with an observed IC50 of 229.33 ± 40.95 nM (Figure 23E). These 
results indicate that DAR has selectivity for RALDH enzymes with the most robust 
inhibition (lowest IC50) observed for RALDH2 in vitro in the presence of the natural 
substrate, retinaldehyde (inhibition of RALDH2 > RALDH3 > RALDH1). 
 
Figure 23. Dose response curves to compare the effect of DAR on chick and human 
RALDH1a isoforms and human mitochondrial ALDH2 (hALDH2). Data points (A-E) 
represent the average ± SEM for triplicate samples. Figure is adapted from Harper et al.47 
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V.2.3.2 DAR is an irreversible inhibitor of RALDH2 
The mechanism of inhibition of DAR on recombinant chicken RALDH2 was 
investigated using various methods to determine if DAR acts as an irreversible inhibitor, 
since WIN 18446 inhibits human RALDH2 in a time-dependent and irreversible manner 
(Figure 24).123. Increasing concentrations of DAR in the enzyme reaction with RALDH2 
resulted in a dose dependent decrease of Vmax (Figure 24A). A hallmark of irreversible 
inhibition is the persistence of inhibition following removal of unbound inhibitor. When 
unbound inhibitor was removed by ultrafiltration (Figure 24B, “UF”) prior to addition of 
cofactor and substrate, RADLH2 activity was not restored. The inhibition effects of DAR 
was observed similar to the results seen when unbound DAR remained present in the 
enzyme reaction (Figure 24B, “ No UF”). In addition, the Vmax for NADH synthesis was 
determined using increasing concentrations of RALDH2 (46 – 365 nM) in the presence of 
DAR (150 nM) (Figure 24C). A plot of Vmax vs. RALDH2 concentration indicated that 
RALDH2 activity was completely inhibited when enzyme concentrations (46 – 91 nM) 
were less than the concentration of DAR [RALDH2] ≤ 150 nM). In the presence of 150 
nM DAR, RALDH2 concentrations (183 – 365 nM) resulted in a linear increase in Vmax 
for NADH synthesis (0.50 – 3.01 µM NADH/min). These results suggested that DAR 
irreversibly inhibits RALDH2. Similar experiments performed on RALDH1 and RALDH 




Figure 24. DAR is an irreversible inhibitor of RALDH2.  
A) All-trans-retinaldehyde concentration-dependent RALDH2 (91 nM) activity in the 
presence of increasing concentration of DAR (0-250 nM; pre-incubated with RALDH2 for 
20 minutes prior to addition of substrate and cofactor). B) RALDH2 activity measured 
before and after ultrafiltration of DAR-inactivated RALDH2 (0-50 nM DAR). C) Maximal 
rate (Vmax) of enzyme activity was determined at increasing concentrations of RALDH2 
(46-365 nM) with DAR concentration remaining constant (150 nM). Figure is adapted from 
Harper et al.47 
 
V.2.3.3 DAR inhibits all-trans-retinoic acid synthesis in a RALDH2 expressing cell 
line 
 (Dox)RALDH2-eGFP, a HEK-293 cell line expressing doxycycline (DOX)-
inducible chicken RALDH2 was employed to assess the effect of DAR on intracellular 
RALDH2 activity (Figure 25). Treatment of the (Dox)RALDH2-eGFP cells with DOX (5 
µg/mL; 24 hours) resulted in the induction of RALDH2-eGFP expression as compared to 
non-induced (Dox)RALDH2-eGFP cells (Figure 25A). In order to determine the toxicity of 
DAR on the (Dox)RALDH2-eGFP cells, cell viability assays measuring DNA content and 
ATP production were performed (Figure 25B). Following treatment with DAR (0 – 50 
µM) for 24 hrs, toxicity curves were determined with IC50 values of 2.94 ± 1.58 µM and 
3.09 ± 0.48 µM, for DNA and ATP production, respectively.  
Next, ex vivo effects of DAR on cells was investigated. DOX-induced RALDH2-
eGFP expressing cells were treated with DAR (0 – 2 µM for 24 hrs). Following isolation 
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of cell lysates, the enzyme reaction was initiated by addition of NAD+ and the substrate 
all-trans-retialdehyde (25 µM). All-trans-retinoic acid (atRA) was then extracted in 
hexanes from the enzyme reaction, dried and resuspended in acetonitrile to prepare samples 
for Liquid Chromatography Mass Spectrometry (LCMS) quantification. The concentration 
of atRA was determined from a calibration curve generated by LCMS using known 
concentrations of atRA (See V.4.3). Treatment of DOX-induced RALDH2-eGFP 
expressing cells with DAR (0 – 2 µM for 24 hours) resulted in a significant inhibition of 
all-trans-retinoic acid synthesis at 0.05 µM (↓42%, p<0.01), 0.50 µM (↓47%, p<0.001), 1 
µM (↓92%, p<0.001), and 2 µM (↓93%, p<0.001) compared to the vehicle treated control 
(one-way ANOVA with Bonferroni’s test for multiple comparisons) (Figure 25B). No 
atRA synthesis was detected in cells not induced with DOX (-DOX). Normalization of 
results in Figure 25C to RALDH2 protein expression in each sample (relative density 
quantified from western blot, inset) indicated a dose-dependent decrease in atRA synthesis 




Figure 25. DAR inhibits all-trans-retinoic acid (atRA) synthesis in a RALDH2 expressing 
cell line.  
A) Induction of chicken RALDH2-eGFP expression in a stably transfected, doxycycline 
(DOX)-inducible HEK 293 cell line ((Dox)RALDH2-eGFP). RALDH2-eGFP expression is 
not detected in cell lysates not treated with DOX (-DOX). B) Toxicity curves measuring 
DNA content and ATP production in cells treated with DAR (- µM) for 24h. C) Inhibition 
of atRA synthesis in (Dox)RALDH2-eGFP cells treated with DAR (0.05-2 µM) or vehicle 
(DMSO) for 24h. Following isolation of cell lysates, the enzyme reaction was initiated by 
addition of NAD+ and all-trans-retinaldehyde (25 µM). All-trans-retinoic acid was 
quantified by HPLC in Burgett lab. No atRA synthesis was detected in cells not induced 
with DOX (-DOX). D) Results in C normalized to RALDH2 protein expression. Relative 
RALDH2 expression was quantified from western blots of (Dox)RALDH2-eGFP cell lysates 
(inset). Figure is adapted from Harper et al.47 
 
 Overall, the novel compound α,α-dichloro-all-trans-retinone (DAR) has been 
shown to selectively inhibit the RALDH isozymes in vitro (chicken RALDH2, RALDH3, 
RALDH1, and human RALDH2) and ex vivo in the nanomolar range in an irreversible 
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manner. DAR has superior selectivity compared to WIN 18446 as it did not have an 
inhibitory effect on the human mitochondrial ALDH2 enzyme.  
V.3 Conclusions 
The lack of selective inhibitors for the important and disease-relevant retinaldehyde 
dehydrogenase (RALDH) isozymes subfamily inspired the design and synthesis of α,α-
dichloro-all-trans-retinone (DAR) using an intelligent drug design approach based on 
enzyme structure and substrate affinity. DAR was synthesized and purified from a complex 
mixture of products due to the high reactivity of the retinyl moiety and the 
dichloromethyllithium reagent. After successful structure characterization of DAR, its 
biological activity was examined through several experiments. The results showed that 
DAR inhibits chicken RALDH1, 2, 3, and human RALDH2 in an irreversible manner, but 
has no inhibitory effect on human mitochondrial ALDH2. These results are promising for 
the development of a therapeutic agent selective for the RALDH enzymes, specifically 
RALDH2 for the treatment of myopia 114,115. The structure of DAR will require 
optimization to improve compound stability and yield of the synthetic route. 
V.4 Experimental section 
V.4.1 General methods 
All reactions were performed in oven-dried glassware under a positive pressure of 
nitrogen unless noted otherwise. Flash column chromatography was performed as 
described by Still et al.55  employing E. Merck silica gel 60 (230-400 mesh ASTM). TLC 
analyses and preparative TLC (pTLC) purification was performed on 250µm Silica Gel 60 
F254 plates purchased from EM Science and Fluka Analytical. All solvents and chemicals 
were used as purchased without further purification. Solvents used in the reactions were 
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collected under nitrogen from a Pure Solv 400-5-MD Solvent Purification System 
(Innovative Technology). Infrared spectra were recorded on a Shimadzu IRAffinity-1 
instrument, or Bruker Tensor 27 spectrometer, and IR spectra peaks are reported in terms 
of frequency of absorption (cm-1). 1H and 13CNMR spectra were recorded on VNMRS 300, 
VNMRS 400, VNMRS 500 or VNMRS 600 MHz-NMR Spectrometer. Chemical shifts for 
proton and carbon resonances are reported in ppm (δ) relative to the residual proton or the 
specified carbon in chloroform (δ 7.26, proton; 77.16, carbon). High-resolution mass 
spectrometry (HRMS) analysis was performed using Agilent 6538 high-mass-resolution 
QTOF mass spectrometer. HPLC purification was performed on Shimadzu LCMS 2020 
system [LC-20AP (pump), SPD-M20A (diode array detector), LCMS-2020 (mass 
spectrometer)]. Semi-preparative HPLC purification was performed using Phenomenex 
Luna C-18(2) column, 5µm particle size (250 mm x 4.6 mm), supported by Phenomenex 
Security Guard cartridge kit C18 (4.0 mm x 3.0 mm); Phenomenex Luna C-8(2) column, 
5µm particle size (250 mm x 4.6 mm), supported by Phenomenex Security Guard cartridge 
kit C8 (4.0 mm x 3.0 mm) and HPLC-grade solvents. 
V.4.2 Compound data 
 
Compounds 5.2 were synthesized with procedure adapted from Solladie et al.125 Retinyl 
acetate 5.1 (520.1 mg, 1.58 mmol) was dissolved in methanol (6.6 mL) under nitrogen at 
room temperature to afford a light yellow, cloudy mixture. To the stirring mixture was 
added K2CO3 (109.4 mg, 0.79 mmol). After 45 minutes, the reaction was completed based 
on TLC analysis (30% EtOAc/hexanes). The mixture was filtered through a cotton plug. 
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The solvent was removed in vacuo to afford a thick, orange oil, which was dissolved in 
DCM (50 mL). The organic layer was washed with saturated NaHCO3 solution (30 mL), 
DI water (20 mL x 2). The combined aqueous layer was back extracted with DCM (20 mL 
x 2). The combined organic layer was washed with brine, dried over Na2SO4, and filtered. 
The solvent was removed in vacuo to afford the desired product 5.2 as an opague, yellow 
gel, which was used without purification (453 mg, quantitative yield). 1H NMR (400 MHz, 
Chloroform-d) δ 6.62 (dd, J = 15.2, 11.2 Hz, 1H), 6.29 (d, J = 15.1 Hz, 1H), 6.22 – 6.05 
(m, 3H), 5.69 (t, J = 7.0 Hz, 1H), 4.31 (t, J = 6.2 Hz, 2H), 2.01 (t, J = 6.4 Hz, 2H), 1.96 (s, 
3H), 1.87 (s, 3H), 1.71 (s, 3H), 1.66 – 1.57 (m, 3H), 1.49 – 1.44 (m, 2H), 1.24 (t, J = 5.6 
Hz, 1H), 1.02 (s, 6H). See Chapter appendix for NMR spectra. 
 
Compounds 5.3 were synthesized with procedure adapted from Solladie et al.125 Retinol 
5.2 (453 mg, 1.58 mmol) was dissolved in dry DCM (8.2 mL) at room temperature. To the 
stirring mixture was added activated MnO2 (1.42 g, 16.3 mmol) as solid. After one hour, 
the reaction was completed based on TLC analysis (20% EtOAc/hexanes). The MnO2 was 
removed by centrifugation (4300G, 5 minutes). The solvent was then removed in vacuo to 
afford desired product 5.3 as a thick, dark orange oil, which was used without purification 
(422.8 mg, 1.49 mmol, 94% yield). The NMR data agreed with published reference125. 1H 
NMR (400 MHz, Chloroform-d) δ 10.10 (d, J = 8.1 Hz, 1H), 7.14 (dd, J = 15.1, 11.5 Hz, 
1H), 6.35 (dd, J = 15.6, 10.9 Hz, 2H), 6.23 – 6.11 (m, 2H), 5.97 (d, J = 8.2 Hz, 1H), 2.33 
(s, 3H), 2.07 – 1.99 (m, 5H), 1.72 (s, 3H), 1.67 – 1.59 (m, 2H), 1.51 – 1.43 (m, 2H), 1.03 
(s, 6H). See Chapter appendix for NMR spectra. 
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Compounds 5.4 were synthesized with procedure adapted from Solladie et al and Corey et 
al.125,126 Retinal 5.3 (422.8 mg, 1.49 mmol) was dissolved in dry EtOH (15 mL) at room 
temperature. To the reaction mixture was added NaCN (72.8 mg, 1.49 mmol) as a solid 
and glacial acetic acid (128 µL, 2.23 mmol) dissolved in EtOH (0.5 mL). After 45 minutes, 
to the mixture was added activated MnO2 (1.29 g, 14.9 mmol). The mixture was stirred at 
room temperature and the progress was followed by TLC (10% EtOAc/hexanes). After 
24h, to the reaction mixture was added more MnO2 (388 mg, 4.47 mmol). After 48h, the 
reaction was completed based on TLC analysis. The MnO2 was removed by centrifugation 
(4300G, 5 minutes). The black residue was washed with DCM (30 mL x3). The supernatant 
was washed with saturated NaHCO3 (30 mL), DI water (30 mL x2). The aqueous layer was 
back extracted with DCM (30 mL). The combined organic layer was washed with brine 
(50 mL), dried over Na2SO4, and filtered. The solvent was removed to afford desired 
product 5.4 as a dark orange oil, which was used without purification (476.2 mg, 97% 
yield). 1H NMR (400 MHz, Chloroform-d) δ 6.99 (dd, J = 15.1, 11.4 Hz, 1H), 6.34 – 6.23 
(m, 2H), 6.18 – 6.09 (m, 2H), 5.77 (s, 1H), 4.17 (q, J = 7.1 Hz, 2H), 2.35 (s, 3H), 2.10 – 
1.94 (m, 5H), 1.71 (s, 3H), 1.66 – 1.56 (m, 2H), 1.52 – 1.44 (m, 2H), 1.29 (t, J = 7.2 Hz, 
3H), 1.03 (s, 6H). See Chapter appendix for NMR spectra. 
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Ethyl retinoate 5.4 (69.5 mg, 0.211 mmol) was dissolved in dry ethyl ether (0.9 mL) under 
nitrogen. Dichloromethane (19.0 µL, 0.296 mmol) was added via syringe. The dark yellow 
solution was cooled down to -78˚C. LDA solution (2.0M in THF, 170 µL, 0.338 mmol) 
was added dropwise slowly over 5 minutes. Upon the addition of LDA, the color of the 
reaction mixture turned dark red/brown. The progress of the reaction was monitored by 
TLC (10% EtOAc/hexanes, CAM stain) every 2 minutes. The reaction mixture was stirred 
at -78˚C for additional 10 minutes, when no further reaction progress was observed on 
TLC. To the reaction mixture, 400 µL of 6N HCl was added to quench the reaction. The 
mixture was warmed to room temperature, diluted with ethyl ether (30 mL), washed with 
1N HCl (15 mL x 2) and with distilled water (15 mL x 2). The combined aqueous phase 
was back extracted with ethyl ether (5 mL x 2). The combined organic phase was washed 
with brine (20 mL) and dried over Na2SO4, and filtered. The solvent was removed under 
reduced pressure to afford crude product as a dark brown oil (70 mg).  
The reaction did not go to completion, and produced multiple products based on TLC 
analysis showing multiple spots. The crude mixture was then separated by pTLC (3 plates) 
eluted with 4.5% EtOAc/hexane. The pTLC plates were covered with multiple thin, 
inseparable bands. Four main, separable bands were collected: band 1 (Rf=0.54, 12.8 mg, 
desired product 5); band 2 (Rf=0.48, 14.9 mg, recovered 4); band 3 (Rf=0.37, 7 mg, 
tetrachloro-adduct possible); band 4 (Rf=0.22, 2.8 mg, mixture of compounds).  
The desired product from fraction 1 was further purified by HPLC using a Phenomenex 
C18(2) Luna semiprep column, 96-98% MeCN/water with 0.1% formic acid gradient (2.5 
mL/min flow rate, start with 3 minutes of 96%, gradient 96-98% in 9 minutes, hold at 98% 
for 8 minutes). This resulted in the pure desired product DAR (yellow oil, 7.7 mg, 10% 
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yield, 12.6% borsm) with retention time at 16.7 minute. See Chapter appendix for NMR 
spectra. 
1H NMR (500 MHz , CDCl3): δ =  7.21 (dd, J = 15.0, 11.5 Hz, 1H, H6), 6.49 (s, 1H, H3), 
6.42 (d, J = 15.1 Hz, 1H, H5), 6.37 (d, J = 18.0 Hz, 1H, H7), 6.20 (d, J = 11.5 Hz, 1H, H9), 
6.17 (d, J = 15.9 Hz, 1H, H10), 5.84 (s, 1H, H1), 2.44 (s, 3H, H17), 2.05 (s, 3H, H18), 2.04 
(m, 2H, H13), 1.68 - 1.59 (m, 2H, H14), 1.52-1.46 (m, 2H, H15), 1.05 (s, 6H, H20). 13C 
NMR (126 MHz, CDCl3): δ = 186.46 (C2), 159.02 (C4), 141.93 (C8), 137.63 (C11), 
137.05 (C10), 134.81 (C5), 134.38 (C6), 130.63 (C12), 130.03 (C7), 129.40 (C9), 118.02 
(C3), 71.02 (C1), 39.60 (C15), 34.28 (C16), 33.17 (C13), 28.97 (C10), 21.77 (C19), 19.18 
(C14), 14.96 (C17), 13.05 (C18). IR (NaCl, cm-1): 3440 (Csp3-H), 2920 (Csp2-H), 1680 
(C=O), 1558 (C=C), 785 (C-Cl). HRMS (ESI): m/z calculated for C21H28Cl2O + H
+ [M + 
H+]: 367.1595, found: 367.1596, Δ = 0.27ppm. 
V.4.3 LCMS calibration curve for all-trans-retinoic acid 
all-trans-retinoic acid (atRA) was quantified as previously described with the following 
modifications: a Shimadzu LCMS 2020 (Shimadzu; Kyoto, Japan) with a Cortecs C18 
column [2.7 μm particle size with VanGuard Cartridge (Waters; Milford, MA)] was used 
to achieve atRA separation. The column compartment was maintained at 25 °C, and the 
autosampler was maintained at 10 °C. The following solvents were used: A, H2O with 0.1% 
formic acid; B, acetonitrile. The column was equilibrated in 70% acetonitrile prior to 
sample loading. 25 μL of sample was injected into the column, and separation was achieved 
at 400 μL/min with the following gradient: 0–3 min, hold at 70% B; 3–15 min, 70% B to 
95% B; 15–20 min, hold at 95% B; 20–21 min, 95% B to 70% B; 21–37 min, re-equilibrate 
at 70% B. Elution of atRA was monitored using a photodiode array detector at 350 nm, 
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followed by MS detection. Retention time of atRA was 20.6 min with an m/z of 300.25. 
atRA was quantified from a calibration curve (Figure 26) generated using known amounts 
of atRA (0–1500 pmol) eluted with the above gradient. 
 
Figure 26. all-trans-retinoic acid LCMS calibration curve 
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Chapter VI : Conclusions and Outlooks 
Since the identification of OSW-1’s cellular targets as disease-relevant proteins 
OSBP and ORP4, the natural product OSW-1 has shown significant potential for 
therapeutic applications. The OSW-1 compound exhibits broad-spectrum anti-viral activity 
through its inhibition of OSBP, and potent anti-cancer activity through its interaction with 
ORP4. The comparable binding affinity of the OSW-1 compound to both OSBP and ORP4 
incumbers its development as effective therapeutic agents. Furthermore, the mechanism of 
action of the OSW-1 compound still remains unclear.  
To gain further insights to the OSW-1 compound’s mechanism of action, a set of 
OSW-1 probe analogs were designed and synthesized, including 1) a deuterated OSW-1 
analog useful for mass spectrometry (MS) quantification of OSW-1; 2) a biologically 
inactive OSW-1 analog useful for serving as a negative control compound, and 3) a series 
of OSW-1 analogs with an introduced amine linker that retains the biological activity of 
OSW-1 while allowing for direct further derivatization. These compounds were prepared 
through either total synthesis and direct derivatization of the OSW-1 compound.  
The deuterated OSW-1 analog was accessed through the total synthesis route, with 
the deuterium labeled installed on the C-3’’ of OSW-1 xylose moiety. This process was 
proven to be lengthy, with the multistep synthesis required from each moiety, and low-
yield, mainly due to the late-stage, low-yielding Schmidt glycosylation reaction utilized to 
assemble the molecule. Once synthesized, the deuterated OSW-1 analog was employed as 
an internal standard to measure the concentration of the OSW-1 compound inside the living 
cells through the Single-probe quantitative Single-Cell Mass Spectrometry. This deuterated 
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OSW-1 analog can be further applied in the future for different mass spectrometry studies 
to probe the mechanism of action of OSW-1. 
The set of OSW-1 analogs with amine linker that retain the biological activity of 
OSW-1 will allow for further direct and selective derivatization of the OSW-1 compound 
for desirable biological studies. These analogs were accessed through two-steps synthesis 
that installed the linker on the OSW-1 molecule and revealed the free amine handle. The 
installation of the linker resulted in two products, C-3” and C-4” linker, in approximately 
equal amount. The analogs with C-3” linker retained the binding affinity of OSW-1 to 
OSBP protein, while the analogs with C-4” linker showed a significant decrease in 
bioactivity as compared to OSW-1. Therefore, alternative methodologies to install the 
linker selectively on C-3” of the OSW-1 molecule should be investigated to limit the 
formation of the biologically inactive C-4” linker. The free amine moiety then allows for 
selective derivatization, since the OSW-1 compound possesses several hydroxyl groups. 
The OSW-1 analogs with C-3” linker can now be derivatized for further studies, such as 
conjugation with a cancer-specific antibody [antibody-drug conjugate (ADC)] to increase 
the selectivity of the OSW-1 compound to cancer cells.  
To increase OSW-1’s potential as therapeutic agent, a new and concise two-
component approach to different OSW-1 scaffolds with an E-ring bridge were proposed to 
allow for the rapid assembly to OSW-1 analogs with increased affinity to OSBP or ORP4. 
Through performing total synthesis of OSW-1, it became apparent that the total synthesis 
route does not allow for rapid derivatization of the OSW-1 structure, since each moiety 
requires several synthetic steps, and the low-yielding assembly of the molecule through 
Schmidt glycosylation. In this new approach, the OSW-1 steroidal aglycon component will 
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be joined with an imine component carrying the side chain and saccharide moieties through 
an imino-ene and cyclization tandem reaction to form the E-ring bridge. This approach was 
demonstrated successfully with the aldehyde to provide the foundation for development of 
the reactions involving the imines.  
A set of OSW-1 analogs with the E-ring modifications are being synthesized 
through the conventional OSW-1 total synthesis route to provide validation for the 
proposed two-component approach. The analogs were assembled through N-glycosylation 
reaction of a steroidal amine moiety containing the side chain, and the OSW-1 disaccharide 
moiety. The Schmidt glycosylation condition failed to produce any glycosylated product. 
Through screening of many glycosylation methodologies, the Fukuyama Mitsunobu 
reaction with mild condition yielded the desired N-linked glycosylated product. Moving 
forward, this glycosylated product will need to be deprotected to remove all the protecting 
groups on the disaccharide moiety, and then cyclized to form the E-ring. 
Beside the main projects involving the natural product OSW-1 described above, 
side projects focused on the development of potential therapeutic applications were carried 
out with quantitative Single-Cell Mass Spectrometry (qSCMS). Stable isotopically-labeled 
anti-cancer drugs cisplatin and gemcitabine were synthesized. These compounds will be 
used as internal standards for the quantification of these drugs in isolated cells from patients 
who are undergoing chemotherapy treatments. This will allow for a personalized treatment 
approach that maximizes the drug’s efficacy while minimizing the toxicity for the patients.  
Through a collaboration project, the first selective inhibitor for retinaldehyde 
dehydrogenase (RALDH) enzymes, α,α-dichloro-all-trans-retinone (DAR), were designed 
and synthesized for potential development of therapeutic treatments for myopia. DAR was 
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evaluated through multiple biological assays to determine that it acts as a selective 
irreversible inhibitor for RALDHs. Even though DAR was successfully synthesized, its 
synthesis suffered from low yield due to the high reactivity of the reagents. Furthermore, 
the DAR compound is quite labile due to the photoisomerization ability of the highly 
conjugated moiety of DAR. Therefore, DAR serves as a great starting point but more 
development to increase the synthetic yield and the stability of the compound is desired for 
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